



MONASH
University

EASTERN HEALTH CLINICAL SCHOOL

**2022
ANNUAL REPORT**

Any enquiries or comments regarding this publication, including requests regarding use or reproduction, should be directed to Eastern Health Clinical School

Monash University

Level 2, 5 Arnold Street
Box Hill, VIC 3128

Tel: +61 3 9094 9546
Email: ehcs@monash.edu
CRICOS provider: Monash University 00008C

CONTENTS

HEAD OF SCHOOL REPORT	4	ACADEMIC OUTPUTS	74
Governance and Oversight	6	PUBLICATIONS	78
Excellence for the Community	8	Aged Medicine Research and Teaching	78
Excellence for the Health Service	9	Dermatology	78
Excellence for the University	9	Eastern Health Intensive Care Research (EHICR)	78
Excellence for Our People	10	Emergency Medicine	79
Future Directions	11	Endocrinology	81
DIRECTORATE REPORTS	12	Gastroenterology	82
Medical Student Programs	12	Haematology	83
Turning Point	16	Infectious Diseases	84
Research and Higher Education	18	Mental Health and Wellbeing Program (MHWP)	85
Eastern Clinical Research Unit (ECRU)	22	Monash Addiction Research Centre (MARC)	86
Health Systems and Equity	24	Nephrology	88
Monash Addiction Research Centre	26	Neurosciences	89
Laboratory Program	30	Nursing and Midwifery	91
Ramesh Nagappan Acute Care Medicine Course	31	Oncology	92
RESEARCH VIGNETTES	32	Respiratory and Sleep Medicine	95
UNIT HIGHLIGHTS	34	Spectrum (Statewide Services for Personality Disorder, Eastern Health)	96
Aged Medicine Research and Teaching (Prof Pēteris Dārziņš)	34	Supportive and Palliative Care Services	96
Cardiology (Dr Jennifer Cooke, A/Prof Andrew Teh, A/Prof Jaya Chandrasekhar, Dr Louise Roberts)	36	Surgical Program	97
Dermatology (Prof John Su)	37	Turning Point	101
Eastern Clinical Research Unit Translational Research Division (ECRU-TRD) (A/Prof Anthony Dear)	38	FINANCE	106
Eastern Health Intensive Care Research (EHICR) (A/Prof Graeme Duke)	39		
Emergency Medicine Research (A/Prof Paul Buntine)	42		
Endocrinology (Prof Chris Gilfillan)	44		
Gastroenterology (Prof Amanda Nicoll)	46		
General Medicine (A/Prof Gary Yip)	47		
Geriatric Oncology (Dr Wee-Kheng Soo)	48		
Haematology (A/Prof Stephen Ting)	49		
Infectious Diseases (Dr Stephen Guy)	50		
Mental Health (A/Prof Judy Hope)	51		
Nephrology (Prof Lawrence McMahon)	52		
Neurosciences (Prof Helen Dewey)	54		
Oncology (Prof Philip Parente)	57		
Respiratory and Sleep Medicine (Prof Frank Thien)	60		
Rheumatology (Dr Christopher Fong)	62		
Spectrum (A/Prof Jillian Broadbear)	63		
Supportive and Palliative Care Services (Prof Leeroy William)	64		
Surgical Program (Prof Shomik Sengupta)	66		

HEAD OF SCHOOL REPORT

It is a pleasure to provide the 2022 Annual Report for Eastern Health Clinical School (EHCS), with thanks to the cast of hundreds who contributed to yet another great year for the School.

EHCS is the primary focus at Eastern Health of research activity for Monash University, and for education of medical students from Monash and Deakin Universities. EHCS is embedded within Eastern Health and represents the partnership responsible for most of the research conducted at Eastern Health. It is a highly productive and mutually beneficial relationship for all stakeholders, and a model for academic / health service partnerships.

EHCS is inclusive, recognising the very high quality and scope of the contributions made by its students, its academic and professional staff, its large cohort of adjuncts, and the broader community at Eastern Health that contributes to teaching and to research. EHCS provides a pivot point for medical student education, and frameworks to support a wide variety of research directions either formally through Monash University, or within Eastern Health using support provided by the School.

This model means that Eastern Health can confidently meet its strategic goals of “Leading in Learning,” “Leading in Research and Innovation,” and “Patients First.” EHCS provides the mechanisms and infrastructure for medical student teaching, clinical trials, other types of clinical research, and ensures the clinical community is able to come together in an academic context in order to contribute to excellence in health service leadership and governance. EHCS works closely with colleagues from other Eastern Health university partners (particularly Deakin and La Trobe) to oversee research at Eastern Health and to ensure implementation of the Eastern Health Research Strategy.



Prof Christina Mitchell (Dean, Faculty of Medicine, Nursing and Health Sciences, Monash University), Prof Ian Davis (Head of Eastern Clinical School), A/Prof Anthony Dear (Translational Research, EHCS), Mary-Anne Thomas (Minister for Health, Minister for Health Infrastructure and Minister for Medical Research), Mr Andrew Hastings (medical research advisor), Mr Tass Mousaferiadis (Eastern Health Board Chair) and Prof Phillip Parente (Director of Cancer Services, Eastern Health)

Monash University implemented its “Impact 2030” strategic plan in 2021, based on three key themes of Climate Change, Geopolitical Security, and Thriving Communities. At first sight it might appear that EHCS activities might relate almost exclusively to Thriving Communities; however, issues of climate change and geopolitical security also affect health directly and indirectly, and represent areas of inequity that we view as responsibilities we must address.

EHCS has evolved considerably since its inception in 2008, when it was formed as a tripartite undertaking of Eastern Health, Monash University, and Deakin University, primarily to provide clinical placements for medical students. This remains core activity for EHCS, but the scope of EHCS activities has expanded considerably, as indicated by our structure. The collaborative agreement is under revision and we hope to finalise this in 2023. The new agreement will take into account the evolution of the School over the years, and will recognise its involvement in multiple areas of education and research embedded within Eastern Health and with external collaborators.

The EHCS organisational structure is based on directorates covering our main areas of activity, as described below. EHCS contributes to other clinical, educational, and research activities through Eastern Health. The School is involved in Eastern Health governance processes, research oversight, medical student and postgraduate medical education, clinical leadership within Eastern Health, and support for unique Eastern Health state-wide services such as Turning Point and Spectrum. Our research program concentrates on clinical issues and related translational questions, although we are increasingly becoming involved in health services and health outcomes research. EHCS is broadly inclusive with a high proportion of senior clinician-researchers across various disciplines. This is reflected in the nature of our predominantly clinical and translational research, and the types of projects our researchers and higher degree research students undertake. In particular, EHCS provides support to Eastern Health for its clinical trials program, ensuring the highest quality data, clinical care for trial patients, and research and financial governance.

You will see in this report that the outcomes overall for EHCS during 2022 were extremely positive. 2022 was the third year of the COVID-19 pandemic and continued to pose challenges for all aspects of EHCS activity. The School was able to be flexible in work practices, including working from home where applicable, but also providing support for individuals and groups experiencing the effects of the pandemic on workforce and usual activities. Our structure provided the ability to cover gaps where people needed to take periods of sick or isolation leave. Our education processes were continually reviewed in the light of the needs of our students. Despite these challenges, and in many cases because of them, EHCS was able to continue most of its research activities, particularly with respect to clinical trials; and we were able to provide an outstanding learning experience for our students, as shown by academic outcomes and feedback from the students of their experiences. This is a testament to the commitment of the staff and students of the School, and I am grateful to everyone for the extraordinary commitment they have shown to be able to produce these outcomes.


EASTERN HEALTH CLINICAL SCHOOL: GOVERNANCE AND OVERSIGHT

EHCS is overseen by a school Executive comprising the Head of School, School Manager, directors of each directorate, the Professor of Surgery, and two other professorial nominees. The EHCS Executive meets five times per year and reports to Monash University's Faculty of Medicine, Nursing & Health Sciences through the Faculty Executive, where EHCS Executive minutes are tabled; and also to Eastern Health through the Executive Director Research / Chief Medical Officer. Additionally, EHCS Medical Student Programs (MSP) reports to Deakin University's Faculty of Health School of Medicine, directly through the EHCS MSP Executive. EHCS provides central administrative support to staff and students for finance, research governance, ethics, human resources, and central university resources.

EHCS comprises five directorates, as illustrated in Figure 1. In addition, administrative oversight of the Monash Addiction Research Centre, physically situated at Monash University Peninsula campus, comes under EHCS.

Actual full-time equivalent (FTE) staff in 2022 were: 5.2 FTE academic staff; 18.3 FTE research academic staff; 54.5 FTE research professional staff; and 14 FTE professional and technical staff, most of whom provide support for EHCS Medical Student Programs, the ECRU clinical research program, the laboratory group based at Box Hill, Turning Point and MARC. Almost all staff are employed through Monash University. These numbers have remained relatively stable aside from a small increase since 2021 in research academic FTE and research professional FTE, representing establishment of the Health Systems and Equity directorate and growth in clinical trial activity through ECRU, respectively.

Fig 1: organisational chart



The current EHCS Strategic Plan was put in place in 2021. The Eastern Health and Monash University strategic plans have since evolved, but the EHCS plan remains relevant and aligned to both as well as for Deakin. Our focus is on “Applied Excellence”, and is centred on four Strategic Themes with underlying Strategic Goals (Fig 2). These form the focus of our activities. The EHCS Executive reviews progress against these goals at each executive meeting.

Fig 2: EHCS Strategic Themes and Goals

Strategic Theme	1. Excellence for the community 	2. Excellence for the health service 	3. Excellence for the university 	4. Excellence for our people 
Strategic Goals	1.1 Best quality clinical outcomes	2.1 Highest quality care	3.1 Outstanding student outcomes	4.1 Promoting staff and student wellbeing
	1.2 Best quality clinical trials	2.2 Leading an integrated, community-focussed research agenda	3.2 High quality research outcomes	4.2 Provision of support systems
	1.3 Understanding and meeting needs	2.3 Adding value to education and vocational training	3.3 Community of clinical educators	4.3 Opportunities for professional growth
	1.4 Bringing networks together	2.4 Leveraging value from health data	3.4 Leadership in university functions	

EXCELLENCE FOR THE COMMUNITY

1.1 Best quality clinical outcomes: Monash University is not responsible for clinical care, but this goal recognises that EHCS is embedded within Eastern Health, and supports Eastern Health’s commitment to provision of highest quality health care. Education through EHCS, and the outcomes of EHCS research, help to inform clinical practice and to assist Eastern Health in its program of continuous quality improvement. We are also committed to working with other providers of health care in the community to improve outcomes and to optimise equity in access to care.

1.2 Best quality clinical trials: Eastern Health recognised through the COVID-19 pandemic that clinical trials are part of excellent clinical care, and the Eastern Health research strategy calls for integration of research at all levels of the organisation. This will now become formalised for accreditation, as the implementation of the National Clinical Trials Governance Framework will directly impact NSQHS Standards 1 and 2. The Memorandum of Agreement between Eastern Health and Monash University, and the planned revised collaborative agreement, formalises the EHCS Eastern Clinical Research Unit as the vehicle by which clinical trials are performed at Eastern Health.

1.3 Understanding and meeting needs: the recent pandemic has demonstrated how the health care needs of the community can evolve rapidly, and how health providers and their academic partners must respond. Monash University EHCS partners with Eastern Health and its other partner universities to ensure that community health care needs are identified and addressed; that gaps in evidence are filled through research; and that multidisciplinary involvement across various health care providers is coordinated for the benefit of individual patients and the wider community. EHCS continues to support a range of research projects and other initiatives aimed at improving communication, optimising outcomes, ensuring equity, and providing the best possible quality of care, through collaboration with various partners in the community. Future work will increasingly involve direct involvement of community and consumer representatives.

1.4 Bringing networks together: EHCS is a great example of academic collaboration with a public health service and with other community health care providers. The various networks intersecting through the School extend widely to involve other academic groups and health services, and increasingly provide systems for data linkage and larger population-scale initiatives, as exemplified by various disease-based registries to which we contribute. For example, Turning Point has a longstanding program of collecting and analysing ambulance data, which has facilitated multiple collaborations and research questions beyond the alcohol and other drug themes originally underpinning the project. EHCS is a key component of Monash Partners Academic Health Sciences Centre. Our students and staff represent a wide variety of disciplines and craft groups, ensuring that our education processes are comprehensive, our outcomes are relevant, and our research questions are based on community needs.

EXCELLENCE FOR THE HEALTH SERVICE

2.1 Highest quality care: EHCS comprises clinicians, students, and trainees, from various disciplines. Our people are embedded in Eastern Health and are key providers of clinical care, clinical governance, and planning. EHCS supports educational initiatives and provides a forum for communication across disciplines, which in turn supports clinical excellence, quality improvement, and clinical governance for provision of the highest standards of health care.

2.2 Leading an integrated, community-focussed research agenda: Our research program in general, and our clinical trials program specifically, is put in place in recognition of clinical needs to be met and evidence gaps to be filled. Each unit drives its own research agenda, but the EHCS structure actively encourages collaborative research across units, disciplines, and diseases. This in turn fosters programmatic research, where all aspects of clinical need and care provision can be considered and improved, rather than working opportunistically, reactively, or in isolation. Turning Point, MARC, and the Health Systems and Equity directorate, all have their primary focus on broader community needs involving but not confined to the Eastern Health sphere of activity. We continue to build links and new research programs with primary care, particularly general practice; and increasingly have impactful input into research programs and meeting clinical needs in underprivileged communities.

2.3 Adding value to education and vocational training: some of the major educational and training initiatives provided through Eastern Health are developed and run through EHCS, adding value for medical students, other health students, and postgraduate health care providers and trainees. Examples include the Ramesh Nagappan Acute Care Medicine course, highlighted on page 31 of this report; the Department of Medicine Grand Round series, which for reasons of COVID-19 was delivered mainly in virtual format during 2022, allowing it to be recorded and streamed; and access to a range of other short courses and training resources. EHCS provides mentorship for research higher degree students, including opportunities for students and to present work. Our Medical Student Programs Scholarly Intensive Placements provide research opportunities for large numbers of medical students throughout the year. EHCS also provides additional support for students who might otherwise struggle to navigate processes for ethics review and approval, infrastructure to support research or training, and of course opportunities to undertake research higher degrees.

2.4 Leveraging value from health data: Eastern Health instituted in 2022 a program to enhance data analytics capability, based on its electronic medical record. This was initially planned to focus primarily on compliance and reporting requirements. EHCS has worked closely with Eastern Health to ensure the project also provides opportunities to use data to improve provision of clinical care at Eastern Health and, as a subset of that, to support research. EHCS is also involved in a Digital Health Cooperative Research Centre project aimed at developing dashboards for various key metrics to assist in accreditation; this work continues to evolve and is spreading to support various research projects and other initiatives that will enhance provision of clinical care.

EXCELLENCE FOR THE UNIVERSITY

3.1 Outstanding student outcomes: EHCS recognises that its medical students and research higher degree students are two of its key stakeholder groups. We aim to ensure that the student experience is as positive as it can be, that student academic outcomes are excellent, and that the School and Eastern Health are seen as desirable places to undertake training and to work. This is core activity for the School and we are gratified to see very positive outcomes in these respects.

3.2 High quality research outcomes: Research informs health care practice and policy, and is a key component of a continuous cycle of improvement. EHCS aims for the highest possible standards for all the research it undertakes. This will be measured by metrics such as student completions, student outcomes, numbers of publications and other presentations of research outcomes, the journals and other fora in which it is published or presented; and measures of research impact, including but not limited to citations, incorporation into practice and policy, national and international collaborations, and new linked projects.

3.3 Community of clinical educators: EHCS has concentrated in recent years on building a cohort of committed and highly capable educators and clinical teachers, embedded within Eastern Health. This group represents much of the academic FTE within the School and includes the contributions of a large number of adjuncts and others. This structure and community of educators ensures exposure of students and trainees to exemplary clinical leaders and the highest quality of clinical practice. EHCS is able to draw on the resources of both Monash and Deakin Universities to ensure that EHCS medical students have the best possible support and educational resources. A key part of education is ensuring that pastoral care oversight is in place, with timely and effective support when needed.

3.4 Leadership in university functions: EHCS is part of the academic communities of Monash and Deakin Universities. We aim to contribute meaningfully to university functions at faculty level and elsewhere, to ensure the perspectives and specific needs of our stakeholders are represented in university processes overseeing education and research. We wish to assist in streamlining and improving university processes, and to lead or otherwise contribute to broader university functions, partnerships, and initiatives. This includes participation in administration, networks, partnerships, governance, curriculum development / delivery / assessment, and expanding research collaborations.

EXCELLENCE FOR OUR PEOPLE

4.1 Promoting staff and student wellbeing: EHCS continues to be one of the leading Schools of Monash University in terms of staff wellbeing metrics. We aim to support our staff and students at every level, including difficulties they may face as a result of the pandemic. EHCS continues to support a range of initiatives, including practical and financial support for staff to participate in various wellbeing programs through Monash University. We will continue to make this a priority.

4.2 Provision of support systems: Education and research are complex activities that require extensive infrastructure for maximum efficacy. EHCS continues to review its activity and processes, taking into account the needs of its students, researchers, and staff. We have instituted new systems and infrastructure to support education and research and to assist our people in their various activities. Support is provided centrally through the EHCS administrative team for financial management, equipment procurement and maintenance, IT, ethics processes, statistical input when needed, and specific expertise where required.

4.3 Opportunities for professional growth: EHCS works at the level of individuals to ensure each person in the School is well supervised and supported, with regular conversations regarding goals, training or other requirements, and processes to build expertise and skill sets and to enhance opportunities for career advancement. EHCS also provides mentorship and practical support for students and researchers. We recognise that our strength is in our people, and that we have a responsibility to support them.

FUTURE DIRECTIONS

EHCS continues to grow and expand, bringing in new research directions, new researchers, and building new collaborations. We have been able to maintain and grow our academic impact throughout the COVID-19 pandemic. Space issues are becoming critical, as our ability to take on new projects is hampered by inability to house the staff and students required to complete them. Various short-, medium-, and long-term options are under consideration to alleviate our space shortage. Our administrative structure is lean but provides valuable and essential support to many areas of the School and for Eastern Health.

EHCS remains committed to be the primary area of academic activity at Eastern Health, and to provide opportunities and improved outcomes for the people we serve: our staff, students, university and health service stakeholders, and the wider community. Areas for development over the next few years will include the following:

- Maintenance and growth of existing programs
- Development of new research initiatives, within existing directorates and through the appointment of new clinician-researchers.
- Improved research infrastructure, with particular emphasis on data extraction, data linkage systems, and links to other health services and health care providers.
- Growth in grant funding and fellowship support.
- Working closely with Eastern Health to improve planning, development, delivery, and evaluation of clinical services and other programs.
- Growth in activity with Monash Partners Academic Health Sciences Centre.
- Incorporate research and education activity wherever possible in Eastern Health.
- Strengthen links with other groups within Eastern Health to encourage thematic research across disciplines.
- Actively recruit and support PhD students, particularly clinician-researchers.
- Optimise links with Monash Partners and share experiences and opportunities between different Monash Partners themes and platforms.
- Promote Eastern Health and EHCS as a great place to learn and work.

I commend to you this EHCS Annual Report for 2022.

Ian Davis

Head, Eastern Health Clinical School

Professor of Medicine, Monash University and Eastern Health

Affiliate Professor, Deakin University

NHMRC Leadership Fellow L3



DIRECTORATE REPORTS:

MEDICAL STUDENT PROGRAMS

CO-DIRECTORS: A/PROF DEB LEACH AND A/PROF CAROLINE DOWLING

2022 has seen the MSP team deliver a busy schedule of teaching across all year levels.

Another pandemic year brought a different set of stresses and challenges to all working in the health system. Even, maybe especially in times like these, students have felt a strong sense of camaraderie as they bonded with their clinical teams. Our life in medicine is made so much richer by the friendships and the networks of colleagues we form over many years. Together we understand what it is like to work a night shift, stress over a sick patient, study so hard for exams but we also have shared humour, memorable moments when lives were saved and exquisitely gratifying instances when someone noticed that you were kind and truly cared.

MSP ACHIEVEMENTS & LEARNINGS IN 2022:

- 250 students received 35,630 days of placement.
 - A suite of self-sign up sessions to facilitate a learner centred approach to scheduling were introduced, enabling students to maximise placement opportunities.
 - A Bedside Coaching program was introduced in order to provide effective catch up of history and physical examination skills that were impacted by pandemic restrictions in 2020 and 2021.
 - Our Clinical Communication Skills Program expanded to provide a session integrated with deteriorating patient scenario teaching. Final year students were coached in how to sensitively deliver serious news to a patient's next of kin following resuscitation from cardiac arrest.
 - Teaching about safe prescribing received an added focus.
 - Many keen "Near Peer" junior doctor teachers added significantly to student learning. Many of these doctors were nominated as Inspiring Teachers with heart-warming citations frequently commenting on their patient centredness and kindness.
 - EHCS partnered with Monash Faculty to successfully deliver a community based Aged Care rotation.
- The Patient Teaching Associate (PTA) Program saw an increase of 40% of patient volunteers through connection with Eastern Health's Volunteer Services Team.
 - Mentorship and facilitation of extra activities for enthusiastic students seeking additional opportunities to enhance their surgical and research skills.
 - A new award was introduced to recognise the quality and presentation of the Scholarly Intensive Projects undertaken by the final year Monash students.
 - 41 students received Individual Student Academic Support Unit (SASU) appointments
- Student feedback was very positive:

 - 93% of students felt valued as a learner
 - 92% of students agreed the teaching they received from clinical staff enhanced their learning
 - 86% of students had an overall sense of well-being while at EH
 - 89% of students would consider employment at EH
 - 86% of students felt well prepared for internship
 - 106 teachers/staff were nominated as being inspirational to EH students
 - 100% student satisfaction with SASU sessions
 - 100% students would recommend SASU support to other students

STUDENT AWARDS:

Deakin

- 1/4 of the Deakin cohort graduated on the Dean's List
- Tenzin Kelsang & Steve Parker-Hill – joint EHCS Deakin Year 3 Award
- Saskia-Aisha Marguccio – Deakin Faculty Dean's Award for EHCS
- Laura Le Mercier – Deakin Faculty Women in Leadership Award for EHCS

Monash

- 10 students of the final year Monash students were awarded a SPA-PE commendation by Faculty for demonstrating excellence in the inaugural Physical Examination assessment
- Daryl Goh - EHCS Pre-Intern Prize (Year 5D)
- Katelyn Mazzochi - EHCS Monash University Year 5D Student Award
- Nesreen Musameh – Scholarly Intensive Project Research Award
- Monika Rezkella – EHCS Year 3B Medicine and Surgery Prize

INSPIRING TEACHERS:

Students nominated any teachers/staff who had gone above and beyond in providing excellent learning opportunities. We are so grateful to all those who have such positive impact on the students.

Abdul Hudaib	EnYe Ong	Liam Dolbey	Rhys Rumley
Adam Pollock	Erica Schmidt	Louis Huang	Richard Barnes
Alex Leaney	Erin Woodward	Louis Pouw	Richard Liu
Alexandra Liacos	Eton Lin	Mia Cooper	Rob Gazzard
Amanda Nicoll	Evan Dyer	Michael Chung	Robert Pucius
Amelia Cooper	Fang Shen	Michelle Nguyen	Rohit Sawahney
Amrita Varma	Gaya Bimal	Mike Angputra	Rohith Valsalan
Amy Cheong	Gerardo Arwi	Miranda McMahon	Rusty Tennakoon
Ananya Sangla	Grace Walpole	Nancy Khav	Ruth Primrose
Andrew Giang	Harry Djumas	Naomi Whyler	Ryan Forbes
Ankur Sidhu	Heidi Gregory	Natalie Sist	Sam Hawthorne
Annie Fung	Hussein Alabodi	Nathaniel Huang	Serena Wong
Antonia Planinic	Ian Wang	Niall Kennedy	Simeon Ngweso
Aruni Malaweera	Isabele Piper	Nick Johnson	Stephen Schultz
Boba Calic	Jack Deng	Nick Tang	Sukumar Navanathan
Brynn McKenzie	Jade Chen	Olivia McGrath	Sumudu Welikumbura
Catherine Rowe	Jan Goonawardena	Patrick Hosking	Tanya Newnham
Charissa Joy	Jasmine Choi	Patrick Rasmussen	Tim Fondum
Christopher Vagias	Jennifer Smith	Paul Buntine	Tim Scully
David Athans	Jessica Kuc	Perkin Chan	Timothy Cryle
David Botross	Joe Vetro	Peter Grossberg	Tushar Goyal
David Sun	Johnathan Hicks	Peter Lim	Vicky Phan
Deb Bernstein	Juliana Wu	Phil Chan	Vivienne Ngu
Deb Leach	Kelly Frilay-Cox	Philip Choi	Will Browne
Dov Degen	Kerrie Davies	Rasitha Tennakoon	Zoha Farooq
Eleanor Bott	Lawrence Vilvarajah	Ray Wang	
Eli Schmerling	Leeroy William	Reginald Ng	

Thank you to all those who supported MSP and the students this year. Monash University, Deakin University, Eastern Health, Box Hill Hospital, Maroondah Hospital, Angliss Hospital, Peter James Centre, Wantirna Health, Healesville Hospital & Yarra Valley Health and of course, all the teachers, doctors, nurses, allied health professionals, volunteers, and administration support staff. Your contributions are truly appreciated.

“Great student engagement, encouraging, gives students opportunities to run consultations with patients, takes time to engage with students and help them feel like a member of the team.”

“Incredibly welcoming and supportive to all members of the team, excellent teaching style with great communication skills, gave me very useful feedback which built up my confidence, empowered me to be a very active contributing member of the team.”



TURNING POINT

DIRECTOR: PROF DAN LUBMAN AM

Turning Point is a national addiction treatment centre, dedicated to providing high quality, evidence-based treatment to people adversely affected by alcohol, drugs and gambling, integrated with world-leading research and education.

In 2022, Turning Point continued to provide high quality care for our clients, as well as highly valued research and education programs.

Research activity continued at a rapid pace again this year with significant work across a broad range of areas, including cultures of high-risk drinking among male hospitality students and workers, exploring low-cost, low-resource ways to increase attendance in addiction treatment, barriers to accessing addiction treatment for women at risk of homelessness, and investigating the impact of the pandemic on alcohol-related harms.

Turning Point also secured \$5 million in research funding, which has provided the opportunity both nationally and internationally, to challenge practice and inform policy direction.

In November, Turning Point partnered with KPMG to launch the ground breaking report 'Understanding the cost of addiction', detailing the impact of addiction on the nation's economy. The report estimates the cost of tobacco, alcohol, other drug and gambling-related harms in 2021 was \$80.3 billion. Alongside this, Turning Point continued to influence policy in areas including the decriminalisation of personal possession of small quantities of illicit drugs, preventing addiction-related suicide, and the harms of online gambling.

The Rethink Addiction campaign continued to build momentum and reach. In 2022, after some COVID-related postponements, the Rethink Addiction National Convention was held in Canberra in September with the theme '*It's time to change the conversation*'.

Another key highlight was the announcement of Turning Point's appointment to establish the new Statewide Specialist Service for people living with mental illness and substance use or addiction. This initiative is part of the implementation of the Victorian Mental Health Royal Commission recommendations. With a core aim of supporting the reformed Mental Health and Wellbeing System to deliver a best practice model of integrated care, there is much exciting work to be done over the coming years.



Prof Dan Lubman AM

An example of the strong links between our research and education functions was demonstrated this year in a project aimed to generate evidence of the role of group-based education and support for affected family members, including linkage to an online peer support group. This work focused on the highly successful BreakThrough family education program that is delivered in partnership with SHARC.

Following extensive redevelopment, Turning Point delivered an updated Addictive Behaviours course (Graduate Certificate, Graduate Diploma and Masters), through Monash University, receiving incredible student feedback.

The work that we do would not be possible without the support we receive from a broad range of partners and collaborators and our incredibly dedicated staff who continually go above and beyond to deliver the breadth and quality of our work.

RESEARCH FUNDING

MDMA-ASSISTED THERAPY TO TREAT AUD AND PTSD

Funder: MRFF

Professor Dan Lubman AM and Associate Professor Shalini Arunogiri are part of an interdisciplinary team of researchers awarded over \$1.9 million to investigate the efficacy of MDMA-assisted psychological treatment to treat people with alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD).

The project is one of seven clinical trials announced by the Federal government under the Medical Research Future Fund (MRFF) to test the use of potential breakthrough combination therapies to treat debilitating mental illnesses.

APP TRIAL TO HELP REDUCE DRINKING

Funder: NHMRC

Associate Professor Victoria Manning received an NHMRC Clinical Trials and Cohort Studies Grant to investigate whether an app can help people with alcohol use disorder (AUD) reduce their drinking.

Associate Professor Manning is leading a team of researchers to conduct a randomised controlled trial of an Alcohol Avoidance Training App (AAT-App), which uses a form of computerised "brain-training" called Cognitive Bias Modification (CBM), to determine whether people with AUD that are not currently accessing treatment can reduce their alcohol consumption.

INVESTIGATING POST COVID ALCOHOL RELATED HARMS

Funder: VicHealth

Turning Point's National Addiction and Mental Health Surveillance Unit (NAMHSU) secured funding from VicHealth to research alcohol-related harms in the post COVID era.

The grant will fund their innovative research project which seeks to understand alcohol-related harms in the post COVID era. Using surveillance data provided by ambulance services, NAMHSU aims to identify geographic 'hotspot' areas of alcohol availability and harm, and create appropriate localised policies to reduce these issues.

EDUCATION PROGRAMS

The Master of Addictive Behaviours program enables the development of specialist knowledge and professional skills to support individuals and communities impacted by addiction.

The course offers a nested program to include a Graduate Certificate (12 months) and a Graduate Diploma (two years), with 83 enrolments across all three programs. In 2022, there were 41 course completions.



Prof Dan Lubman AM & A/Prof Shalini Arunogiri



Dr Rowan Ogeil, Prof Dan Lubman AM & A/Prof Deb Scott



A/Prof Victoria Manning

RESEARCH AND HIGHER EDUCATION

DIRECTOR: PROF IAN DAVIS

The Research and Higher Education directorate covers research that is not clinical trials. It meets four times per year and consists of unit heads, researchers, and higher degree students. The directorate exists to help bring researchers together to optimise use of resources, assist with building internal and external collaborations, provide resources for performance or analysis of research, help ensure projects are completed and published or presented, incorporate laboratory and other necessary support, and to provide opportunities for higher degree research students. EHCS supports student stipends, conference attendance, publishing requirements, and the logistics of collaborations with external partners.

The result of this is a community across Eastern Health that is aware of work being done by others, and is constantly looking to see where we can support each other. It enables researchers to take advantage of solutions developed by others for the same or similar challenges. Most importantly, it helps us support our strategic goals of research excellence, and of ensuring that research is seen by all as a key component of everyday clinical care at Eastern Health.

EHCS continues to have excellent research impact for its academic outputs. The number of publications continues to grow, and other measures of quality and impact such as field-weighted citation impact, publications in the top 10% of citations, publications in top journals, and international collaborations, are also increasing. Data obtained from SciVal as at May 2023 are shown below, noting that citation data for 2022 are still incomplete.

	Overall	2017	2018	2019	2020	2021	2022
Scholarly Output	2600	357	414	387	428	499	464
Citations	35670	8803	8666	7037	6548	3814	1441*
Field-Weighted Citation Impact	1.81	1.42	1.83	2.18	1.91	1.97	2.08
Outputs in Top Citation Percentiles (top 10%, field-weighted)	16.2	14.3	16.7	13.2	18.9	17.8	16.3
Publications in Top Journal Percentiles (top 10% by CiteScore Percentile)	39.7	43.1	39.5	36	40.8	39.4	39.2
Academic-Corporate Collaboration (%)	4.0	5.0	3.1	2.1	4.9	3.6	3.9
International Collaboration (%)	39.6	38.7	37.2	39	40.4	42.3	39.5

* Incomplete data.

The Research and Higher Education directorate is also a vehicle for communication to researchers about grant and other funding opportunities; new initiatives including those through Monash Partners; reporting on Faculty processes such as the Faculty Research Committee, Faculty Graduate Research Committee, and Early Career researchers; oversight of higher degree research student recruitment, progress, and milestones; coordination of the research seminar series; and communication about other relevant activities such as information technology, databases and platform resources.

EHCS celebrated Investigator Grant success (Dr Louisa Picco, EL1; and Prof Ian Davis, L3). Prof Davis was admitted as a Fellow of the Australian Academy of Health and Medical Sciences, while Prof Suzi Nielsen entered the AAHMS Mentorship Program.

OTHER GRANTS:

- A/Prof Anthony Dear received an NH&MRC Development Grant for “Development of a Novel Photo-Angioplasty Device for the Treatment of Occlusive Peripheral Vascular Disease”.
- A/Prof Victoria Manning was awarded an NHMRC Clinical Trials and Cohort Studies Grant to investigate whether an app can help people with alcohol use disorder (AUD) reduce their drinking.
- A/Prof Shalini Arunogiri (Turning Point) was awarded an EH Foundation Grant for “PeerLEAD Peer navigation and Linkage in the Emergency department for Alcohol and Drugs”.
- Dr Jasmin Grigg received the 2022 William and Katherine Winter Fund Travel Grant.

Dr Pavel Sluka served as the research higher degree coordinator, and also provided oversight of the BMedSc(Hons) program. At the end of 2022, EHCS had 20 enrolled PhD students, 6 MSurg students, and 1 MPhil student. Five new research higher degree students were in the process of applying for 2023.

The Department of Medicine Grand Round weekly seminar series at Box Hill Hospital is run through EHCS. The Grand Rounds cover a wide range of topics and include visiting speakers, case-based presentations, and learning opportunities particularly aimed at basic physician trainees. The Grand Round series is an opportunity for trainees and junior staff to see how research can be integrated into a clinical career, and to encourage them to consider including research, or a higher degree, into their own training.

Eastern Health and EHCS are both active participants in Monash Partners Academic Health Science Centre (MPAHSC). The MPAHSC themes of Monash Partners initiatives are Cancer and Blood Diseases; Cardiovascular Disease; Critical Care; Trauma and Perioperative Medicine; Infection and Inflammation; Metabolic Medicine; Neuroscience, Mental Health and Sleep; and Women’s and Children’s Health. EHCS Head of School is a member of the Monash Partners Executive, as well as sitting on the Cancer and Blood Diseases theme executive and other committees, including digital health and health services research. Various other Eastern Health and EHCS senior staff represent Eastern Health on other Monash Partners themes. MPAHSC platforms support clinical research, data management, data linkage systems, registries, health systems research, consumer involvement, workforce development, and implementation science. EHCS continues to encourage its staff to be involved in MPAHSC initiatives and to take on leadership roles.




Fig 3: Output Subtypes (Top 5)

HIGHER DEGREE STUDENTS AND PROJECTS

PhD	
Student	Project Title
Anthony Hew	Frequent mental health presenters - characteristics and opportunities for intervention
Anuj Bohra	Enhancing quality, and utility of disease assessment modalities in Crohn’s disease
Ashish Srinivasan (PhD conferred)	The use of biologic therapy in inflammatory bowel disease
Bronwyn Maddock	Interprofessional education programs for preregistration health care students – what works, for whom and in what circumstances and why?
Chuan Foo	Understanding mechanisms of airway and lung disease using hyperpolarised gas MRI
Gebresilasea Ukke	Development of a diabetes prevention program for postpartum women with high metabolic risks in ET
Georgia Bolt	Personalised CBM in older adults with hazardous alcohol use: A novel cognitive intervention
Hannah Silva	Evaluation of the long-term outcomes of the low FODMAP diet in irritable bowel syndrome
Helena Cangadis-Douglass	Utilising routinely collected primary health care data to understand prescribing of opioids
Henry Yao	Genitourinary cancer survivorship – management of adverse effects of cancer treatment and improvement of quality of life during cancer survivorship
Hui Yi Ng	Detection of circulating tumour DNA in thyroid cancer for risk stratification and prognostication
Jie (Jenna) Yang	Research on exploring the best practice for management of concurrent chronic pain and opioid use disorder
Justin James	A model to select Early Breast Cancers where Sentinel Node Biopsy is not necessary
Lily Curtis	Alcohol consumption practices during COVID-19 and beyond
Louisa Picco (PhD conferred)	Implementation of prescription drug monitoring programs: Measuring the intended and unintended outcomes of identifying high-risk opioid use
Monica Jung	Utilising primary health care data to understand and optimise prescribing of drugs of dependence
Penelope Casey	Delirium in hospitalised adults: Nurses’ recognition and documentation practices
Ramez Bathish	Examining the philosophies, practices and experiences of AOD residential rehabilitation
Ruchira Nandurkar (PhD submitted)	Local and Systemic Detection and Management of Dislodged Tumour Cells to Reduce Post-Treatment Recurrence
Shananthan Balachandran	Novel Combination Therapies for Epithelial Thyroid Cancer
Wubet Takele	Epidemiology of maternal malnutrition and gestational weight gain in the Amhara region, Ethiopia

Master of Surgery	
Student	Project Title
Antara Karmakar	Are you there?: Longitudinal detection of tumour-derived DNA in blood and urine during management of bladder cancer
Chris Ip	Using Multiparametric MRI to Avoid Unnecessary Primary Prostate Biopsies in Men
Enoch Wong (MSurg conferred)	Assessing the role of sarcopenia and frailty in upper gastrointestinal malignancy: Can we do better?
Student	Project Title

Master of Surgery	
Ghadir Omran (MSurg submitted)	Genital Protectors in Sport: Are they fit for purpose?
Janindu Goonawardena	Predicting patients who would benefit from oesophagectomy following neoadjuvant chemoradiotherapy
Joshua Kealey	Upper tract urothelial carcinoma registry: Guiding best clinical practice and patient care
Mo Li (MSurg conferred)	WATIP: Water Irrigation Post TURBT - a pilot study
Ruth Snider	A contemporary tailored approach to recurrent urinary tract infections in females
Shantanu Joglekar	Reducing occupational scatter radiation dose exposure at ERCP

Master of Philosophy	
Student	Project Title
Ifeoluwa Adesina	Advancing Women in Healthcare Leadership: Exploring the Intersection of Race, Gender and Ethnicity

WINTER AND SUMMER STUDENT SCHOLARSHIPS

Winter Scholarship	
Student	Project Title
Amarnath Sangeetha Menon & Igor Subasic De Azevedo	Development of a novel photo-angioplasty device for occlusive peripheral vascular disease
Sophie Moore	Autoimmune Hepatitis Database
Victoria Phan	Real-world treatment patterns and outcomes in advanced breast cancer
Felicity Huang	Five Year Follow up of Thunderstorm Asthma Cohort 2016 to 2021
Ian Wang	Pancreatic cancer: Understanding Routine Practice and Lifting End results (PURPLE)

Summer Scholarship	
Student	Project Title
Chen Wang	Development of a novel photo-angioplasty device for occlusive peripheral vascular disease
Neha Shibu	Real-world treatment patterns and outcomes in advanced breast cancer
Lucy Porter	INHALE - INvestigation of Health outcomes in Australian Lung canCEr Registry
Jacqueline Tse	Pancreatic cancer: Understanding Routine Practice and Lifting End results (PURPLE)
Felicity Huang	Audit of Large Vessel Vasculitis Involving the Aorta
Sadaf Zafir	Challenges and strategies for maintaining healthy romantic relationships when one partner is diagnosed with borderline personality disorder
Jiayi Zhang	The Experience of Chronic Pain in Individuals with Borderline Personality Disorder
Martin He	Assessing treatment effectiveness in people diagnosed with Borderline Personality Disorder
Miles Ong	Holding HOPE: Evaluation of a local Hospital Outreach Post-suicide Engagement program
Angela Ran	Improving management of Borderline Personality Disorder in Emergency Department settings

EASTERN CLINICAL RESEARCH UNIT (ECRU)

DIRECTOR: PROF IAN DAVIS

Eastern Health has a Memorandum of Understanding with Monash University that supports ECRU as the vehicle through which clinical trials are performed at Eastern Health. This model ensures that clinical research at Eastern Health is of the highest quality. The ECRU system includes oversight of clinical research governance across all research staff involved in clinical trials through ECRU, and provides a central system to ensure consistency of processes, documentation, budgets, financial oversight, trial logistics, management of consumables and equipment, ethics submission and post-approval processes, staff training, staff development activities, insurance and indemnity, GCP certification, and regular reporting. Most ECRU staff are employed by Monash University, and the Memorandum of Agreement ensures that credentialing and clinical governance are appropriately documented and meet the requirements of Eastern Health.

This model is an excellent example of how collaborations between a health service and a university partner can be mutually beneficial. The quality of clinical research performed through ECRU has enabled Eastern Health to achieve “super partner” status with contract research organisations such as IQVIA. This reputation and status in turn ensures that trials are frequently offered to us, and that our patients have access to the most up-to-date potential treatment options in addition to outstanding standard care. Eastern Health has full cost recovery through the transparency of ECRU finances. Surplus revenue is re-invested within EHCS and Eastern Health, with most of the resources going to support research capability, such as salary support for quarantined research time for fellows or for senior clinician-researchers.

The financial model ensures that resources are used judiciously and in such a way that underfunded research can also be supported productively, such as clinical trials initiated and led by investigators, or funded through grants. As a result, more than 40% of clinical trials performed at Eastern Health are of this nature, and about 75% of trial participants at Eastern Health are involved in such trials. This is critically important: industry-sponsored trials are immensely valuable, but investigator-initiated trials are invariably driven by medical or scientific need, and may represent attempts to fill gaps in the evidence base that cannot be filled by industry-sponsored trials. This is fundamental to Eastern Health’s commitment of “Patients First.” We are proud that Eastern Health made a policy of prioritising continuation of clinical trial activity during the COVID-19 pandemic, ensuring that our patients continued to have access to these vital options.

The advantage to Monash University is that its academic standing continues to grow as it actively supports academic clinical research through trials, with resultant high impact publications and grant funding. This environment is very attractive to students, trainees, and established clinician-researchers, and helps retain them in our system.

2022 saw the implementation of a new clinical trials management system (CRIO), which is also in use in various other major clinical research centres. CRIO will fill an important gap and address the attendant risks of a system where various processes and documents previously were paper-based but can now be electronic. This will reduce the risk of protocol deviations, enhance trial participant safety, ensure that documentation is completed in a timely fashion, and simplify processes and reduce time commitment for investigators. CRIO was funded through ECRU and is being implemented for new studies, with a view to expanding the coverage of existing and new trials over time.

ECRU continued to provide ongoing support for clinical trials in COVID-19. Support was also provided for other groups not usually associated with ECRU, including surgical disciplines (particularly urology and orthopaedics), intensive care, emergency medicine, women’s health, paediatrics, anaesthetics, and mental health. ECRU continues conversations with Epworth Healthcare regarding further support for trials at Epworth Eastern.




Fig 4: Breakdown of ECRU Trials in 2022 by Unit




Fig 5: Active ECRU Trials in 2022 by Recruitment Status

HEALTH SYSTEMS AND EQUITY

DIRECTOR: A/PROF JACQUELINE BOYLE

The Health Systems and Equity directorate was established in 2022 in response to an identified need to centre on, respond to, and involve the community in health research, and to focus on integrating improvements in care across health services and the health continuum.

We aim to do this by working across faculties including health, arts, and education, and working with health and social care providers across community, government, and non-government organisations. Our work aims to involve community at all stages.

Our methodologies include biostatistics, qualitative research and participatory research such as experience-based co-design. Some examples of our work include: working with the Migrant and Refugee Health partnership on ethical conduct in research with refugee and migrant communities, undertaking systematic reviews to assess individual and intervention characteristics on the effectiveness of prevention of gestational diabetes mellitus (GDM), using experience based co-design to integrate post-partum/interconception services for women after GDM in pregnancy, working with the preconception health network, and CRE Health in Preconception and Pregnancy to develop core indicators for monitoring or preconception health and healthcare.

Our team is growing and comprises three post-doctoral fellows and a number of PhD, Masters, and Honours students, and the MD Scholarly Intensive Program.

Our members have the following national and international leadership roles that facilitate stakeholder engagement and translation of research:

DR. SIEW LIM

- The American Diabetes Association: Chair in precision medicine GDM prevention group consensus report development
- Committee member International Society of Behavioural Nutrition and Physical Activity, Capacity Building Network
- Chair Equity, Diversity and Inclusion Working Group Nutrition Society of Australia
- Editorial Board member, International Journal of Behavioural Nutrition and Physical Activity

A/PROF BOYLE

- Chair of Steering Committee: Australian Health Research Alliance Women’s Health Research and Translation Network
- Co- Chair and convenor: National Preconception Health Network
- Council Member: Migrant and Refugee Health Partnership
- Member: RANZCOG Aboriginal and Torres Strait Islander Health Committee
- Member: RANZCOG Statements and Guidelines Group

RESEARCH GRANTS LED BY HS&E 2022:

PROJECT: REDUCING CARDIOVASCULAR RISKS IN WOMEN WITH A HISTORY OF GDM: A FOCUS ON EQUITY

This project will assess and address inequity in the Diabetes Victoria Life! Prevention program.

Funder: National Heart foundation Vanguard Grant \$75,000

Investigator Lead Dr. Siew Lim

PROJECT: EQUITABLE PRECONCEPTION CARE TO OPTIMISE PREGNANCY OUTCOMES

This project will undertake the first phase of experience-based co-design for inter-conception care for Chinese women who have had GDM

Funder: CRE HiPP \$10,000

Lead Investigator: Dr Siew Lim

PRECONCEPTION HEALTH RESOURCES FOR YOUNG PEOPLE IN THE NT

Funder: Victorian Assisted Reproductive Treatment Authority \$15,000

Lead Investigator: A/Prof Boyle

CONSUMER LED CO-DESIGN OF AN EFFECTIVE ONLINE AUDIT TOOL TO MEASURE CONSUMER AND COMMUNITY INVOLVEMENT IN HEALTHCARE

Funder: Eastern Health Foundation: \$30,000

Lead Investigator; A/Prof Boyle

Co-Production project development in women's mental health

Funder: Women’s Health Research and Translation Network \$40,000

Lead Investigator: A/Prof Boyle

STUDENTS IN 2022

PHD STUDENTS:

- Gebresilasea Ukke: Funded by Monash Graduate Scholarship and Monash International Tuition Scholarship
- Wubet Takele: Funded by Monash Graduate Scholarship and Monash International Tuition Scholarship

MPHIL STUDENT:

Ifeoluwa Adesina: funded by Advancing Women in Healthcare Leadership NHMRC partnership grant

AWARDS:

Dr Lim: FMNHS ECR Travel Grants \$3000 to attend the ADA Scientific Sessions

MONASH ADDICTION RESEARCH CENTRE

DIRECTOR: PROF DAN LUBMAN AM AND
DEPUTY DIRECTOR: PROF SUZANNE NIELSEN

The Monash Addiction Research Centre (MARC) has 130 academic members across 30 departments in six faculties and two institutes, making it one of the largest addiction centres in the world.

MARC’s mission is to provide national thought leadership, education, and research excellence to develop, deliver and evaluate effective policy and practice approaches for addiction.

In FY2022, MARC secured more than \$26M in research funding and published 207 peer-reviewed articles. This success demonstrates the enormous impact MARC members are making in the field of addiction, and the importance of interdisciplinary collaboration in finding solutions to the challenges of addiction.

In May, MARC held its annual symposium for the first time since 2019, bringing together everyone in one room to celebrate the incredible addiction-related projects being carried out across Monash by researchers at all career stages. Prof Alison Ritter AO, an international expert in drug policy, launched the day as the keynote speaker and we were fortunate to have Fiona Patten MP join us for our afternoon panel discussion ‘Changing the Conversation’.

In early 2022, MARC launched its new policy webinar series, bringing together a range of experts and voices to discuss and unpack current policy challenges and opportunities in the addiction field. The first in the series, ‘Making addiction a national priority - the need to end stigma’ was a resounding success with more than 250 registrations.

MARC also continued its professional development offerings for EMCRs with an in-depth policy workshop, as well as a science communication workshop series. MARC’s network of talented PhD students continued to grow and thrive, and we were delighted to see our first PhD scholars graduate.

In 2022, MARC continued to strengthen its policy and advocacy work, including a submission to the Commonwealth Post-Market Review of Opiate Dependence Treatment Program (ODTP) Medicines in October 2021. In March 2022, MARC published a position statement supporting the decriminalisation of the personal possession and use of small quantities of all prohibited drugs and contributed to, and were signatories of, a statement on the alcohol industry’s review of its Alcohol Beverages Advertising Code (ABAC) scheme.



Prof Suzanne Nielsen and Prof Dan Lubman AM

MARC SYMPOSIUM PRIZE WINNERS

Best PhD Poster Award – Sarah Haines for her poster presentation titled ‘Consumer experience of Prescription Drug Monitoring Programs (PDMP) in Victoria: Perspectives from people who use opioids to manage chronic pain.’



Sarah Haines

Best EMCR Poster Award – Dr Leanne Francia and Amelia Berg for their poster titled ‘Language Matters: The influence of language on treatment-seeking for people experiencing alcohol and other drug harms in hospital and primary care settings’.



Dr Leanne Francia and Amelia Berg

RESEARCH FUNDING

ENHANCING PHARMACIST INVOLVEMENT IN CARE (EPIC) MATOD IMPLEMENTATION STUDY

MARC Investigators: Prof Suzanne Nielsen, A/Professor Dennis Petrie, Dr Ali Cheetham

Funder: ADRIA

Access to Medically Assisted Treatment for Opioid Dependence (MATOD) is poor in many parts of Victoria, with a large geographic disparity in service provision. The Enhancing Pharmacist Involvement in Care (EPIC)-MATOD project has developed a model of care to expand treatment capacity by using community pharmacists at their full scope of practice, in collaboration with MATOD prescribers, in areas where access to prescribers is poor. The project is led by the Monash Addiction Research Centre and Frankston Mornington Primary Care Partnership’s RAD-FMP initiative, in collaboration with local and state government and peak professional and consumer organisations.

CRIMINAL JUSTICE OUTCOMES OF INJECTING DRUG USE AND METHAMPHETAMINE SMOKING

MARC Investigators: Prof Paul Dietze, Dr Bernadette Ward, A/Prof Mark A Stooze, Dr Keith Sutton

Funder: Australian Research Council

Injection drug use and methamphetamine smoking is associated with the majority of illicit drug-related harms and associated costs in Australia. This project will extend our studies of people who inject drugs and people who smoke methamphetamine through record linkage to social and criminal justice datasets. The project will characterise the trajectories of participants through social services (e.g. public housing) and law enforcement systems to provide a comprehensive account of social and criminal justice impacts of injection drug use and methamphetamine use in Australia for the first time.

RESEARCH PROJECTS

UNDERSTANDING EMERGING OPIOID-RELATED HARMS THROUGH IMPROVED SURVEILLANCE, DRUG CHECKING AND INFORMATION SHARING SYSTEMS

MARC Investigators: Prof Suzanne Nielsen, Dr Tina Lam, Louisa Picco

In Australia, increases in unintentional heroin deaths and overdoses have been observed in recent years, yet, it is not clear what is driving these changes. To understand rising opioid-related harms, there is a need for systems to gather timely information on changing opioid overdose patterns and risk factors, including the involvement of emerging drugs.

This project focused on developing novel methods for monitoring for emerging harmful substances.

This was a multi-centre project led by MARC’s Deputy Director Suzanne Nielsen and coordinated by MARC members Tina Lam and Louisa Picco, in collaboration with the Medically Supervised Injecting Room (MSIR) at North Richmond Community Health, the Uniting Medically Supervised Injecting Centre (MSIC), RMIT University, Western Sydney Local Health District, the Victorian Institute of Forensic Medicine (VIFM), the University of Technology Sydney, and the University of Lausanne, Switzerland.

This project was funded by the National Centre for Clinical Research on Emerging Drugs (NCCRED) Seed funding.

REACH - REDUCING ALCOHOL RELATED HARM IN GENERAL PRACTICE

MARC Investigators: Dr Liz Sturgiss, Prof Grant Russell, Prof Suzanne Nielsen, Dr Tina Lam, A/Prof Chris Barton

Alcohol is a major source of harm. More than 1200 deaths each year and 43,736 Disability Adjusted Life Years (DALYs) are attributable to alcohol in Victoria alone. Risky alcohol use has ramifications for health and wellbeing, and affects families and the wider community through absenteeism, family violence, assaults, and motor vehicle collisions. People from low-income groups are affected by alcohol related harms more, and at lower levels of alcohol intake, than people from higher income groups.

General practice plays an essential role in reducing alcohol-related harm in communities, as nearly 85 percent of Victorians see a GP at least annually. Brief interventions (BI’s) involve assessing the amount of alcohol a person is using, and offering individualised advice on how to reduce the associated health risks. These are effective in reducing the average amount of alcohol people consume in a week, and are recommended in the RACGP Preventive Care guidelines for all patients over the age of 15 years. Despite their effectiveness and the support for this approach in evidence-based guidelines, clinicians do not routinely provide this intervention in daily practice.

This project tested a new approach for embedding brief interventions for alcohol in general practice. The project team partnered with six general practices situated in low-income communities in North West and South East Melbourne to test a new package of resources. It used both qualitative and quantitative data to assess the acceptability, feasibility, and relative effectiveness of the intervention.

This project was funded by the Victorian Health Promotion Foundation.

MAPPING THE ALCOHOL AND OTHER DRUG PATIENT JOURNEY TO IMPROVE TREATMENT ACCESS AND ENGAGEMENT IN CARE

MARC Investigators: Prof Suzanne Nielsen, Dr Tina Lam, Dr Michael Savic, A/Prof Lisa Kuhn, Dr Nadine Andrew

Alcohol and other drugs (AOD) are involved in 137,000 Australian hospital admissions and 28 percent of ED injuries. This harm is preventable. Understanding patients’ journeys through health systems can inform more effective delivery of evidence-based treatments. This study used novel approaches to combine big data and qualitative methods, including graphical journey mapping, to comprehensively document the patient journey to identify opportunities for increasing connection to, and retention in AOD care.



This project was funded by the National Centre for Healthy Aging (NCHA) - Living Labs Program.

LABORATORY PROGRAM

EHCS provides support for the laboratory facilities at 5 Arnold St. Most of the work in the laboratory relates to the uro-oncology laboratory program, led by Prof Ian Davis and Prof Shomik Sengupta and concentrating primarily at present on urothelial bladder cancers. Key staff are Dr Pavel Sluka and Mr Hady Wardan, who perform most of the uro-oncology laboratory work but also provide essential support to multiple other units who use the lab facilities. Other units with substantial laboratory programs include nephrology, endocrinology, gastroenterology, oncology, haematology, and the ECRU-TRD program led by A/Prof Tony Dear. Many EHCS research higher degree students include laboratory projects as part of their research, and are ably supported and mentored by the lab team as well as their clinical and research supervisors. We also have a steady stream of scholarly intensive program students, or summer/winter scholarship students, who need laboratory services. ECRU clinical trials staff also need to use the services of the laboratory for various functions, such as the centrifuges or the -20°C or -80°C freezers or liquid nitrogen. The laboratory team is also responsible for the management of the laboratory, including OHS compliance measures.

The uro-oncology laboratory research program continued its productivity in 2022. We have developed a robust system for detection of very small amounts of tumour DNA, using panels of gene mutations that are frequently expressed in either muscle-invasive or non-muscle-invasive bladder urothelial cancers. The droplet digital PCR technique has now been tested in large numbers of patient tumour samples and we have shown it to be more accurate and sensitive than conventional Next Generation Sequencing techniques. We have used the methodology to look for tumour DNA in blood and in urine. The results of this work led to the award of an NHMRC Investigator Grant to Prof Davis, which will be used to support the laboratory components of a suite of clinical trials where the method will be applied. The overall objective is to identify patients at higher or lower risk of adverse cancer outcomes and to tailor their treatment accordingly, so that patients at higher risk can escalate their treatment while those at lower risk may be able to avoid unnecessary treatment. Some of this work has been supported with funding from the Eastern Health Foundation.

Our PhD student Ruchira Nandurkar and our MSurg student Mo Li used this technology as major parts of their research projects. The work continues with our current MSurg student, Antara Karmakar.

Other projects in the uro-oncology laboratory are:

- **Water irrigation:** Mo Li (MSurg student), Ruchira Nandurkar (PhD student). This project was funded by an ANZUP Below the Belt Research Grant. It showed that postoperative irrigation of the bladder with water after resection of non-muscle-invasive bladder cancers was safe, and may be an effective option to reduce recurrence or progression to invasive cancer. This is now the subject of an NHMRC Clinical Trials and Cohort Studies grant application and the outcome of the application is expected in early 2023.
- **Australian Multicentre Prospective Registry to Evaluate Practice and Patient Outcomes in Upper Tract Urothelial Carcinoma:** Josh Kealey (MSurg student). This project involves setting up a prospective registry to collect and analyse the patterns of incidence, diagnosis, treatment and outcomes of upper tract urothelial cancers, where clinical outcomes are less well understood and where data on management in Australia are lacking. The project is linked with an existing national database of bladder cancers, managed by ANZUP Cancer Trials Group.

RAMESH NAGAPPAN ACUTE CARE MEDICINE COURSE

A/PROF ROBERT MACGINLEY

2022 brought the next iteration of the Ramesh Nagappan Acute Care Medicine course, which has been running for the last 15 years and has continued in the last 7 since Ramesh's death. It provides a unique education opportunity to cover all areas of acute medicine in very practical lectures and case-based workshops that appeal to many. The junior doctor or final year medical student gets a unique 2-day comprehensive experience not otherwise available to them in their training. The middle level doctor gets an update for their career that allows them to use it as a comprehensive refreshing of skills and knowledge that practically is applicable to their everyday work. In addition, the unique curriculum also appeals to those consultants of varying specialities that get an “up to date” discourse on areas relevant to their day to day work.

The course is divided into three areas, including various acute medicine topics, critically unwell patients care, and some lectures in professionalism. All through the course are opportunities to test their mettle with regular quizzes. In the new hybrid format for 2022 we had half the audience online and the seamless delivery was a credit to our “tech” man Mr Peter Mellow. Similarly, the efficient comprehensive administration was due to the dedication of Ms Emma McRae. From 2021 we have had only the acute medicine topics, finding the small group Advanced Life Support sessions too difficult to provide due to COVID restrictions and the online or hybrid nature of the course. Eastern Health has started its own ALS courses for our cohort as a separate event.

Day one started with an opening lecture about the “new” education requirements that the Medical Board has prescribed for physicians. This was followed by a morning taking us through topics of severe airways disease, critical care of patients including some acute cardiac care and gastrointestinal bleeding, and an excellent discourse on the Public Health needs we face in 2022 (beyond those of COVID-19), which to all was a reminder that other issues have not left us.

Day two included the many facets of acute issues in the brain and nervous system and the acute issues facing people with cancer. Importantly the acute kidney issues were made clear. In addition, we learn more on how to care for ourselves as much as others.

Overall the course completed a successful weekend where both components of the hybrid format gave over 70 attendees their required teaching learning and assessment in this unique area of acute care medicine. The ACM remains a unique short course offering from Monash university in this key area of need.



RESEARCH VIGNETTES


THE DYNAMIC II TRIAL

ONCOLOGY (A/PROF RACHEL WONG AND DR MARGARET LEE)

Approximately 80% of patients with stage II colon cancer are cured with surgery alone. There is clinical equipoise regarding the benefit of adjuvant (postoperative) chemotherapy in this clinical setting, and may be considered in patients with high-risk histopathological features. Circulating tumour DNA (ctDNA) in peripheral blood can detect micrometastatic disease allowing for a more precise prediction of cancer recurrence. The DYNAMIC II trial was the first study to utilise ctDNA to inform adjuvant chemotherapy decision making in colon cancer.

The DYNAMIC II study randomly assigned 455 patients in Australia and New Zealand in a 2:1 fashion to either ctDNA-guided chemotherapy or clinician's choice (standard-management) of adjuvant chemotherapy. The primary outcome was recurrence-free survival (RFS) at 2-years, with a key secondary endpoint of chemotherapy use.

There was no difference in 2-year RFS between the groups (93.5% in the ctDNA-guided group versus 92.4% in the standard-management group). Chemotherapy was delivered to 15% of the ctDNA guided group versus 28% of the standard-management group. Therefore, the strategy of using ctDNA results to guide adjuvant chemotherapy decision choice in resected stage II colon cancer significantly reduces unnecessary chemotherapy without compromising the risk of cancer recurrence.



AMERICAN UROLOGICAL ASSOCIATION TV

UROLOGY (A/PROF CAROLINE DOWLING)

The American Urological Association (AUA), the world's biggest professional urological organisation, featured the Eastern Health Clinical School (EHCS)/Monash University Urology research team as part of AUA TV's Thought Leadership Series on diversity and inclusion.

The approach was made due to the AUA's interest in the functional urology work being done at Eastern Health, with a focus on the amazing female research team at EHCS/Monash University, led by Associate Professor Caroline Dowling and Professor Shomik Sengupta.

The video also featured Dr Antara Karmakar (Master of Surgery student), Dr Ruth Snider (Master of Surgery student), and Ms Ruchira Nandurkar (PhD student).

The video was themed around 'community care meets research excellence', with a narrative around a network that has grown out of the amalgamation of community hospitals and services. This network must continue to deliver high volume, high quality work across a vast area, whilst maintaining a 'community feel', and being inclusive of patients and staff. This is now coupled with burgeoning research and education and the management of complex conditions in a much more tertiary/quaternary/university hospital setting.

Associate Professor Dowling said the AUA TV feature was "a terrific honour and opportunity for the unit, Eastern Health and EHCS". Video link [here](#).



UNIT HIGHLIGHTS

AGED MEDICINE RESEARCH AND TEACHING

PROF PĒTERIS DĀRZIŅŠ

ADaPt EH PROJECT

The Actionable Dashboards Project at Eastern Health (ADaPt EH) goes from strength to strength. This collaborative work between the Digital Health CRC, Monash (EHCS and FIT), Eastern Health, ACHA and the Victorian Department of Health involves the development, delivery and evaluation of dashboards generated from the EMR reflecting measures and indicators for the ACSQHC Standards. Greg Duncan is the Project Manager and Cathy Ngo the EHCS Research Fellow, with Ian Davis and Pēteris Dārziņš as investigators on the Project Control Group.

Initial plans were to trial the effect of dashboards on workloads and workflows in preparation for quality assessment cycles, but ACHA has announced a move to short notice assessments requiring a shift in focus and evaluation. The dashboards available to date (Standard 7 Blood Management and Standard 4 Medication Safety) have been very well received and already considered for how they may be further extended into clinical care. Interim assessment has been overwhelmingly positive with increasing pressure for further development. Interest in the dashboards and requests for extensions have led to explorations for further funding and resources to deliver the remaining dashboards more quickly and include a number of “live” dashboards reflecting high risk issues for current inpatients. Fingers crossed for that project extension! If you wish to view the dashboards or find out more about them contact Greg Duncan (Gregory.duncan@monash.edu) or Cathy Ngo (Cathy.ngo@monash.edu) for a chat and arrange a demonstration if you haven’t already seen them.



FINAL SIGN-OFF FOR COMPLETION OF THE DCMEDSREC PROJECT

From 2018 to 2021, the Australian Digital Health Agency funded a research program to pilot new digitally enabled models of care through partnerships between industry, government and healthcare provider organisations. This program, named the Digital Health Test Beds, funded 15 test beds to stimulate innovation consisting of exploratory research projects where new innovations and ideas were tested in real-world settings to pilot immediately usable solutions with a particular focus on the use of My Health Record (MHR).

Monash EHCS led a successful application in partnership with Eastern Health and the Pharmaceutical Society of Australia, with Greg Duncan and Pēteris Dārziņš leading the project and Cathy Ngo as the project Research Fellow.

This implementation test bed explored the adaptation and adoption of new digital ways of working in the community pharmacy setting. For the first time, using MHR, community pharmacists had systematic access to discharge summaries and other relevant information about a patient’s hospital admission. For the intervention a structured post-discharge medicines reconciliation service named DCMedsRec was developed using discharge summaries from a patient’s MHR alongside other sources to create a best possible medication history, and identify and resolve any discrepancies between medications and records. Finally, a Health Literacy focussed systematic counselling session was delivered to consolidate understanding of current medication use. The outcome of interest was 30-day unplanned re-admissions, measured using the EH Electronic Medical Record. 54 community pharmacies in the Box Hill Hospital catchment area delivered the service.

This test bed aimed to:

- Develop and evaluate a community pharmacy-based medicine reconciliation service designed to integrate with the MHR Discharge Summary.
- Determine any barriers to its wider implementation.

RESULTS

The project was planned as a randomised controlled trial but the pandemic and public health messages to ‘stay at home’ severely disrupted patient recruitment early in the implementation, and ultimately led to closing recruitment and not achieving participant numbers planned. However, a number of very positive outcomes were achieved including identifying barriers and facilitators to implementation of such work and recommendations for future activities in the field.

Through this test bed, an intervention that uses MHR to support medicine reconciliation in a community pharmacy setting was developed and piloted. Positive feedback on the solution was received from all main stakeholders (patients, community pharmacists and hospital pharmacists), highlighting the benefits of undergoing a systematic process to generate a best possible medication history. Both community and hospital pharmacists noted that this intervention could “close the loop” as it offered community pharmacists access to discharge summaries and hospital pharmacists the ability to support long-term community care. A wider implementation of this intervention could potentially reduce medicine misadventure risks in the post-discharge process and support a service-focused rather than supply-focused approach to patient care.

PRESENTATIONS

Nicola Hogan. Management of behaviours of concern and psychotropic deprescribing in the COVID-19 Supportive Care Unit

CARDIOLOGY

DR JENNIFER COOKE, A/PROF ANDREW TEH,
A/PROF JAYA CHANDRASEKHAR, DR LOUISE ROBERTS

Clinical research continues to be a vital aspect of our department. As always, there were many people who were involved in conducting research including our research coordinators, led by Dr Louise Roberts, medical students, junior medical staff, and cardiology advanced trainees.

There is no doubt the COVID pandemic affected many of the investigator initiated clinical studies, for a variety of important reasons. In light of this change in circumstances, our unit decided to pivot our existing research interest in the use of smart devices towards their use in COVID patients, for which we received generous funding from the Eastern Health Foundation. We were able to successfully collaborate with the Austin Hospital to recruit 200 inpatients with COVID 19 and compare the accuracy of two smart watches with gold-standard pulse oximetry. The results of this study were presented by Dr Kevin Rajakariar, one of our advanced trainees, who was selected as a finalist for the basic/advanced trainee new poster prize at the Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand 2022 and awarded 2nd place at the annual Eastern Health Division of Medicine Research Awards.

Despite the COVID pandemic cutting patient recruitment short, our research into the role of smart watches in the diagnosis of atrial fibrillation, funded by the Eastern Health Foundation, resulted in an important publication by Dr Chris Ford in JACC: Clinical Electrophysiology.

Research collaboration remains an important aspect of our clinical research at Eastern Health. One example was a randomised trial of intravenous magnesium for management of atrial fibrillation, a collaborative study between the cardiology and emergency departments across Box Hill and Maroondah Hospitals, which was also funded by the Eastern Health Foundation. The results of this study were also published in JACC: Clinical Electrophysiology. Ongoing collaborative research with the emergency department remains active at Eastern Health, as well as collaborative studies into unexplained stroke with the neurology department.

Eastern Health's cardiology unit continues to be involved in the state-wide Victorian Cardiac Outcomes Registry and the Melbourne Interventional Group registry. Publications as a result of this involvement included a study by one of our previous cardiology residents Dr Hamish Prosser (now an advanced trainee in New Zealand), published in Clinical Research in Cardiology. This confirmed the benefit of ACE inhibitors in patients post percutaneous intervention for acute coronary syndrome, including those with preserved ejection fraction.

A/Prof Jaya Chandrasekhar was awarded an Eastern Health Foundation grant for platelet reactivity testing for antiplatelet drug-responsiveness in patients with coronary stents.

A high bleeding risk is increasingly being recognised in patients undergoing coronary stenting and requiring treatment with two blood thinners. The blood thinner combination of aspirin and clopidogrel or aspirin and ticagrelor for 12 months is routine post coronary stent. In patients with high bleeding risk and in patients experiencing bleeding events, physicians will consider de-escalation of treatment by stopping aspirin and continuing clopidogrel or ticagrelor alone (monotherapy). One-third of patients in general, however, are clopidogrel non-responders, in whom clot tendency and risk of recurrent clinical adverse events may remain enhanced despite medication use. Ticagrelor is more potent than clopidogrel and despite monotherapy may result in higher bleeding risk. Switching to monotherapy in these patients without objectively testing platelet responsiveness may be deleterious.

This project will fund the purchase of the equipment for platelet reactivity testing in patients with high bleeding risk being considered for monotherapy. Demonstration of high platelet reactivity on clopidogrel or low platelet reactivity on ticagrelor will allow the physician to re-evaluate the best ongoing therapy for a given patient.

DERMATOLOGY

PROF JOHN SU

Dermatology clinical trials at Eastern Health in 2022 continued to focus on new therapies for inflammatory skin diseases including atopic dermatitis (abrocitinib, upadacitinib, and eblasakimab), alopecia areata (ritlecitinib), bullous pemphigoid (dupilumab), and generalized pustular psoriasis (imsidolimab). Drs Su and Yazdabadi are currently leading a multicentre study examining comorbidities and disparities in health care of inflammatory dermatoses with a particular focus on atopic dermatitis. Dr Su also continues a Monash University collaboration with Dr Adrian Lowe at the MSPGH on the PEBBLES study examining risk factors and preventative strategies for atopic dermatitis.

Dr Ly is coordinating an Australian consensus statement on the management of paediatric eczema led by our department and has recently produced a podcast for Eastern Health with Dr Van Ammers on skin biopsy technique. Our department continues to host a national eczema education day for the Australasian College of Dermatologists. Dr Su was recently nominated to join the scientific committee for the International Society of Atopic Dermatitis and will also present three invited lectures at the World Congress of Dermatology this year. He is also honoured to represent Monash University and Eastern Health in hosting the 15th International Symposium of Atopic Dermatitis in Melbourne, 2025, the centenary of the birth of its founder George Rajka.

EASTERN CLINICAL RESEARCH UNIT TRANSLATIONAL RESEARCH DIVISION (ECRU-TRD)

A/PROF ANTHONY DEAR

ECRU-TRD operations commenced a return to normal activities during 2022, reflecting a relaxation of most restrictions associated with the COVID-19 pandemic. The Unit continued to advance several translational research projects including: i) repurposing of epigenetic drugs for prevention and treatment of COVID-19; ii) evaluation of anti-thrombotic activity of novel type 2 diabetes treatments to prevent complications of vascular disease; iii) clinical evaluation of a novel medical treatment for abdominal aortic aneurysm (AAA) disease; and iv) development of a novel photo-angioplasty device “Lumi-Solve” for the management of post-angioplasty restenosis in peripheral vascular disease.

Whilst the COVID-19 pandemic has been largely controlled with the development of effective vaccines and delivery programmes intense interest remains in discovering novel non-vaccine-based therapies for the prevention and treatment of severe COVID-19. Repurposing of existing, approved agents for the prevention and treatment of severe COVID-19 disease offers an attractive option in this space. We have identified the epigenetic drug romidepsin, currently used in the treatment of blood cancers, as an agent with promising therapeutic potential in the management of COVID-19 with our studies demonstrating inhibition of the critical ACE2 molecule required for cellular entry of the SARS-CoV-2 virus. Our ongoing studies will evaluate the mechanisms of action of romidepsin-mediated reduction in ACE2 expression to further characterise the potential therapeutic benefits of this agent.

The Metformin in Abdominal aortic aneurysm Trial (MAT) continued to recruit patients both nationally and internationally with EHCS among the top-ranked national recruitment sites. The trial aims to evaluate the well-established anti-diabetic medication metformin for its potential to offer, for the first time, the exciting prospect of a medical treatment to prevent AAA growth and rupture.

ECRU-TRD recently published results of a pilot clinical trial undertaken by the Unit of the GLP-1R agonist liraglutide; The Evaluation of Liraglutide Antiplatelet Activity in Type 2 Diabetes (ELIAD) trial. The trial assessed the potential anti-thrombotic effects of the anti-diabetic medication liraglutide, with results suggesting further benefits for patients with type 2 diabetes treated with GLP-1R agonists in the prevention of vascular disease via a subtle anti-thrombotic action.

ECRU-TRD together with its collaborators at the CSIRO, Baker Heart and Diabetes Institute, Monash University's Institutes of Medical Engineering (MIME), Department of Diabetes and Pharmaceutical Sciences (MIPS) together with the recent addition of the University of Queensland continue to develop Lumi-Solve, a novel light-activated angioplasty device for the treatment of arterial restenosis post balloon angioplasty. Improvements in Lumi-Solve prototype design have generated a significant novel intellectual property portfolio and have stimulated successful partnering with potential manufacturers heralding an exciting new phase in the development of the device.

ECRU-TRD continues to foster an environment supportive of academic endeavour at undergraduate and postgraduate levels with a broad range of translational research projects available to students. A number of medical, biomedical and engineering students have made significant contributions to the Unit's translational research projects during 2022 including Amarnath Sangeetha Menon, Kylie Choong, Dhruv Bhatnagar and Chen Wang (Medicine, Monash University) together with Aldous Tria, Loren Spiegel, and Anak Dharma (Engineering, Monash University).

Publications and Useful Links

<https://pubmed.ncbi.nlm.nih.gov/33966506/>
<https://pubmed.ncbi.nlm.nih.gov/35382966/>
<https://globalhealthasiapacific.com/global-health-asia-pacific-may-2022-may-2022/0806529001654063794>
(page 9 of magazine)

EASTERN HEALTH INTENSIVE CARE RESEARCH (EHICR)

A/PROF GRAEME DUKE

OUR RESEARCH TEAM

Research doesn't happen without help from nurses, doctors, data analysts, Allied Health, ward clerks, administration assistants and equipment staff. We are grateful for the support from so many people in ICU and across Eastern Health.

The Eastern Health Intensive Care Research Team has undergone a review and restructure to facilitate and optimise our support of all research-related activity across all three campuses, embed this into regular clinical practice, support all our staff to see and experience research as an essential component of clinical care. Our dedicated research support team now includes a clinical lead (Graeme Duke), a Clinical Research Manager (Nicole Robertson), Research Nurse (Kym Gellie), Intensive care Research data analyst (Steve Hirth), and PhD supervisor (Peter Chan), with most of our senior clinicians taking on roles as principal investigators as outlined below. We thank all the intensive care staff for assisting us with screening, enrolling, data collection and entry. We also thank the Eastern Health Human Research Ethics Committee and the Eastern Health Executive for their advice and support of this endeavour.

CONTACTS

- A/Prof Graeme Duke – graeme.duke@easternhealth.org.au
- Nicole Robertson – nicole.robertson@easternhealth.org.au
- Kym Gellie – kym.gellie@easternhealth.org.au
- Dr Peter Chan – peter.chan@easternhealth.org.au

PHD COMPLETED

Candidate: Dr Peter Chan. Title.: **Non-Contact Patient Monitoring in the Intensive Care Unit using Infrared Thermography**. School of Public Health and Prevention Medicine, Monash University, Victoria, Australia



Cheelim Liew , Kym Gellie, Nicole Robertson and Jenny Ng

TRIALS COMPLETED IN THE PAST 12-MONTHS

- **Validation of Infrared Video for monitoring vital signs.** Principal investigator: *Peter Chan (specialist)*
- **Nurse Decision making and the management of vasoactive medications.** Principal investigator: *Stephanie Hunter (research nurse 2017-2022)*. PhD program
- **INTENT** - randomised controlled multicentre study of supplemental parenteral nutrition in patients unable to receive full enteral nutrition. Principal investigator: *Lina Breik (ICU dietitian)*
- **Hospital-acquired complications:** the relative importance of hospital - and patient - related factors. Published Med J Aust. doi:10.5694/mja2.51375. Principal investigator: *Graeme Duke*
- **PATIENTEER** - extended 12-month pilot project to investigate use of eMR data to improve clinical decisions and real-time monitoring of patient status and outcomes. Principal investigator: *Peter Chan (specialist)*
- **COBRA:** Code Blue Retrospective Audit in a Metropolitan Hospital. doi: 10.1111/imj.15637. *Rob Paul (Advance trainee)*
- **ICED in the ICU** - documentation of ICU daily goals of care. Principal investigator: *Nick Ryan (Advance trainee)*
- **Expert consensus guidance on chest physiotherapy and rehabilitation of patients with rib fractures:** an international, multi-disciplinary expert panel e-Delphi study. *Investigators - EH Physiotherapy Department.*
- **Physiotherapy services in intensive care. A workforce survey of Australia and New Zealand.** Profile current ICS physiotherapy services and make recommendations to ANZICS to be included in their update Minimum Standards for Intensive Care. Investigators - *EH Physiotherapy Department*
- **Allied Health COVID education** - EH Physiotherapist developed framework for PT skills development to a minimum skillset of ICU. *Lead investigator: Val Bulmer/ Jacinta Simpson*
- **Intra-abdominal pressure monitoring** - assessing local knowledge on intra-abdominal pressure set-up, monitoring and reporting. *Principal Investigator: Simon Nourish (ICU CNS; Master's program.)*

CURRENTLY ENROLLING MULTICENTRE TRIALS

- **BLENDER** - randomised controlled trial of liberal vs conservative O2 therapy during ECMO. Principal investigator: *John Dyett (specialist)*. Box Hill Hospital is 2nd highest recruiting site
- **REMAP-CAP** - international registry and platform trial of interventions for community acquired (including viral pandemic) pneumonia. Principal investigator: *Joanne Simpson (specialist)*
- **ARISE** - multicentre randomised controlled trial in ANZ comparing fluids or vasopressors in sepsis; joint project with Emergency Department. Principal investigator: *Paul Buntine (ED physician)*

INTER/NATIONAL RESEARCH REGISTRIES

- **SPRINT-SARI** - continuous national registry for COVID positive patients. Principal investigator: *Peter Chan (specialist)*
- **EXCEL** - continuous national registry of ECMO delivery and outcomes. Principal investigator: *John Dyett (specialist)*
- **ECMOCARD** - continuous international registry of COVID positive patients needing mechanical ventilation or ECMO for respiratory failure. Lead investigator: *Cheelim Liew (nurse specialist)*
- **ELSO** - continuous Extracorporeal Life Support Organization (ELSO) Registry; a comprehensive international data registry of patients receiving ECMO, supporting clinicians clinical research, and regulatory agencies. *John Dyett, Cheelim Liew.*
- **ANZICS Point Prevalence Program** - annual snapshot observational survey of current clinical practice in intensive care focusing on specific therapies not reported elsewhere. Lead investigator: *Graeme Duke (specialist)*
- **ANZICS APD Data** - continuous detailed de-identified clinical data registry of all ICU admissions submitted weekly. Principal investigators: *Steven Hirth / Graeme Duke.*
- **ANZICS Critical Care Resources report** - annual audit of clinical activity and clinical resources compared to national benchmarks. Principal investigators: *Graeme Duke/Steve Hirth/Di Parker.*

EASTERN HEALTH (LOCAL) RESEARCH PROJECTS

- **MET Prediction Tool** - predictors of ED admissions at high risk for MET. Principal investigator: *Joanne Simpson (specialist)*
- **TOM-CAT** - a pilot study of tissue oxygenation using mechanical vs conventional chest compression in adult in-hospital cardiac arrest. Lead investigator: *Cheelim Liew (nurse specialist)*.
- **Clinical Decision Support for Mechanical Ventilation** - analysis based on real-time eMR data. Principal investigators: *Steven Hirth / John Dyett.*
- **Clinical evaluation of the national hospital acquired complication program** - ongoing audits of ICU, Subacute (PJC), acute care, and Anaesthesia complications. Principal investigator: *Graeme Duke (specialist)*.
- **DECODE** - audit of care of the dying patient in ICU. Principal investigators: *Graeme Duke, Maria de Freitas.*
- **EPIC: Geographic access to Extra-corporeal Membrane Oxygenation (ECMO) in Victoria** - demographics of the Victorian ECMO population utilising geographic 'heat' and choropleth mapping to quantify access according to socioeconomic status and origin of referral. Lead investigator: *Joanna Chow, Julia Hart, John Dyett.*
- **SWIFT** - Staff Wellbeing in the Front Line. Tracking nurse wellbeing using shift allocations. Lead investigator: *John Dyett (specialist)*
- **SEPSIS Alerts** - retrospective review of Lighthouse sepsis alerts in eMR. Lead investigator: *Eanna Lowney (advanced trainee ICU)*
- **Trainee Assessment and ICU Feedback Process.** Principal investigator: *Philippe LeFevre (specialist)/ Steve Hirth.*
- **Audit of Clinical Documentation in ICU** - admission note, Daily Goals of Care, ANZICS data, Discharge Summary. Principal investigators: *Graeme Duke/Steve Hirth*
- **Vent On** - audit of eMR documentation of patient ventilation hours for ANZICS reporting. Principal investigator: *Nicole Robertson (Research Coordinator)*
- **Arterial Blood Gas order eMR workflow** - ICU EMR Special Interest Group.

FUTURE TRIALS

- **Mega-Rox** - MEGA randomised Registry Trial comparing conservative vs liberal oxygen targets starting in March 2023
- **Bone Zone** - randomised controlled trial, evaluating bone loss prevention with Zoledronic Acid or Denosumab in Critically Ill Adults starting in mid 2023.
- **Ganaxolone** - a double-blind, randomized, placebo-controlled study in conjunction with Neurology Service to evaluate the efficacy and safety of IV Ganaxolone in status epilepticus, starting in 2023. Principal investigator: *A/Prof Patrick Carney.*

EMERGENCY MEDICINE RESEARCH

A/PROF PAUL BUNTINE

The Emergency Program has continued its rapid expansion through 2022, with a major theme being one of collaboration. We continue to work with many units across Eastern Health, including mental health, SPECTRUM, cardiology, neurology, ICU, aged care medicine, pharmacy, and allied health, and are involved in ongoing projects with Austin Health, Monash Partners, Deakin University and Monash University. Our publication count continues to rise, with 15 peer review publications and 1 commentary published in 2022, in addition to multiple student and junior clinician posters presented at ICEM and the ACEM Spring Symposium. Highlights of this research program include:

- An ongoing collaboration with SPECTRUM and mental health to improve the care of individuals with borderline personality disorder across our EDs. This program of research continues to grow and has benefited enormously by the incorporation of several lived experience team members from SPECTRUM.
- We received the first ever internationally awarded grant from the Society to Improve Diagnosis in Medicine for the FORMAT project, a collaborative project with Aged Medicine. This InReach initiative involves the upskilling of clinical and nursing staff to form a small falls assessment team to allow onsite assessment of residents of aged care facilities rather than sending patients to ED for assessment. A pilot intervention in 2022 resulted in >90% of patients assessed being able to stay in their place of residence, with overwhelmingly positive feedback from their carers and families. The grant money will allow us to rigorously examine various research outcomes for incorporation into future improvement cycling.
- Involvement as a recruitment site for the NHMRC funded ARISE-fluids study. This important study will compare early sepsis resuscitation strategies. We are currently recruiting at Box Hill and Maroondah EDs, with a go live date for Angliss set in early 2023.
- Contribution to the EDNAV registry – this project, coordinated via Austin Health and the Forensics Department, aims to identify emerging patterns in recreational drug use via pathology sampling from ED attenders who present with an altered conscious state after using an illicit substance. Reports are generated weekly and disseminated to participating EDs to inform clinicians regarding current recreational drug use patterns across metropolitan Melbourne.
- Supervision of 4 Monash SIP students and 2 PhD students. Few ED research studies are funded and there is limited capacity for ED clinician involvement in research during their busy clinical shifts. As a result of this, the contribution of these students to our research capability is substantial and I am continually impressed by the outcomes that can be achieved during a very short SIP rotation. Congratulations to Nesreen Musameh for winning the best overall 2022 SIP oral presentation award for her work analysing results from a survey examining ED staff baseline attitudes and knowledge regarding individuals with BPD.



ENDOCRINOLOGY

PROF CHRIS GILFILLAN

The endocrinology unit at Eastern Health covers inpatients at 3 acute hospitals and outpatients through 18 clinics across the eastern suburbs of Melbourne. We service patients in our region with endocrine disorders including diabetes, thyroid disorders, metabolic bone disease, pituitary and adrenal disease, and dyslipidaemias.

Research is an integral part of the activities of the unit from Scholarly Intensive Projects completed by final year medical students through higher degrees undertaken by graduates who have completed specialty clinical training to sponsored clinical trials of new therapeutics in endocrinology. Recently, as a result of our excellent reputation as recruiters we have been involved in several trials of second and third generation COVID-19 vaccines.

INVESTIGATOR INITIATED PROJECTS

- Novel therapeutics in thyroid cancer: A project examining the effects of SMAC mimetics in combination with a library of compounds looking for synergistic effects in reducing cell viability. The project has identified combinations of promise and is now exploring mechanisms of synergy (funded by EH foundation) (PhD project Shan Balachandran).
- ctDNA in thyroid cancer: A project examining the feasibility of monitoring cell-free circulating tumour DNA (ctDNA) in patients with advanced thyroid cancer and the effects of redifferentiation therapy and I-131 on ctDNA detection as an exploratory aim of the I-First clinical trial (funded by MRFF). In addition, patients will be recruited to a long term study of ctDNA in predicting recurrence in low risk thyroid cancer treated with hemithyroidectomy alone (PhD Project Hui Yi Ng).
- Biofeedback on the glycaemic impact of food: A project extending the work of an earlier grant seeking to change health-related behaviour in diabetic and pre-diabetic patients by using an artificial intelligence algorithm to identify foods and forewarn the user of the likely glycaemic impact of a meal, based on individualised continuous glucose monitoring (funded by Monash Institute of Medical Engineering).
- The introduction of a cloud-based remote monitoring system for patients with gestational diabetes with the aim of improving glycaemic and clinical outcomes and improving the healthcare experience for both patients and clinicians and reducing the cost burden on the health system. The response to implementation will be measured and analysed to provide evidence of benefit along the axes indicated above (funded by Net-Health corporation) (PhD project Dr Will Lau).
- Skeletal muscle health in older women after hip fracture. Supplementary work on existing samples examining RNA expression and pathway activation. This will be complementary to the skeletal muscle mass measurements, histopathology, and protein expression work already undertaken (Funded by the EH foundation) (post-doctoral work Ming Li Yee).

HIGHER DEGREES

PhDs

- Shan Balachandran – Novel therapeutics in thyroid cancer (mid candidature review completed)
- Hui Yi Ng – ctDNA in thyroid cancer (in first year of part time PhD)
- William Lau – Implementation of remote monitoring system in gestational diabetes (commencing in 2023)

REGISTRAR COLLEGE PROJECTS (PART OF FRACP REQUIREMENTS)

- Mitchel Munnings: An audit of adrenal incidentalomas and outcomes of investigation
- Frank Gao: An audit of hyponatraemia presentations during COVID
- Yeung Ae Park: Pseudo Cushing's syndrome

SCHOLARLY INTENSIVE PROJECTS (MEDICAL STUDENTS)

- Rahdika Chalikavada: Utilizing artificial intelligence systems to promote real-time dietary feedback and healthy behavioural changes in diabetes management; the Glook 3!! Trial
- James Caleo: An audit of the adrenal vein sampling service following its implementation in 2020

SPONSORED CLINICAL TRIALS

Foresight: A trial of a long acting preparation of growth hormone compared to conventional therapy in adult growth hormone deficiency

Astra Zeneca MEDI-0832: A trial of a GLP1/glucagon agonist in the treatment in patients with type 2 diabetes and chronic kidney disease

BI obesity 1404-0036 (Boehringer Ingelheim): A trial of a GLP1/Glucagon agonist as a weight loss medication in patients with obesity

BI 1404-0002: A trial of a GLP1/Glucagon agonist on the treatment of patients with type 2 diabetes compared to semaglutide

BI 1404-0038: A trial of a GLP1/glucagon dual agonist in the treatment of obese non-diabetic subjects

BI 1404-0041: A trial of a GLP1/glucagon dual agonist in the treatment of subjects with type 2 diabetes

CLEAR: A trial of a new non-statin cholesterol lowering therapy to prevent cardiovascular disease in patients with statin intolerance

GPGN (Lilly): A trial of a GLP-1/GIP agonist in the treatment of type 2 diabetes to prevent cardiovascular disease

GPIJ (Lilly): A cardiovascular outcomes trial of a GLP1-GIP dual agonist in obese subjects without diabetes but with CVD

PROLIA: A study comparing persistence with denosumab versus alendronate in the treatment of osteoporosis

Novovax 2019nCov-311: COVID vaccine trial - phase 2 of this trial soon to commence

Lilly (GZBK, GZBM, GZGQ): Three trials of a GLP1/GIP/glucagon triple agonist for the treatment of obesity complicated by cardiovascular disease, obstructive sleep apnoea and type 2 diabetes

Pfizer C3991026: Trial of an oral GLP1 agonist in patients with diabetes

GASTROENTEROLOGY

PROF AMANDA NICOLL

The Department of Gastroenterology has remained actively involved in a range of clinical and translational research throughout 2022. This has been under the directorship of Professor Amanda Nicoll, supported by senior clinician researchers including Dr Rohit Sawhney, Dr Stephen Bloom, Dr Alex Hodge, Dr Abhinav Vasudevan, and Dr Ola Niewiadomski. Our research team also includes study coordinators led by Ms Emma Dimitri and assisted by Ms Sasha Trantino and Ms Adele O'Brien.

We have one PhD student currently, Dr Anuj Bohra, who is on track to submit his PhD in 2023, on enhancing disease assessment modalities in Crohn's disease. Ms Hannah Silva and Dr Ashish Srinivasan have submitted their theses for assessment. Dr Diana Lewis was awarded her PhD earlier this year.

This year, one of our consultants, Dr Charlotte Keung, won the prestigious Douglas Piper Award for the best young researcher at the Australian Gastroenterology Week for her work on use of Allogeneic Human Amnion Epithelial Cells in refractory perianal Crohn's disease.

The IBD clinical/research fellowship position is continuing with a focus on up-skilling Advanced Gastroenterology Trainees in the management of inflammatory bowel disease, and combines clinical duties with research and education. Similarly, the Hepatology fellowship continues to support research and further clinical experience in hepatocellular carcinoma, fatty liver disease, and drug-induced liver injury, and improving the management of cirrhosis.

The Unit continues to be active with investigator-initiated studies in fields of inflammatory bowel disease including through the ANZIBD consortium (AURORA, PROACTIVE), hepatocellular cancer (pro-FAITH), autoimmune/cholestatic liver disease (PROSPER), viral hepatitis, drug induced liver injury, and cirrhosis and portal hypertension, enabled by valuable collaborations with other departments at Eastern Health (including haematology, psychiatry and pharmacy), as well as colleagues in Victoria, interstate and overseas.

We are actively participating and recruiting for many pharmaceutical trials investigating cutting edge treatments for inflammatory bowel disease, hepatocellular cancer, alcoholic hepatitis, cirrhosis, and portal hypertension.

Numerous publications have been achieved in the last year by researchers in our group on varied topics including therapies and outcomes in IBD, the role of imaging in inflammatory bowel disease, hepatitis C as well as treatment and outcomes of hepatocellular cancer. We have presented our research at local and international meetings.

GENERAL MEDICINE

A/PROF GARY YIP

The Department of General Medicine, by virtue of its throughput, is able to engage consistently in Health Economics research in the context of each new model of care or new care pathway that is implemented at scale. A leading example is presented here.

REFRESH (REDUCING HEART FAILURE READMISSIONS AT EASTERN HEALTH) PROGRAM

The burden of disease of heart failure exacerbations on acute hospital utilisation is well documented. The majority of patients presenting to EH with this condition are admitted to General Medicine. Launched in 2022, REFRESH is a multi-intervention quality improvement program aimed at reducing heart failure readmissions. This collaborative venture between General Medicine and Cardiology was initially kickstarted by sponsorship from Safer Care Victoria, and has continued to gather momentum.

The interventions that have been implemented are:

- Electronic Medical Record heart failure 'powerplan' to streamline investigations, treatment and follow-up for inpatients;
- Heart failure ambassador nurse review of inpatients at Box Hill Hospital;
- Promotion of Hospital in the Home (HITH) for patients to receive treatment at home, thereby reducing inpatient bed days;
- Patient education template embedded into the 'Talk to you tomorrow' service that provides rapid follow-up post-discharge;
- Dedicated General Medicine Heart Failure specialist clinics at Box Hill and Maroondah Hospitals.

In the planning phase are other interventions including an electronic heart failure medication checklist, and a repurposed COVID monitor program to facilitate heart failure self-monitoring with feedback guidance in the community.

The overarching research has as its primary outcome 30-day all-cause readmissions, and secondary outcomes of length of stay, proportion of patients who receive HARP and cardiac rehabilitation support, HITH utilisation, and cost analysis. Data for publication are anticipated to become available in late 2023.

General Medicine also collaborates consistently in research with its key partner, the Department of Pharmacy, due to the implications of quality use of medicines in the frail patient population. Through the support of an Eastern Health Foundation grant, an investigator-initiated prospective cohort study of rational use of antipsychotic medications was conducted in 2022.

FORGET-ME-NOT STUDY

The objective was to evaluate the impact of a suite of interventions on the pattern of antipsychotic medication prescribing at the 12-week timepoint post hospital discharge. Specifically, patients who were discharged on one or more antipsychotic medications prescribed for the indication of delirium or dementia, were given a "forget-me-not pack." The pack primarily includes an authoritative information sheet on delirium and dementia, courtesy of Dementia Australia and the Australian Commission on Safety and Quality in Health Care.

The more active intervention is a written 'deprescribing plan' that is tailored by a senior pharmacist (and co-signed by medical team members) for each individual enrolled patient, that is then communicated verbally and in written form with the patient's general practitioner.

The premise is that the patient and carer are empowered and prompted by the information sheet to ask their general practitioner about the role and timing of deprescribing, and the general practitioner is aided by a hospital endorsed recommendation on the schedule for deprescribing. The primary research outcome is the proportion of patients in whom there was cessation or reduction of the target antipsychotic medication at 12 weeks post discharge. Final analysis and publication occurs in late 2023.

In terms of individual achievements, a member of our specialist physician staff, immunologist Dr Jason Fok, was this year appointed as Associate Education Editor on the editorial board of The Journal of the Royal College of Physicians of Edinburgh, which is the beginning of an international academic collaboration.

GERIATRIC ONCOLOGY

DR WEE-KHENG SOO

I am pleased to provide an update on geriatric oncology activities at Eastern Health and Eastern Health Clinical School, which continue to grow in 2023.

Our paper on integrated geriatric assessment and treatment effectiveness (INTEGRATE) was published, showing that an integrated oncogeriatric model of care, underpinned by comprehensive geriatric assessment, improved quality of life and reduced unplanned hospital admission in older people with cancer starting systemic anticancer therapy (Lancet Healthy Longevity, September 2022; [https://doi.org/10.1016/S2666-7568\(22\)00169-6](https://doi.org/10.1016/S2666-7568(22)00169-6)).

Eastern Health has started Ageing Resiliency in Cancer Clinics to support geriatric oncology activities at Box Hill Hospital and Maroondah Hospital. These clinics are staffed by a geriatric oncologist and geriatric medicine advanced trainee to provide geriatric assessments to cancer patients. In addition, a joint Eastern Health and North Eastern Integrated Cancer Service (NEMICS) project is in progress, looking at frailty screening in older people with prostate cancer to identify vulnerable patients who may benefit from a comprehensive geriatric assessment.

Other geriatric oncology activity highlights involving EHCS staff include:

- Plenary presentation on “Frailty through the lens of geriatric oncology” and Best of the Best oral abstracts at the Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting
- Strengthening ties with community health supportive care through a research project in progress on “Implementation of a referral pathway for cancer survivors to access allied health services in the community”
- Strengthening ties with primary care through a review paper in progress on “The role of general practice in caring for older patients with cancer”
- Participation in the online multidisciplinary forum on “Tackling Ageism in Cancer Care”



HAEMATOLOGY

A/PROF STEPHEN TING

The Haematology Unit continues to provide optimal care for all patients with haematology blood cancers and/or haemostasis and thrombosis problems. This incorporates care as inpatients, outpatients, day haematology / oncology medical patients, hospital in-the-home patients and via the symptom urgent review clinical unit.

A major component of this service includes clinical trials treatment options, which are led by disease focused haematologists who are experts in their sub-specialty fields and in collaborative administration with a dedicated clinical trials team that has grown significantly throughout this academic year commensurate with trials activities. As of the end of 2022, the Haematology Unit had 56 recruiting and non-recruiting clinical trials open with 14 studies in start-up.

These trials covered the full spectrum of diseases including acute leukemia, chronic leukemia, myeloproliferative neoplasms, aplastic anaemia-bone marrow failure, lymphoma, myeloma, amyloidosis and cancer-related thrombosis with the latest anticoagulant via factor XI inhibition.

All these clinical trials are research focused with patient outcome aims, and dissemination of findings via publications. The attached publication list is attestation to the Haematology Unit's active participation in both clinical and basic science research and its academic endeavour.

Systemic AL amyloidosis is a protein misfolding and deposition disease, where amyloid deposits in organs, leading to their failure and premature death if appropriate treatment is not commenced promptly.

Despite gains in our understanding of the disease, and additional therapies available over the last two decades, 25% of our patients will die within 6 months of diagnosis.

The Victorian and Tasmanian Amyloidosis Service (VTAS) was created in 2014 at Eastern Health to offer a centre of excellence in Melbourne and ensure that all amyloidosis patients can receive an accurate and rapid diagnosis, and have access to world's best treatments and clinical trials. Over 500 patients have now been treated at VTAS.

The multi-national “Andromeda” study was run through ECRU. This trial compared standard of care Bortezomib, cyclophosphamide and dexamethasone (“VCD”) for new diagnosed systemic AL amyloidosis with VCD and daratumumab, an anti-CD38 monoclonal antibody used in multiple myeloma.

VTAS was the second largest recruiter globally to the study. The addition of daratumumab to standard of care VCD saw a doubling of complete remissions, cardiac responses and renal responses with a reduction in early cardiac death. The results were published in the New England Journal of Medicine, and is now seen as the new standard of care globally. As a result of this trial, the Australian government has agreed to fund daratumumab-VCD on the PBS for newly diagnosed systemic AL amyloidosis, the first time the PBAC has had a positive recommendation for any therapy in amyloidosis.

VTAS is now involved in two clinical studies examining monoclonal antibodies that directly target amyloid deposits, with the hope that further reductions in sudden cardiac death and a greater percentage of full organ recovery is observed.

INFECTIOUS DISEASES

DR STEPHEN GUY

Clinical research has been a key area of focus for the Infectious Diseases Department over the pandemic years, and this is set to continue into the future. Opportunities for Infectious Diseases to participate in research are expanding and strong collaborative networks exist in Australia (and beyond) with several Investigator initiated projects of high impact under development. Additionally, the clinical services provided by the Infectious Diseases Department provide an opportunity to have EHCS students for clinical rotations.

In 2022, Infectious Diseases Department members recorded eight publications (five COVID related and three non-COVID related).

Active projects and trials:

- ASCOT - an investigator initiated adaptive platform trial for treatments for COVID – currently with no open arms and evaluating future domains
- SNAP - an investigator initiated adaptive platform trial for treatments for Staphylococcus aureus bacteremia – to commence site activation in early 2023
- Dynamics of SARS-CoV-2 in the Immune Compromised Host - anticipated to commence early 2023
- HIV clinical quality registry - supporting consistent care for people living with HIV/AIDS - anticipated to commence early 2023
- Analysis of Remdesivir therapy for COVID-19 in Australia - awaiting analysis
- NAAN - National Antibiotic Allergy network – assessing and managing reported antibiotic allergies in patients - anticipated to commence early 2023

MENTAL HEALTH AND WELLBEING PROGRAM (MHWP)

A/PROF JUDY HOPE

KEY STAFF:

Dr Peter Brann: Director CYMHS Research and Evaluation
Dr Hema Jayaram: Director Older Persons Research and Evaluation

KEY INVESTIGATOR-INITIATED STUDIES:

- HOPE: an investigation of the characteristics and effectiveness of a post-suicide engagement program.
- BPD in ED: a collaborative investigation of the effect of an educational intervention on the outcomes for staff and consumers with borderline personality disorder. This study has attracted an Eastern Health Foundation grant.
- ICA Sensory project: an evaluation of the effect of transformation of psychiatric intensive care units on staff and patient experience.
- ECG project: evaluating the equivalence of limb lead ECG use in acute psychiatric inpatient units.

MULTICENTRE COLLABORATIVE STUDIES

CADET – an investigation of the use of candesartan in depression. Deakin University, IMPACT group.

SCHOLARLY PROJECTS

The MHWP hosted over 14 scholarly projects in 2022, with diverse topics such as: the impact of COVID19 on emergency mental health presentations, experiences of sexual harassment by psychiatry trainees, Restorative Just Culture in mental health settings, and Consumer and Carer experience of mental health care in emergency settings. A Cairnmillar Honours student was also hosted in 2022, with a first rank thesis result.

PUBLICATIONS

The MHWP published the highest ever number of annual publications in 2022: 17 original peer reviewed articles, 4 conference papers and one book chapter. Particular congratulations to our Lived Experience team, who published their paper on co-designing quality principles:

Otto J, Makela E, Alam S, Lim H, Maccar R, Hall A, Neef D, Ryan S, Bourke C, Foster G, Vivekananda K. (2022) **Co-designing consumer and carer peer support principles to assess quality.** Advances in Mental Health, DOI: 10.1080/18387357.2022.2026235

MENTAL HEALTH RESEARCH ANNUAL FORUM

The Mental Health Research Forum celebrates research work done across all mental health services. The 2022 Forum was conducted online in October 2022, featured 15 presenters from mental health, pharmacy and gastroenterology and was attended by over 100 participants.

CONFERENCE PROCEEDINGS:

RANZCP:

- Y Bandara, J Hope. Psychiatry trainees’ experiences of sexism and sexual harassment within the RANZCP and at College events. Australian and New Zealand Journal of Psychiatry 2022 May 1 (Vol. 56, No. 1_ SUPPL, pp. 217-217).
- J Segal, R Howard, J Hope. Characteristics of patients who receive dual long-acting injectable (LAI) medication in a public metropolitan mental health service. Australian and New Zealand Journal of Psychiatry 56 (1_ SUPPL), 246-246.
- J Hope, P Williamson, C Dixon, M Nunn, E Fraser, L Oades. Preparing a whole clinical mental health workforce for collaborative recovery-oriented practice through changes in knowledge, attitudes, skills, importance, confidence and language. Australian and New Zealand Journal of Psychiatry 56 (1_ SUPPL), 173-173.
- Y Bandara, M Marrows, E Bain, E Bandara. The good, the bad and the entertaining: pop culture representation of mental illness and psychiatry. Australian and New Zealand Journal of Psychiatry 56 (1_ SUPPL).

NEPHROLOGY

PROF LAWRENCE MCMAHON

INVESTIGATOR INITIATED STUDIES

Our Investigator-initiated studies of muscle mass in chronic kidney disease are being performed by our Research Fellow Dr Limy Wong who is a nephrologist at Eastern Health and Senior Research Fellow in the Monash University Eastern Health Clinical School. She has recruited patients and performed measurements for the Sarcopenia in Patients with Chronic Kidney Disease (SPARSE) Study to better understand sarcopenia in people with chronic kidney disease, and to investigate the role of fibroblast growth factor 23 (FGF23) in the development of sarcopenia. These studies have a clinical component performed with our Research Nurses with recruitment of over 100 people with chronic kidney disease looked after at Eastern Health, and a laboratory component consisting of cell culture studies of myocytes and the effects of various mediators, including FGF23, working closely with our laboratory scientists.

Dr Louis Huang is leading a randomised controlled trial of an incremental start to peritoneal dialysis that has almost finished recruitment and will provide important pilot data on the safety of starting this form of dialysis in an incremental manner rather than a standard prescription. This study involves collaboration with Austin Health and Monash Health.

Dr Kathryn Ducharlet is recruiting patients aged 70 years and above with an estimated Glomerular Filtration Rate (eGFR) <20mL/min to undertake an education package “Your future, your health” that focuses on future treatment decision making and identify end-of-life care preferences. This aims to establish the feasibility, acceptability and impact of this specific patient education for this group of patients and measure program outcomes.

AWARDS:

A Royal Australasian College of Physicians Jacquot Research Establishment Fellowship 2022 (\$90,000) was awarded to Dr Limy Wong, who received the same Fellowship in 2021. This was to support her research focus in understanding the biological basis of sarcopenia in patients with chronic kidney disease and investigating a possible connection between sarcopenia and renal osteodystrophy.

An Eastern Health Foundation Grant 2022 (\$30,000) was awarded to Dr Kathryn Ducharlet for her project “Your future your health, Advanced Care Planning prospective feasibility study for older people with advanced chronic kidney disease at Eastern Health”.

A Robert C Bulley OAM Research and Innovation Grant 2022 (\$14,980) was awarded to Dr Louis Huang to support the “Incremental Peritoneal Dialysis Study”, an investigator initiated, multi-site randomised controlled clinical trial based at Eastern Health.

PARTICIPATION IN NATIONAL COMMITTEES:

Australian and New Zealand Society of Nephrology: Dr Kathryn Ducharlet – Co-Chair Kidney Supportive Care Special Interest Group

Australasian Kidney Trials Network: A/Prof Matthew Roberts – Chair, Scientific Committee; Dr Louis Huang – Chair, Peritoneal Dialysis Work Group

Australian and New Zealand Dialysis and Transplant Registry: A/Prof Matthew Roberts – Chair, Haemodialysis Work Group; Dr Darren Lee – Member, Transplant Work Group

INDUSTRY SPONSORED CLINICAL TRIALS

We are currently recruiting participants for the following industry-sponsored clinical trials:

- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)
- A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
- A randomized, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Flnerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD)
- Incidence of de novo HLA Antibody formation after Transfusion with blood products in patients with and without chronic kidney disease: A prospective observational study (HABIT Part 2)

CONFERENCES:

SPEAKER:

Dr Kathryn Ducharlet was an Invited Speaker for a plenary session at the ISN World Congress in Malaysia on “Dialysis in the Octogenarian”, 27 February 2022

Dr Kathryn Ducharlet was an Invited Speaker for the Symposium “End of life care, symptom management and voluntary assisted dying for people with advanced kidney disease” at the Australian and New Zealand Society of Nephrology Annual Scientific Meeting in Sydney, 19 October 2022

WEBINAR:

ISN-Cochrane Webinar: Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis, 6th May 2022. Moderator: Prof Lawrence McMahon. Speakers: Dr Vivian Mah, Ms Mel Corken, Dr Suet-Wan Choy

ABSTRACT PRESENTATION:

- Ratnayake C, Crombie T, Fraenkel M, McMahon LP and Wong L. Haemoptysis in a stable kidney transplant patient previously seropositive for anti-GBM and ANCA glomerulonephritis. Posters. *Nephrology* 2022;27:68-114.
- Wong L, Nguyen D, Howard J, McMahon LP. Relationship between sarcopenia and frailty in CKD: a cross-sectional study. Posters. *Nephrology* 2022;27:68-114.
- Wong L, Kenny R, Howard J, McMahon LP. Molecular alterations in skeletal muscle in chronic kidney disease: a systematic review. Posters. *Nephrology* 2022;27:68-114.
- Wong L, Kenny R, Howard JL, McMahon LP. Molecular mechanisms underpinning muscle atrophy in CKD. *J Am Soc Nephrol* 2022;33:TH-PO828.
- Alikahn M, Kishimoto K, Law J, Wong L, Kitching AR. Neutralizing the IL-7Ra (CD127) limits injury in experimental anti-MPO glomerulonephritis. *Oral and poster presentation. 20th Vasculitis and ANCA workshop April 2022, Dublin, Ireland.*
- Defining causes of allograft loss attributed to chronic allograft nephropathy: a 5-year multicentre audit. Mulley W, Hughes P, Collins M, Wyld M, Clayton PA, Lee D, Van der Jeugd J, Tan S, Fernando S, Kuo SF-T, Sadia J, Pilmore H, Lim W. Transplantation Direct 8(12S):p S21 December 2022.
- Two-year rejection risk in kidney transplant recipients following mycophenolate dose reduction in Australia and New Zealand. Lee D, Polkinghorne K, Mulley W. Transplantation Direct 8(12S):p S68 December 2022.
- Mycophenolic acid area under the curve assessment after mycophenolate mofetil dose reduction in kidney transplant recipients. Malaweera A, Metz D, Mulley W, Lee D. Transplantation Direct 8(12S): p S69 December 2022.

NEUROSCIENCES

PROF HELEN DEWEY

STROKE:

The Stroke trials team has gone from strength to strength in 2022. Box Hill Hospital continued to rank top three in recruitment worldwide for TEMPO2, TASTE and ETERNAL trials. The results of these investigator sponsored trials will answer critical questions in how we treat minor, medium and large strokes in the future.

Dr Ross Cody, 2022 Stroke Fellow, had a particularly productive fellowship year with the unit. He was awarded an Eastern Health Foundation Grant for his TIA improvement project, as well the Best Poster Award at the Stroke Society of Australasia Annual Scientific Meeting in Christchurch for his presentation entitled “Effect of the COVID-19 pandemic on treatment metrics for large vessel occlusion stroke at Box Hill Hospital”. Academic output from our previous stroke fellows in 2022 includes three original research papers, three papers in press, and four conference abstracts.

Dr Philip Choi received \$300,000 philanthropic support to expand BUILDS (Bridging the Urban and Regional Divide in Stroke Care) to the North West Regional Hospital, Burnie, Tasmania and Sale Hospital in Central Gippsland for 12 months. BUILDS is a novel Tele-Stroke Unit model, piloted in partnership with Echuca Regional Health. It was made possible by an Avant Foundation Grant awarded in 2021.

MULTIPLE SCLEROSIS AND NEUROIMMUNOLOGY (MSNI) UNIT:

The Multiple Sclerosis and Neuroimmunology (MSNI) Unit continues to build on another year of active clinical and translational research under the leadership of Dr Katherine Buzzard. Our research team welcomed new lead study coordinator, Amanda Fiora, supported by Maddie Robertson and Carly Shaddick. We are conducting multiple pharmaceutical sponsored studies in Multiple Sclerosis (MS) and other non-MS neuroimmunological disease, including:

- FENTrepid - Phase III, double blind, double dummy study to evaluate efficacy & safety of Fenebrutinib (BTK inhibitor) in adults with PPMS.
- Nova Extension - Randomized, open label rater blinded study of the efficacy, safety & tolerability of 6 week extended interval dosing of Tysabri (Natalizumab) in RRMS patients (Part 1). OLE (Part 2) with Subcutaneous and Intravenous Tysabri.
- Lemtrada OBS13434 - observational study of participants who received Lemtrada (Alemtuzumab) (10 year follow up).
- Ensemble - open label single arm study to evaluate the effectiveness & safety of Ocrelizumab in early RRMS patients.
- TOP - Tysabri observational study – safety & efficacy registry
- Kesimpta MSGO portal / EAFToS: Secondary use of data study characterising Kesimpta (ofatumumab) onboarding and utilization in RRMS patients using MSGO, with a non-interventional primary use of data sub-study comparing patient reported outcomes to clinical outcomes.
- METEOROID WN43194 - Phase III, randomized, double blind study using Satralizumab as a monotherapy or in addition to baseline therapy in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).
- WN42636 Luminesce - Phase III, randomized, double blind placebo-controlled study using Satralizumab in Generalized Myasthenia Gravis.

The Eastern Health MSNI Unit remains the national coordinating site for pregnancy registries in Multiple Sclerosis patients on disease modifying therapies (Gilenya, Aubagio, and Lemtrada).

The MSNI Unit participates in many investigator-initiated studies in Multiple Sclerosis and other non-MS neuroimmunological diseases:

- ACTIVE MS - Active participatory health monitoring in people with MS. Pt self-monitoring at home using smartphone apps.
- CLOBAS - Cladribine Long-term efficacy Biomarker Australian Study Phase IV. Primary objective to monitor outcomes of RRMS patients on Cladribine over 6 years.
- IMPROVE MS - 6 centre study using iPad tools in clinic setting to identify sub-clinical disease progression in MS.
- MS REACTOR - Prospective clinic and home-based serial monitoring of cognition in RRMS.
- MSBase - An international registry dedicated to evaluating outcomes data in multiple sclerosis (MS).
- Crystal Ball - Predicting biomarkers in MS.
- MGBase - An international registry evaluating outcomes data for patients with Myasthenia Gravis.
- Autoimmune Encephalitis and other Neuroinflammatory Conditions - Both a prospective and retrospective study identifying biomarkers (immune signatures, imaging and EEG correlates) and cognitive outcomes in patients with AE and other neuroinflammatory conditions.

Dr Katherine Buzzard was one of the successful chief investigators on an MRFF grant worth \$1.7 million to investigate the use of IVIG in Australia (VALUE-Ig study). This grant will use the MGBase registry to investigate the use of IVIG in myasthenia gravis in Australia.

The MSNI Unit looks forward to another busy and productive year in 2023!

DEMENTIA:

Dementia trials activity continues to be high, and ECRU remains one of the top three recruiting sites for dementia trials in Australia. We are running and leading studies in Alzheimer's disease (AD) and both sporadic and familial frontotemporal dementia (FTD). The positive findings from the lecanemab study, a monoclonal anti-amyloid antibody, were presented at the 2022 December Clinical Trials in Alzheimer's Disease meeting. These results mean that a second disease modifying therapy for AD will likely be licensed in the USA. An application is pending for our TGA, and if successful, means that an infusion therapy could be available in Australia by the end of 2023. This will have enormous implications both for the trials landscape and health system delivery.

We have completed recruitment for a study in AD and FTD on the Chronobiology of Dementia, examining sleep and circadian rhythm disruptions. This is a collaboration with the Institute for Breathing and Sleep and the Florey Institute. Results should be available by mid-next year.

In June 2022, Prof Amy Brodtmann received a Victorian Medical Research Acceleration Fund grant with her collaborator Prof Adam Vogel, Head of Speech Pathology in the School of Health Sciences at The University of Melbourne. We are examining the utility of novel biomarkers for dementia diagnosis, testing whether we can use a blood test and voice sample to shorten time to diagnosis and improved diagnostic accuracy. This is an EH-wide project, with participants recruited from in- and outpatients.

A/Prof David Darby was successful in an EHMRf grant for a project developing a new cognitive assessment tool for dementia, together with ECDC colleagues and CDAMS colleagues, including Dr Julie Baird.


Dr Maja Christensen, 2021-22 ECDC Cognitive Fellow, received a Central Clinical School RTP Postgraduate Research Scholarship for her PhD candidature, in which she will enrol on return from her maternity leave.

Prof Brodtmann was awarded the Mervyn Eadie Award, a named lecture at the 2022 Australian and New Zealand Association of Neurologists Annual Scientific Meeting, in recognition of her contributions to neuroscience research.

EPILEPSY:

The Eastern Health epilepsy team continue to pursue opportunities to develop novel epilepsy research projects, as well as collaborating with research partners both locally, nationally and internationally. It has been a particularly busy time for research activity in epilepsy at EH, with Dr Patrick Carney using a period of sabbatical leave to further develop research capacity and collaborations. Key highlights include:

- Funding via the EH Foundation has supported continuation of research into models of care in the epilepsy clinic. This research continues the fruitful collaboration with the allied health research team on applying the STAT model (Specific Timely Appointments for Triage) to clinic management in the epilepsy clinic.
- Dr Carney has been an associate investigator on two MRFF research projects. The Personalised Selection of Medication for Newly Diagnosed Adult Epilepsy (PERSONAL) trial, will use machine learning algorithms to help predict medication selection with the intent of optimising patient outcomes via reduced adverse events and improved efficacy. EH will also contribute baseline data extracted from the FIRST Audit database to inform the machine learning classifier as well as recruiting for the study. Furthermore, we will recruit for the SELECT trial which will study sodium selenate as a disease modifying treatment for epilepsy. This is the first ever trial of a disease modifying treatment for epilepsy and reflects a paradigm shift in the way we approach epilepsy care.
- The EH epilepsy team are taking a leading role in large, novel linkage study looking at outcomes for patients with a first ever seizure. Dr Carney and Dr Moksh Sethi are currently involved in the first phase which involves a validation study of an operational definition for first seizures via hospital coding data. Following this, a state-wide linkage study will be performed providing vital insight into outcomes in this prevalent patient group.
- Furthermore, as part of the unit's research interest in first seizure, the research team have initiated a survey of Australian and Aotearoa New Zealand neurology services to bench mark delivery of first seizure care in the region with a view to identifying treatment gaps and advocating for improved service delivery.
- We continually to strongly support the Australian epilepsy Project, a world leading study of advanced diagnostic and classification techniques in epilepsy funded by the MRFF. Dr Carney has recently been appointed part of the steering committee of this project to ensure the study can meet its research goals.
- We continue to be engaged in research into new investigational agents in conjunction with the Eastern Clinical Research Unit (ECRU) and the Australian Epilepsy Clinical Trials Network (AECTN). The team will commence two studies this year including an outpatient study on a new investigational agent in patients with medication refractory epilepsy (the RENAISSANCE study). In addition, we are involved in an inpatient study in collaboration in the ICU on the treatment of medication refractory status epilepticus (the MARINUS study).



ONCOLOGY

PROF PHILIP PARENTE

The Oncology unit continues to maintain a broad-based research program involving clinical trials as well as basic and translational research. Oncology accounts for the majority of ECRU clinical trials, with 100 active clinical trials in 2022. Our unit's trial activity mainly centres on genitourinary, lung, melanoma, breast, and gastrointestinal cancers. We actively collaborate with multiple groups and have several ongoing basic and translational research projects, as described below.

ACTIVE RESEARCH PROJECTS:

Anis Hamid:

- ANZUP-funded retrospective study to profile the methylome and transcriptome of metastatic hormone sensitive prostate cancer (mHSPC), to better understand the epigenomic landscape of mHSPC and clinical correlates
- Integrative molecular characterization and biomarker validation in mHSPC
- MEMENTO (Metastatic Prostate Cancer Methylation and Transcriptional Biomarker Study)
- US Dept of Defense-funded project focused on biomarker development in independent clinical trials of mHSPC

Arsha Anton:

- KRAB: Renal Cell Cancer Registry (WEHI)
- TABITHA: Breast Cancer Registry (WEHI)

Ian Davis:

- MOSES prostate cancer support study.
- Urothelial cancer ctDNA laboratory project / NHMRC Investigator Grant

Margaret Lee:

- FORECAST1 organoid study
- Organoid biobank study
- PREDICT: Patient Derived Tumour Organoid Treatment Sensitivity to guide neoadjuvant therapy decision making in locally advanced rectal cancer. AGITG Rectal Cancer Research Grant - \$200,000

Margaret Lee and Rachel Wong (associate investigators):

- Personalising first-line treatment for patients with metastatic colorectal cancer. Cancer Australia 2022 Priority-driven Collaborative Cancer Research Scheme \$599,617

Phillip Parente:

- ePAD Prostate Cancer Registry (WEHI)
- MASTER Melanoma Registry (WEHI)
- Monash University Victorian Lung Cancer Registry

Rachel Wong:

- ACCORD Colorectal registry (WEHI)
- Monash University Upper Gastrointestinal Cancer Registry (UGICR)
- Associate investigator on Penelope Schofield's MRFF Super-ED grant for Cancer of Unknown Primary (\$2.3M)
- Associate Investigator on Victorian Cancer Agency (VCA) 2021 Quality and Safety in Cancer Care Research Grant (QSCCRG) – 'HER2 testing in advanced gastric cancer – understanding and reducing variation in current practice to improve patient survival' \$600,000
- INHALE lung cancer registry (WEHI)
- ProPatient, based on the Monash upper gastrointestinal cancers registry (<https://www.propatientproject.org>)
- PURPLE pancreatic cancer registry (WEHI)
- TRACC Advanced Colorectal Cancer registry (WEHI)
- Associate Investigator on Victorian Cancer Agency Quality and Safety in Cancer Care Research Grant – \$596,468 this is for BETTER-TRACC – BEenchmarking and Tracking TrEatment and ResulTs in the Routine care of Advanced Colorectal Cancer

Shomik Sengupta:

- BLADDA Bladder Cancer Registry (WEHI)
- ACCEPT-U upper tract urothelial cancer registry
- iTestis Testicular Cancer Registry (WEHI)

RESEARCH FUNDING SPECIFIC TO EASTERN HEALTH:

Alysson Wann:

- COVID prevention in cancer patients - a prospective study evaluating uptake rates of vaccines, Evusheld and patient's perspectives on its effectiveness.
- Operational efficiency of improved allocation of appointment slots in the outpatient clinic environment.
- Rates of low risk febrile neutropenia cancer patients eligible potential for ambulatory care at Eastern Health.

Bianca Devitt:

- Gilead Investigator Grant (Co-applicant, 18 months \$60,000) - Feasibility and safety of a bone turnover marker directed Denosumab dosing strategy for the treatment of patients with bone metastases from breast cancer – A Pilot Study.

Wee-Kheng Soo:

- Improving Cancer Care in Older Men with Prostate Cancer (NEMICS Grant \$38,000)

Margaret Lee:

- SPACE-FLOT: Survival and Patterns of Care in the Era of FLOT based Chemotherapy in Gastric and Gastroesophageal Cancer (Eastern Health Foundation Grant \$30,000)

Shomik Sengupta, Ian Davis, Pavel Sluka.

- Eastern Health Foundation: Development & validation of a method for detection of circulating tumour DNA in non-muscle-invasive urothelial cancer of the bladder. Robert C Bulley OAM Research and Innovation Grant. \$26,800 for 2021.

CONFERENCE PRESENTATIONS:

Bianca Devitt:

- Herbison H, Miller A, Shnier D, Greenberg S, Devitt B. Consensus guidelines for breast cancer staging during pregnancy. A Delphi Study. San Antonio Breast Cancer Conference 2022 (poster presentation)
- Herbison H, Miller A, Shnier D, Greenberg S, Devitt B. Consensus guidelines for breast cancer staging during pregnancy. A Delphi Study. MOGA ASM 2022 (oral presentation)
- Javid A, Lok SW, Wong V, Baron-Hay S, Boyle F, Collins I, Cuff K, de Boer R, Gately L, Georgiou C, Greenberg S, Karki B, Nottage M, Rainey N, Torres J, Yeo B, Devitt B, Gibbs P, Anton A. CDK4/6 Inhibitors (CKD4/6i) in Advanced Hormone-Receptor-Positive (HR+) HER2-Negative (HER2-) Breast Cancer: prescribing practices and outcomes in a real-world, Australian cohort. COSA ASM 2022 (accepted) (poster presentation)
- Scott, B (Host), Petty, R., Devitt B. (2022) An evaluation of the value and future developments of multidisciplinary teams. EMJ podcast. October 19. <https://www.emjreviews.com/oncology/podcasts/an-evaluation-of-the-value-and-future-development-of-multidisciplinary-teams/>

Ian Davis:

- NHT treatment intensification: standard of care for patients with mHSPC. Urological Association of Asia 2022 Congress – Commercial Xtandi Symposium, Sydney, Australia (invited speaker).
- Reap what you sow: Treatments for mHSPC in use today. The maturing treatment landscape of mHSPC. An Astellas-sponsored symposium at ESMO Congress 2022. Paris, France (virtual presentation) (invited speaker).
- Refining the Treatment Strategy for Advanced Prostate Cancer with Latest Evidence. Virtual Prostate Cancer Symposium supported by Hong Kong Urological Association and Hong Kong Society of Uro-Oncology (invited keynote speaker).
- Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, co-operative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). ASCO Annual Meeting, Chicago, USA, 3-7 June 2022. Presentation selected by ASCO for inclusion in the 2022 “Best of ASCO” seminar series. J Clin Oncol. 2022; 40: 5004.

- Treat like high volume [debate topic]. Advanced Prostate Cancer Consensus Conference, Lugano, Switzerland, 28-30 Apr 2022 (scientific panel, invited speaker).
- Key studies in prostate cancer: Highlights of the 2022 ASCO-GU meeting. Astellas Taiwan Insight in GU oncology from ASCO-GU 2022 (virtual meeting).
- The evolving landscape of advanced prostate cancer: latest clinical trial data in mHSPC. Astellas Taiwan mHSPC Virtual Advisory Board Meeting (invited speaker). Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, co-operative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). ASCO Annual Meeting, Chicago, USA, 3-7 June 2022. Presentation selected by ASCO for inclusion in the 2022 “Best of ASCO” seminar series. J Clin Oncol. 2022; 40: 5004.
- The art of PSMA theranostics (session chair). How We Do PSMA Theranostics – ProsTIC Preceptorship 2022, 1-2 April 2022, Melbourne, Australia.
- Consumer and Community Involvement in Clinical Trials: Planning, Development and Design Webinar (speaker and panel member). Online symposium hosted by Monash Partners and Sydney Health Partners.

Anis Hamid:

- ASCO Annual Meeting 2022; Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 5027. Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). Hamid A, Hofman MS, Bressel M, Emmett L, Joshua AM, Spain LA, Horvath L, Crumbaker M, Pasam A, Callahan J, Tubbs A, Fernandez L, Wenstrup RJ, Kong G, Lewin JH, Tran B, Azad A, Schonhoft JD, Hicks RJ, Sandhu S.

Wee-Kheng Soo:

- Cancer Nurses Society of Australia (CNSA)-Clinical Oncological Society of Australia (COSA) Webinar 2022, Australia. Models of care to support older people with cancer - Integrated models of oncogeriatric care for older people with cancer.
- COSA ASM 2022 Best of the Best Oral Abstracts – Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial.
- COSA ASM 2022 Plenary – Frailty through the lens of Geriatric Oncology.
- Panellist on the Geriatric Oncology Early Emerging Researcher (GOEER) and COSA Online Forum 2022, Australia. Tackling Ageism in Cancer.

RESPIRATORY AND SLEEP MEDICINE

PROF FRANK THIEN

In 2022, with the COVID-19 environment as the “new normal”, we have continued our clinical trial and investigator-initiated research, maintaining a strong and diverse research profile. This includes investigator-initiated studies of long term follow up of thunderstorm asthma, allergen immunotherapy in thunderstorm asthma, and eosinophilic exacerbations of COPD, as well as focused activities in the areas of sleep medicine, and in allergy/immunology. Our PhD scholar, Dr Chuan Foo is continuing his research in magnetic resonance lung imaging for assessment of bronchial thermoplasty for severe asthma. In addition, we contribute to national and international registries in severe cutaneous adverse drug reactions, interstitial lung diseases, and severe asthma. Our industry sponsored clinical trial activity remains strong with our clinical trial Respiratory Lead Ms Emma Jackson and her team of study coordinators providing excellent support. Our Department members continued with a solid publication record in 2022.

SLEEP RESEARCH

The Sleep Research program continues to focus on barriers to sleep in hospital for both patients and healthcare workers in collaboration with Turning Point and the Sleep Health Foundation. The sleep apnoea and ethnicity research stream continues with EH Foundation Grant support for 2020 in collaboration with Monash BASE. Other research streams focussing on cardiovascular consequences of sleep apnoea and vigilance testing in the laboratory setting have also led to successful publications.

ALLERGY IMMUNOLOGY RESEARCH

Under the leadership of Dr Jason Fok, Box Hill Hospital is now part of the centre of excellence network for urticaria and angioedema (UCARE and ACARE respectively for the urticaria and angioedema components), governed by the Global Allergy and Asthma European Network (GA2LEN). Box Hill Hospital is the first centre recognised in Victoria (for UCARE) and Australia (for ACARE). This international collaborative network promotes understanding of these diseases by fostering and collaborating clinical, epidemiological and translational research. Dr Fok also has research collaboration with The Australasian Mastocytosis Society (TAMS). The preliminary findings on mastocytosis patient journey were presented in the 2021 Australasian Society of Clinical Immunology and Allergy (ASCIA) Annual Scientific Meeting. In regards to primary immunodeficiency research, Dr Fok has collaborations with Alfred Health and Monash Health looking at characterisation of genetic analysis in patients with immunodeficiency.

PHD SCHOLAR

Dr Chuan Foo continued his PhD on the topic “Functional lung imaging using novel and emerging MRI techniques”. His main research is on MRI lung scanning before and after bronchial thermoplasty for severe asthma as part of the NHMRC grant “Unravelling a clinical paradox: why does bronchial thermoplasty work in asthma and how can we improve patient outcomes?” (APP1180854; 2020-2024 \$1,060,200). He passed his PhD confirmation milestone on 14 November 2022 with very positive reviews.

NATIONAL AND INTERNATIONAL REGISTRIES

- AUSCAR - AUStralasian registry of Severe Cutaneous Adverse Reactions records patients with a history of allergy or have experienced a severe drug reaction to study how to best manage, diagnose and prevent severe adverse drug reactions.
- AILDR - The Australasian Interstitial Lung Disease Registry is a bi-national database established since 2016, incorporating prospective epidemiological and investigational data at centres across Australasia of ILD patients to better understand the nature of ILD and assist in developing future clinical research. Eastern Health in the 4th highest contributor to the registry of 18 centres nationally.
- ASAR - The Australasian Severe Asthma Registry records and follows patients with a diagnosis of severe asthma with respect to the clinical history, treatments and outcomes.
- ABenRA - This subset of ASAR follows clinical course and outcomes of patients who have been prescribed the anti-IL5 receptor monoclonal antibody, benralizumab.

CLINICAL TRIALS

We continued to be active in clinical trials recruiting in the last 2 years in the following respiratory disease areas:

IDIOPATHIC PULMONARY FIBROSIS

- FGCL-3019-091 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
- ENV-IPF-101 - A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in subjects with Idiopathic Pulmonary Fibrosis (IPF)
- Horizon - A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis

BRONCHIECTASIS

ASPEN - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- EFC 15805 - A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation
- GB4431 - A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease

ASTHMA

GSK NIMBLE 206785 - A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab



RHEUMATOLOGY

DR CHRISTOPHER FONG

The Eastern Health Rheumatology Department research interests in the areas of back pain, osteoarthritis, osteoporosis, psoriatic arthritis, and lupus.

It collaborates with other Monash University departments and Eastern Health department in providing the optimal support for patients around Eastern Health areas, and access to novel therapies.

It has partnered with Arthritis Australia and International Rheumatology Research organisation to promote consumer and patient involvement in research. Endorsement of the OMERACT Core Domain Set for shared decision-making interventions in rheumatology trials: results from a multi-stepped consensus-building approach Seminars in Arthritis and Rheumatism.

Current studies include:

- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care.
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care.
- A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis.

We have participated and published “Australian Living Guidelines for Inflammatory Arthritis,” which assists clinicians to manage rheumatology patients on perioperative use of opioids and weaning off medications. This is available and updated continuously on the internet via MagicApp. This app is also used for the COVID-19 pathway and the Internal Medicine Journal (IMJ). A patient representative is part of this guideline development group.

Our work in amitriptyline in back pain has been published in the Journal of American Medicine. Current work with our valued registrars and medical students include developing pathways for managing suspected temporal arteritis, back pain guidelines in emergency department, evaluating risk factors for sepsis and COVID-1 infections in rheumatology patients, a follow study up of patients with sarcoidosis, and a clinical cohort of Still's Disease. We have partnered with Allied Health / Physiotherapy research to optimise care for patients with osteoarthritis in the community and evaluating exercise and walking in osteoarthritis.

SPECTRUM

A/PROF JILLIAN BROADBEAR

Spectrum is the Centre of Excellence for Treatment, Training, and Research for Personality Disorder and Complex Trauma. Spectrum was launched by the Victorian Government in 1999 as a Statewide Service and is auspiced by Eastern Health. In 2022, Spectrum engaged in numerous clinical projects, both funded and unfunded, including collaborative projects within and outside of Eastern Health. These ranged from epidemiological studies with the National Ambulance Surveillance System (NASS) and the Coroner’s Court of Victoria, to conducting qualitative consumer interviews to learn more about how men experience borderline personality disorder. Spectrum also supervises research projects for higher degree students (Clinical Psychology) and psychiatry registrars.

Spectrum presented three symposia at the annual congress of the Royal Australian and New Zealand College of Psychiatry (Sydney, May, 2022). The titles of the symposia were:

- Core Competencies Framework for the Treatment of Personality Disorder.
- Models of Care for People Diagnosed with Borderline Personality Disorder (BPD).
- Building Stronger Bridges and Safer Harbours by Working Together: New Ways of Thinking and Practising Mental Health Care for Borderline Personality Disorder (BPD).

We also held our annual conference in November 2022 at the Melbourne Convention Centre. The title of the conference was ‘Navigating Diagnostic and Treatment Challenges: Is it Borderline Personality Disorder and/or Complex Post-Traumatic Stress Disorder?’

Finally we held our annual Spectrum Research Forum in November 2022 (a virtual event).

A/Prof Sathya Rao (Executive Clinical Director of Spectrum) was awarded an OAM in the Queen’s Birthday Honours in 2022.

Research funding (current):

- 2020 Borderline Personality as Social Phenomena. ARC Linkage Project with RMIT University (CI: Prof Renata Kokanovic; \$567,500 over 4 years).
- 2022 Management of Borderline Personality Disorder in the Emergency Department – Expanding the Horizon (Hope, Buntine, Broadbear, Brann) Eastern Health Foundation (\$16,200).
- 2023 A Qualitative Investigation of Service Users’ Experiences of Mentalization Based Treatment (MBT) (Donald, Nesci) Eastern Health Foundation (\$23,400).

SUPPORTIVE AND PALLIATIVE CARE SERVICES

PROF LEEROY WILLIAM

The Eastern Health Supportive & Palliative Care Service has continued to progress its activities during 2022, despite the challenges that have affected healthcare. Listed below are our publications, presentations, teaching, and other works from 2022.

There have been many presentations nationally about voluntary assisted dying (VAD), as other states and territories begin the process of implementing their VAD legislation. Our experiences have been valuable to prompt important reflections in this area and how we can reduce the conflation between palliative care and VAD. Publications from our work in COVID and the multi-site implementation of screening for psycho-existential symptoms have been important additions to the academic literature.

We continue our research into delirium in palliative care, as part of the NHMRC Ideas Grant funding the international multi-site project. Our partnership with the Public Health & Palliative Care Unit at La Trobe University continues and will support a two-year research proposal investigating length of stay on the specialist palliative care unit, end-of-life prescribing, and local general practitioner involvement in palliative care. Additionally, we are progressing a study which involves: (i) investigating quality of life, towards the end of life (EOL) for Eastern Health palliative care inpatients, and (ii) the extent of health and social services used among people who died within Victoria over a 3-year period.

We have also been involved in collaborative work with the Eastern Health nephrology team, ambulatory services, as well as the progressive neurological diseases state-wide service based at Calvary Health. Sam Breen deserves a special mention, as she obtained a high distinction in her Honours study, supported by some of our university academics. Congratulations also to Naomi Gleadle and Ebony Remyn who both presented their work at the ANZSPM Conference, with Naomi winning the best trainee project prize.

No doubt 2023 will remain challenging for all of us working in healthcare, but we will strive to maximise the opportunities that may occur to improve our care through research at Eastern Health.

RESEARCH

- Hoise A, Agar M, Hawkins F, Johnson CE, **Walpole G**, Casey P, Cook A, Chye R, Oehme J et al. Driving quality in delirium care through a patient-centred monitoring system in palliative care. Multi-site NHMRC Ideas Grant. *Chief Investigator for Eastern Health site – Walpole G*
- Ducharlet K, Colquhoun L, Brean S, **William L**, McMahon L. Advance care planning and end of life care for patients with advanced renal disease
- William L, **Waran E**, **Lakhani A**. What is the impact of length of stay on palliative care outcomes? A retrospective review
- **William L**, **Waran E**, **Lakhani A**. Service use and Quality of Life for Eastern Health Palliative Care Patients
- **Gregory H**. My-Neuro-Palliative-Care: My-NP-Care - an integrated approach for people living with a progressive neurological disease
- **Hatzipashalis S**. Exploring Experiences of Suffering for Non-English Speaking Patients Living With Advanced Cancer
- **Waran E**, **Zhang J**, **Lakhani A**, **William L**. End of life experiences of patients undergoing voluntary assisted dying
- **Waran E** (PI). RESONANCE - Phase II randomised double-blind controlled trial of medical cannabis versus placebo for patient with life-limiting advanced malignancy
- **Waran E** (PI). DEPART Pain – Phase III randomised controlled trial comparing duloxetine with pregabalin for neuropathic pain in patients with cancer

PRESENTATIONS

- Hospice New Zealand Palliative Care Conference, 11/2022 - Remembering Our Authentic Selves Together (**William L**)
- Hospice New Zealand Palliative Care Conference, 11/2022 - The realities of assisted dying in Victoria - Reflections for our future (**William L**)

- Tasmanian Palliative Care Conference, 11/2022 - Quality of Life and Our Lens of Optimism (**William L**)
- Palliative Care Outcomes Collaboration Symposium – New Frontiers in Palliative Care Outcomes, 11/2022 - Holistic assessment and care: the importance of assessing chronic symptoms. (**William L**)
- Monash Medicine Education Curriculum Conference 11/2022 – Can you call the family? Integrating clinical communication skills into MED5103: developing conversation ready interns (**Walpole G**, Leach D)
- Monash Medicine Education Curriculum Conference 11/2022 – Will you speak with the family? Discussing dying and planning for a good death: searching serious illness conversation in the palliative care curriculum (**Walpole G**)
- Australian & New Zealand Palliative Radiation Oncology Group Members Forum, 10/2022 - Voluntary Assisted Dying in Australia and New Zealand – Radiation Oncology Perspective (**William L**)
- 57th Australian & New Zealand Society of Nephrology Annual Scientific Meeting, 10/2022 - End of Life Care & Kidney Disease: symptom management decision making and voluntary assisted dying - A case-based discussion. (Ducharlet K, Fleming D, Brennan F, **William L**, Wester N, Mewett G, Fraenkel M)
- Australian & New Zealand Society of Palliative Medicine Conference, 9/2022 – Antidepressant discontinuation and hyperactive delirium at the end of life (**Gleadle, N**, **Walpole G**)
- 27th Congress of the Japanese Society for Palliative Medicine, 7/2022 – Barriers of palliative care promotion to the public: how can we develop palliative care culture? (**William L**)
- Grand Round Prince of Wales Hospital, 6/2022 - Lessons from Victoria – the impact of the Voluntary Assisted Dying legislation (**William L**)
- Talking HealthTech Autumn Summit, 5/2022 – The Role of Technology & Palliative Care (panel discussion – Cooper M, Lacey J, Margelis G, William L)
- Waipuna Hospice Symposium, 5/2022 – The Revolution Will Not Be Televised (**William L**)
- ANZICS/ ACCM Conference, 4/2022 – Humanising Culture (**William L**)
- ANZICS Leadership Course, 4/2022 – Compassionate Leadership (**William L**)

- Monash University Alumni Masterclass, 4/2022 – Humanising Healthcare: Leadership in the Transformation (**William L**)
- Palliative Care Social Work Australia Webinar, 3/2022 – The Future of Palliative Care: Challenges and Opportunities (**William L**)

OTHER WORKS, INCLUDING INTERVIEWS FOR PUBLICATION/MEDIA

- Supplementary Questions. Inquiry into the provisions of the Voluntary Assisted Dying Bill 2021. ASQON NSW Parliament; 02/2022. <https://www.parliament.nsw.gov.au/lcdocs/other/16708/ASQON%20-%20Leeroy%20William%20-%20received%2015%20February%202022.pdf> (**William L**)
- Australian & New Zealand Society of Palliative Medicine Conference, 9/2022 (Poster) – Characteristics of Deaths Without a Terminal Phase in Inpatient Palliative Care: A Descriptive Retrospective Chart Review (**Remyn E**, **Walpole G**, **William L**)
- Maxim Institute Podcast: The Urgent Case for Accessible Palliative Care (**William L**) - <https://www.maxim.org.nz/article/accessible-palliative-care/>

TEACHING

- Honours supervision, **Samantha Brean**. What tools, frameworks or guidelines are available to facilitate Advance care planning (ACP) discussions within vulnerable and disadvantaged adult populations? A systematic review and narrative synthesis. Monash University – **High Distinction**
- Queensland Palliative Medicine Trainee Education Day, 9/2022 – Voluntary Assisted Dying
- Victorian Palliative Medicine Training Education Program, 4/2022 – Advance Care Planning: Victorian legislation, evidence and practice
- Death & Dying (2nd Yr Medical Students) – Voluntary Assisted Dying (VAD): Conscientious Objection (Podcast) – University of Melbourne (**William L**)
- Eastern Health Grand Round, 7/2022 – The Rise and Fall of PRACCS (Palliative Residential Aged Care Consult Service)
- Final year medical student teaching at Monash University
- Teaching of 3rd year and final year medical students from Monash and Deakin Universities via placements

SURGICAL PROGRAM

PROF SHOMIK SENGUPTA

The various general and specialty surgical units, ICU and Anaesthetics all continued to have a strong academic presence in 2022. We acknowledge the efforts put in at all levels from medical, nursing & allied health staff to help promote research and teaching within these units. The activity and achievements are detailed in subsequent sections below.

ANAESTHESIA

PROJECTS:

Clinical Trials

- ROCKET (Reduction of Chronic Post-Surgical Pain with Ketamine); PI: Dr Gordon Mar
- VAPOR-C (Volatile Anaesthesia and Perioperative Outcomes Related to Cancer); PI: Dr Tarin Ward
- LOLIPOP (Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain); PI: Dr Raja Rengasamy
- CHEWY Trial (Chewing gum to treat post-operative nausea in women); PI: Dr Sue Chew
- POISE-3 (PeriOperative Ischaemic Evaluation-3 Trial); PI: Dr Libia Machado Munoz

Audits

- An Analysis of Perioperative Pain Management In Women Undergoing Caesarean Section; PI: Dr Stephanie Harris
- Audit of Preadmission and Day of Surgery Cancellations for Elective Cases; PI: Dr Sarah Lee
- The Association of Acute Illness Hospitalisation with Cognitive Trajectory in the Sydney Memory and Aging Study; PI: Dr Lucia Chinappa-Quinn
- Preadmission Opioid Use and Perioperative Risk in Colorectal Elective Surgical patients; PI: Dr David Barlow and Dr Gordon Mar
- Consent for Sugammadex Use in Women of Childbearing Age; PI: Dr Joanna Simpson and Dr Tabara Dione
- Media Consumption Change Pertaining to COVID-19; PI: Dr Raja Rengasamy and Dr Aihua Wu

POSTERS:

Presented at 2022 ANZCA ASM

- Rami Dennaoui, Gregory Leverett, Alexander Ho, Raja Rengasamy, Aihua Wu. Patients’ knowledge on COVID-19 pandemic and their attitude towards masking healthcare workers.
- Rami Dennaoui, Gregory Leverett, Alexander Ho, Raja Rengasamy, Aihua Wu. Media consumption change pertaining to COVID-19.
- David Cappellari, Aihua Wu. Cost matters in older hospitalised patients with hip fracture.
- David Cui, Aihua Wu. Perioperative acute kidney injury in elderly patients after hip fracture surgery (CHIEF Study).
- Harrison Yao, Aihua Wu. Anaemia and blood product usage in younger adults after femur fracture surgery: a cohort study.
- Harrison Yao, Aihua Wu. Comparing rates of renal impairment between younger and older adults after femur fracture surgery: a cohort study.

BREAST AND ENDOCRINE SURGICAL RESEARCH

ACTIVE PROJECTS:

- Implementation of intra operative quick PTH monitoring during parathyroid surgery.
- Meta-analysis of existing preoperative clinical models to predict sentinel node status in operable breast cancers.
- Meta-analysis of existing preoperative radiomics based models to predict sentinel node status in operable breast cancers.
- Audit of the skin and nipple sparing mastectomies within the EH breast surgery unit.
- A model to select early breast cancers where sentinel node biopsy may be avoided.
- Developing and implementing a quality assurance and research database for the breast and endocrine surgery unit.

PRESENTATIONS:

Hua L, Benyani SV, James J & Law M. Rationalizing treatment of Lactational mastitis based on Microbiology and clinical outcome (Accepted for poster presentation RACS ASC 2023 Adelaide, Australia).

ENT

POSTERS

- Metastatic melanoma of the tonsil and neck lymph node masquerading as tonsillitis – a case report and literature review. Dr Keith Choong
- Kikuchi-Fujimoto lymphadenitis of the cervical lymph node – a case report and literature review. Dr Keith Choong
- An extremely rare case of skull base giant cell tumour of soft tissue origin. Dr Keith Choong.
- Improving the triaging process for ENT referrals from general practice: An audit of rejected referrals in a Victorian public hospital. Dr Joel Ang and Mr Sor Way Chan
- The use of Telehealth for new referrals in ENT outpatients clinic. Dr Joel Ang and Mr Sor Way Chan
- An audit of ENT conditions in Australian General Practice. Dr Joel Ang and Mr Sor Way Chan
- Right IJV thrombosis secondary to infected SCM haematoma: A subacute complication of chiropractic manipulation. Dr Joel Ang and Mr Sor Way Chan
- Answer to prayer raises more Questions: The resolution of a T4N0 glottic SCC following low dose radiotherapy. Dr Joel Ang and Mr Sor Way Chan

PRESENTATIONS

Creating an Algorithm for Treatment of Head and Neck Squamous Cell Carcinoma of Unknown Primary. M Blom, F O'Duffy, MJR Magarey. Australia and New Zealand Head and Neck Cancer Society 23rd ASM Gold Coast, Australia, August 2022.

Staged Neck Dissection Prior to Transoral Robotic Surgery for Oropharyngeal Cancer – Does it Reduce Post-Operative Complication Rates? A Multi-Centre Study of 91 Patients. A Tescher, MJR Magarey, B Dixon. Australia and New Zealand Head and Neck Cancer Society 23rd ASM Gold Coast, Australia, August 2022.

Difficult Cases in Transoral Robotic Surgery including Supraglottic Laryngectomy. MJR Magarey. 2022 Surgical Robotics Innovation Summit, Sydney, Australia, June 2022.

PLASTIC SURGERY RESEARCH

ONGOING PROJECTS

- ALLERGAN, CMO-AP-FAS-0505; CONTOUR Australia: Condition of Submental Fullness and Treatment Outcomes Registry.
- Thermodynamics in Free Flaps (Collaborative project between Department of Plastic Surgery, Eastern Health, Department of Intensive Care, Eastern Health, and Dept Engineering, Monash University).
- Referral practices of general surgeons to plastic surgeons for post-mastectomy reconstruction
- A Multi-Centre Analysis of Breast Surgery with the Breast Q PROMs Score (Multi-centre Study – Peter MacCallum, Eastern Health, St Vincent’s Hospital, and the Austin Hospital).
- Flexor Tendon Rehab Protocols: A Prospective Study (Multi-Disciplinary Study between Department of Hand therapy and Department of Plastic Surgery, Eastern Health).

PRESENTATIONS

- Lin F. Australian Society of Aesthetic Plastic Surgeons (ASAPS) Annual Conference. October 14-16, 2022 Melbourne. Session 2: Non-surgical modality for body contouring.
- Lin F. Aesthetics 2022, August 7, 2022 Sydney. The aspiration manoeuvre and stability of position.
- Lin F. Australian Society of Aesthetic Plastic Surgeons (ASAPS) Non Surgical Symposium 2022. June 2-5, 2022, Gold Coast, Australia. Anatomy for Injectors Cadaver Dissection Course: Dissector and faculty.
- Lin F. Australian Society of Aesthetic Plastic Surgeons (ASAPS) Non Surgical Symposium 2022. June 2-5, 2022, Gold Coast, Australia. Session 5C: Body contouring.Lin F. Australian Society of Aesthetic Plastic Surgeons (ASAPS) Non Surgical Symposium 2022. June 2-5, 2022, Gold Coast, Australia. Session 8A: Treating submalar depression using HA in Asian patients.
- Lin F. Australian Society of Aesthetic Plastic Surgeons (ASAPS) Non Surgical Symposium 2022. June 2-5, 2022, Gold Coast, Australia. Session 9C: Novel use of micro-botulinum toxin for skin quality.
- Lin F. Australian Society of Aesthetic Plastic Surgeons (ASAPS) Non Surgical Symposium 2022. June 2-5, 2022, Gold Coast, Australia. Session 10B: Novel use of high dose botulinum toxin for body contouring.
- Lin F. Australian Society of Aesthetic Plastic Surgeons (ASAPS) Non Surgical Symposium 2022. June 2-5, 2022, Gold Coast, Australia. Session 10B: HIFEM and RF.
- Lin F. Merz Aesthetic Nurse Academy Annual Conference, May 21, 2022, Sydney. Session 1: Anti-wrinkle and soft tissue fillers. Microtox.
- Lin F. Merz Aesthetic Nurse Academy Annual Conference, May 21, 2022, Sydney. Session 3: Facial contouring.
- Lin F. Merz Aesthetic Nurse Academy Annual Conference, May 21, 2022, Sydney. Session 4: Neocollagenesis.

- Lin F. Merz Aesthetic Nurse Academy Annual Conference, May 21, 2022, Sydney. Session 5: Skin lifting and tightening.
- Lin F. Australian Society of Cosmetic Dermatologists ASCD 2022 Symposium, Feb 25-27, 2022, Melbourne. Session 3A: The aspiration manoeuvre and stability of position.
- Lin F. Australian Society of Cosmetic Dermatologists ASCD 2022 Symposium, Feb 25-27, 2022, Melbourne. Session 7B (Session moderator and presentation): HIFEM and RF in body contouring.
- Rozen WM. The Effect Of Chemotherapy On The Complication Rates Of Breast Reconstruction: A Systematic Review And Meta-Analysis.
- Royal Australasian College of Surgeons, Australasian Annual Scientific Congress, Adelaide, Australia, May 2023.
- Rozen WM. Systematic Review of Breast-Q: A Tool to Evaluate Post-Mastectomy Breast Reconstruction.
- Royal Australasian College of Surgeons, Australasian Annual Scientific Congress, Adelaide, Australia, May 2023.
- Rozen WM. Squamous Cell Carcinoma Arising in Mycobacterium Ulcerans of the Scalp: A Case Report.
- Royal Australasian College of Surgeons, Australasian Annual Scientific Congress, Adelaide, Australia, May 2023.
- Rozen WM. Preoperative and Intraoperative Perforator Assessment: Advances in CT Angiography of the Abdominal Wall. 2nd Congress of International Confederation of Plastic Surgery Societies (ICOPLAST), Dubai, UAE, May 2023.
- Rozen WM. Advances in the Application of CT Angiography of the Abdominal Wall.
- 2th Congress of WSRM (World Society of Reconstructive Microsurgery), Singapore, Aug 2023.
- Rozen WM. Minimally Invasive Options for Dupuytren’s Disease: Percutaneous Needle Fasciotomy and Collagenase.
- ASPS (Australian Society of Plastic Surgery) and Australasian Foundation of Plastic Surgery, Plastic Surgery Conference, Gold Coast Convention and Exhibition Centre, Gold Coast,

- Queensland, Australia, June 2022.
- Rozen WM. The Innervated Rectus Abdominis Perforator Turndown (RAPT) Flap For Preserving Rectus Continuity: A DIEP Alternative?
- ASPS (Australian Society of Plastic Surgery) and Australasian Foundation of Plastic Surgery, Plastic Surgery Conference, Gold Coast Convention and Exhibition Centre, Gold Coast, Queensland, Australia, June 2022.
- Rozen WM. Technological Advances in Preoperative Planning for Free Flaps in Breast Reconstruction.
- ICOPLAST (International Confederation of Plastic Surgery Societies, First World Congress, Swissotel Lima, Lima, Peru, May 2022.
- Rozen WM. The Effect of Adjuvant Therapies on Microvascular Complications in Breast Reconstruction
- ICOPLAST (International Confederation of Plastic Surgery Societies, First World Congress, Swissotel Lima, Lima, Peru, May 2022.
- Rozen WM. New Frontiers in Microvascular Imaging Techniques: How I Do It.
- 11th Congress of WSRM (World Society of Reconstructive Microsurgery), Cancun, Mexico, June 2022.
- Rozen WM. Applying Plastic Surgery Principles To Ovarian Tissue Transplantation.
- 2022 Royal Australia and New Zealand College of Obstetrics and Gynaecology (RANZCOG) Symposium, Melbourne Park, Victoria, Australia, Feb 2022.
- Rozen WM. Plast Reconstr Surg Glob Open Keynotes Podcast: The Innervated Rectus Abdominis Perforator Turndown (RAPT) Flap For Preserving Rectus Continuity: A DIEP Alternative?
- PRS-GO Podcast, Accessed online: <https://journals.lww.com/prsgo/pages/podcasts.aspx>, Feb 2022.

UPPER GI SURGERY RESEARCH

COMPLETED PROJECTS

- User-friendly CT measurement methods of common bile duct fluid density to predict presence of choledocholithiasis
Team: J Goonawardena, N Bull, S Joglekar, L Hua, D Lim, R Cade, S Hassen, A Fox
Presented at ANZHPBA 2022, Sunshine Coast QLD and awarded best paper
- Prevalence and outcomes of pulmonary lesions on CT chest on patients with suspected pancreatic cancer
Team: K Ji, J Goonawardena, S Joglekar, S Hassen
Presented at ANZHPBA 2022, Sunshine Coast QLD
- PAP trial: single blinded randomised controlled trial evaluating effects of postoperative abscess packing versus no packing
Team: J Goonawardena, K Cheung
Presented at World Society Emergency Surgery WSES 2022 and Genera Surgeons Australia 2022 Sydney - awarded best paper
- Systematic review on utility of Gadolinium-based contrast agents for ERCP
Team: T Hung, J Goonawardena, S Hassen, A Fox
Presented at Royal Australian and New Zealand College of Radiologists Annual Scientific Meeting 2022, Queenstown New Zealand
- Systematic review: Is it time for indocyanine green guided lymph node dissection in gastric cancer surgery?
Team: J Goonawardena, K Cheung
Presented International Gastric Cancer Congress 2022, MDAnderson cancer centre, Texas, USA
- Changes in the pancreas anatomy with massive splenomegaly
Team: W Tjang, J Goonawardena, S Hassen
Presented at Monash SIP student presentations
- Are the screening guidelines for branch duct intraductal papillary mucinous neoplasms cost effective in an Australian setting?
- Abnormal pancreaticobiliary junction anatomy and pancreatitis

PRESENTATIONS:

- PAP trial: single blinded randomised controlled trial evaluating effects of postoperative abscess packing versus no packing – oral presentation by Dr Janindu Goonawardena at 9th International Congress of the World Society of Emergency Surgery (WSES) 2022, Perth
- Systematic review on utility of Gadolinium-based contrast agents for ERCP – ePoster presentation by Tim Hung at Royal Australian and New Zealand College of Radiologists Annual Scientific Meeting 2022, Queenstown NZ
- Is it time for indocyanine green guided lymph node dissection in gastric cancer surgery? – presentation by Dr Janindu Goonawardena at the International Gastric Cancer Congress 2022, Texas, USA
- User-friendly radiological measurement methods of common bile duct fluid density to predict presence of choledocholithiasis – oral presentation by Janindu Goonawardena at the Australian and New Zealand Hepatic, Pancreatic and Biliary Association (ANZHPBA) and the Australian and Aotearoa New Zealand Gastric and Oesophageal Surgery Association (AANZGOSA), the 2022 Annual Meeting, Sunshine Coast, QLD
- Sarcopenia is prevalent and decreases survival in patients undergoing major upper gastrointestinal resection for malignancy – oral presentation by Dr Enoch Wong at the Australian and New Zealand Hepatic, Pancreatic and Biliary Association (ANZHPBA) and the Australian and Aotearoa New Zealand Gastric and Oesophageal Surgery Association (AANZGOSA), the 2022 Annual Meeting, Sunshine Coast, QLD
- Utility of additional chest imaging for detecting metastases in patients with suspected pancreatic cancer – oral presentation by Dr Katharine Ji at the Australian and New Zealand Hepatic, Pancreatic and Biliary Association (ANZHPBA) and the Australian and Aotearoa New Zealand Gastric and Oesophageal Surgery Association (AANZGOSA), the 2022 Annual Meeting, Sunshine Coast, QLD

AWARDS:

- Can change in sarcopenia during neoadjuvant therapy predict survival after oesophageal cancer surgery? - oral presentation by Dr Shantanu Joglekar at the Australian and New Zealand Hepatic, Pancreatic and Biliary Association (ANZHPBA) and the Australian and Aotearoa New Zealand Gastric and Oesophageal Surgery Association (AANZGOSA), the 2022 Annual Meeting, Sunshine Coast, QLD
- Fully Covered Expandable Metal Stent for Early, Definitive Endoscopic Management of Bile Duct Injury – eposter presentation by Dr Shantanu Joglekar 15th World Congress of the International Hepato-Pancreato-Biliary Association 2022, New York, USA
- Defining the Patterns of Liver Enzyme Derangement in Acute Cholangitis: Is It Enough to Be Cholestatic? - eposter presentation by Dr Shantanu Joglekar 15th World Congress of the International Hepato-Pancreato-Biliary Association 2022, New York, USA
- Awarded best free abstract paper presentation at the Australian and New Zealand Hepatic, Pancreatic and Biliary Association (ANZHPBA) and the Australian and Aotearoa New Zealand Gastric and Oesophageal Surgery Association (AANZGOSA), the 2022 Annual Meeting, Sunshine Coast, QLD - Dr Janindu Goonawardena
- Best research paper award at the General Surgeons Australia Annual Scientific Meeting, Sydney 2022 - Dr Janindu Goonawardena

UROLOGY RESEARCH

HIGHER-DEGREE STUDENTS

- Ruchira Nandurkar (PhD) and Ghadir Omran (MSurg) have submitted their theses, Josh Kealey (MSurg) finalising for submission
- Antara Karmakar enrolled and commenced MSurg
- Ruth Snider continuing MSurg

CONFERENCE INVOLVEMENT BY UNIT MEMBERS

AUA 2022 (New Orleans)

- AUATV featured video on EH Urology Unit leadership & affirmative action for diversity USANZ 2022 ASM (Gold Coast)
- Shomik Sengupta - ANZUP trials and why urologists should get involved (Plenary talk)
- Caroline Dowling - Diversity, equity and inclusion: USANZ (Plenary talk), Session chair (Functional urology breakout)
- Courtenay West – poster session moderator
- Briony Norris – robotics & oncology (chair) workshop faculty, session chair (renal)
- Dixon Woon – oncology workshop faculty
- Mel Caruso – Nursing Program (ANZUNS) scientific convenor

USANZ Qld section mtg

- Caroline Dowling – keynote invited speaker

USANZ Trainee week (Melbourne)

- Adam Landau (organising committee, session chair)
- Panellists: Angus Lecuona, Peter Wong & Shomik Sengupta

ANZUP 2022 (Adelaide)

- Shomik Sengupta – Bladder/urothelial cancer panellist in MDT Masterclass, Poster walkabout chair

UAA 2022 (Sydney)

- Shomik Sengupta – scientific co-convenor, workshop chair & faculty
- Caroline Dowling – session chair (pelvic organ prolapse)
- Courtenay West – session chair (stones & endo-urology)

SIU 2022 (Montreal)

- Shomik Sengupta – session chair (advanced prostate cancer)

PCFA video featuring Mel Caruso, Prostate Cancer Specialist Nurse: <https://youtu.be/CjGYQ-EGyEQ>

GENITOURINARY CANCER SURVIVORSHIP

Genitourinary cancer survivorship – management of adverse effects of cancer treatment and improvement of quality of life during cancer survivorship: Henry Yao (PhD student).

This project brings together several initiatives with the common theme of understanding the experiences of patients with genitourinary cancers and include study into the following topics:

- Overactive bladder in patients with newly diagnosed prostate cancer and following treatment for localised prostate cancer. EHCS collaborated with University of Calgary in studying this topic. Part of this study was funded by the Movember grant in Canada and involved looking into incidence of overactive bladder in patients diagnosed with prostate cancer and following treatment with radical prostatectomy. Systematic review of the literature was conducted looking at the impact of radical prostatectomy and radiotherapy on bladder function.
- Outcomes after high intensity focused ultrasound (HIFU) treatment for prostate cancer. We collaborated with A/ Prof Peter Royce at Alfred Health to study the outcome of HIFU treatment for prostate cancer including quality of life outcome measures.
- Sexual function after robot-assisted radical prostatectomy. EHCS collaborated with Nottingham University Hospitals NHS Trust to look into factors that can impact on sexual function recovery following RARP for men with localised prostate cancer.

- Management of bladder neck contractures. EHCS collaborated with Western Health to examine the outcome of mitomycin injection for the treatment of bladder neck contractures. We also collaborated with University of Calgary to examine the outcome of YV plasty for the management of bladder neck contractures.
- Quality of life outcomes in penile cancer patients. This ongoing project is done in collaboration with Professor Catherine Paterson and will examine the impact of penile cancer diagnosis and management on quality of life of patients and carers.

GENITAL PROTECTORS IN SPORT: ARE THEY FIT FOR PURPOSE?

Dr Ghadir Omran

One of our HDR students, Ghadir Omran, completed his Masters of Surgery in late 2022. His project was examining the use of genital protectors for the prevention of sporting injuries especially in cricket. Noting an absence of Australian testing or accreditation standards, Ghadir set out to investigate ways to test genital protectors in terms of their resilience against impact. His experiments aiming to replicate real-life conditions during match play were done by utilising bowling machines at indoor nets at the Hawthorn Cricket Centre and at outdoor nets at Nettleton Park (pictured, with thanks to the STC South Camberwell Cricket Club: <https://www.stccricket.com.au/>). Ghadir's thesis was well received by examiners and has recently been certified. We congratulate him on the anticipated conferring of his degree in the near future.



ACADEMIC OUTPUTS

RESEARCH FUNDING

EHCS received a total of \$13.3M in research funding in 2022, representing 12 grants - 7 in Category 1; 5 in Category 2.

Figures in previous EHCS Annual Reports were based on grants awarded, not funds received.

For comparison: research funding actually received in 2021 was \$11.8M.

Funding Category	Funding Subcategory	Funding Awarded	Award Count
Category 1	Medical Research Future Fund (MRFF)	\$3,062,190	2
	National Health and Medical Research Council (NHMRC)	\$6,192,341	4
	Other	\$75,000	1
Category 1		\$9,329,531	7
Category 2	Commonwealth (own purpose)	\$679,135	2
	State/Territory/Local (other)	\$50,000	1
	State/Territory/Local (own purpose)	\$334,520	2
Category 2		\$1,063,655	5
Total		\$10,393,186	12

Field of Research - Division	Field of Research - Group	Funding Awarded	Award Count
11 Medical and Health Sciences	1117 Public Health and Health Services	\$160,000	1
16 Studies in Human Society	1605 Policy and Administration	\$40,000	1
UNKNOWN	UNKNOWN	\$10,193,186	11

PUBLICATIONS

These figures are derived from the Monash University Pure system and are likely to be incomplete in terms of outputs by adjuncts, and incomplete collection of conference presentations.

Summary				
Output Indicator - Research	2022		Total	
	Output Count	% of Total	Output Count	% of Total
Research	221	79%	221	79%
Not Research	58	21%	58	21%
Total	279	100%	279	100%

Research	2022		Total	
Output Subtype (Top 5)	Output Count	% of Total	Output Count	% of Total
Article (journal)	193	87%	193	87%
Review Article (journal)	26	12%	26	12%
Chapter (Book)	1	0.5%	1	0.5%
Other Report	1	0.5%	1	0.5%
Total	221	100%	221	100%
External Co-Authorship Type ¹	Output Count	% of Total	Output Count	% of Total
External Australian Co-Authorship	176	80%	176	80
External International Co-Authorship	66	30%	66	30%
Total External Co-Authorship	184	83%	184	83%
Quality International Co-Authorship ²	38	21%	³ 38	21%

Not Research	2022		Total	
Output Subtype (Top 5)	Output Count	% of Total	Output Count	% of Total
Article (journal)	22	38%	22	38%
Comment / Debate (journal)	11	19%	11	19%
Letter (journal)	7	12%	7	12%
Meeting Abstract (journal)	5	9%	5	9%
Chapter (Book)	4	7%	4	7%
Review Article (journal)	4	7%	4	7%
Other	5	9%	5	9%
Total	58	100%	58	100%
External Co-Authorship Type ¹	Output Count	% of Total	Output Count	% of Total
External Australian Co-Authorship	37	64%	37	64%
External International Co-Authorship	17	29%	17	29%
Total External Co-Authorship	42	72%	42	72%
Quality International Co-Authorship ²	10	24%	³ 10	24%

RESEARCH

		2022	Total
Field of Research - Division	Field of Research - Group	Output Count	Output Count
13 Education	1302 Curriculum and Pedagogy	1	1
13 Education		1	1
17 Psychology and Cognitive Sciences	1701 Psychology	1	1
17 Psychology and Cognitive Sciences		1	1
UNKNOWN	UNKNOWN	219	219
UNKNOWN		219	219
Total		221	221

NOT RESEARCH

		2022	Total
Field of Research - Division	Field of Research - Group	Output Count	Output Count
UNKNOWN	UNKNOWN	58	58
UNKNOWN		58	58
Total		58	58



PUBLICATIONS

AGED MEDICINE RESEARCH AND TEACHING

Taylor C, Wagner I, Jaboury S, Bucki T, Srivastava R. **Australian Geriatric Oncology Clinic - Characteristics of the first 220 patients, the interventions and treatment recommendations made.** Geriatric Oncology. doi.org/10.1016/j.jgo.2021.12.015

Lee C, Beavers J, Pham J, Hackett L, Miller J, Buntine P. **Impact of the Canadian CT head rule supplemented by the original published minimum inclusion criteria to assist emergency department clinicians’ assessment of patients presenting post fall from residential aged care: a retrospective audit.** BMC Geriatrics. doi.org/10.1186/s12877-022-03284-0

DERMATOLOGY

Lopez, D.J., Singh, A., Waidyatillake, N.T., Su, J.C., Bui, D.S., Dharmage, S.C., Lodge, C.J. and Lowe, A.J. **The association between domestic hard water and eczema in adults from the UK Biobank cohort study.** Br J Dermatol, 187: 704-712. Goh MSY, Yun JSW, Su JC. Management of atopic dermatitis: a narrative review. Med J Aust 2022; 216 (11): 587-593. doi.org/10.5694/mja2.51560

Davenport R, Su JC, Nathalie J, Richmond CM, Yang Tan T, Robertson SJ. **Clinical overlap of PHACE and LUMBAR syndromes.** Pediatr Dermatol. 2022 Sep;39(5):752-756. doi.org/10.1111/pde.15031

Lopez DJ, Lodge CJ, Bui DS, Waidyatillake NT, Abramson MJ, Perret JL, Su JC, Erbas B, Svanes C, Dharmage SC, Lowe AJ. **Establishing subclasses of childhood eczema, their risk factors and prognosis.** Clin Exp Allergy. 2022 Sep;52(9):1079-1090. doi.org/10.1111/cea.14139

Chan O.B., Su J.C, Yazdabadi A, Chan A. **Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor.** Asia Pac J Oncol 2022 Apr;18(2):e154-e156. doi.org/10.1111/ajco.13585

Sivasaththivel M, Howard MD, Yazdabadi A. **Acral fibromyxoma: a rare plantar nodule.** BMJ Case Rep. 2022 Jun 24;15(6):e247565. doi.org/10.1136/bcr-2021-247565

Rahimi H, Mirnezami M, Yazdabadi A. **Bilirubin as a new antioxidant in melasma.** J Cosmet Dermatol. 2022 Nov;21(11):5800-5803. doi.org/10.1111/jocd.15240

Gan C, Howard MD, Mulcahy A, Yazdabadi A. **Painful ulcerations: the sole clinical sign of mixed cryoglobulinaemia secondary to marginal zone lymphoma.** BMJ Case Rep. 2022 Apr 7;15(4):e247780. doi.org/10.1136/bcr-2021-247780

EASTERN HEALTH INTENSIVE CARE RESEARCH (EHICR)

Breik L, Tatucu-Babet OA, Paul E, Duke G, Elliott A, Ridley EJ. **Micronutrient intake from enteral nutrition in critically ill adult patients: A retrospective observational study.** Nutrition. 2022 Mar;95:111543. doi.org/10.1016/j.nut.2021.111543

Chan, P.Y., Ryan, N.P., Chen, D., McNeil, J. and Hopper, I. **Novel wearable and contactless heart rate, respiratory rate, and oxygen saturation monitoring devices: a systematic review and meta-analysis.** Anaesthesia, 77: 1268 1280. doi.org/10.1111/anae.15834

Chan, P.Y., Tay, A., Chen, D. et al. **Comparison of cutaneous facial temperature using infrared thermography to standard temperature measurement in the critical care setting.** J Clin Monit Comput 36, 1029–1036 (2022). doi.org/10.1007/s10877-021-00731-y

Cody R, Mohsenifard M, Yip G, Aldridge E, Bridge F et al. **Worth the risk? Contemporary indications, yield and complications of lumbar punctures in a metropolitan Australian health service.** Intern Med J. 2022 Mar 30. doi.org/10.1111/imj.15761

Corrigan C, Duke GJ, Millar J, et al. **Admissions of Children and Adolescents With Deliberate Self-harm to Intensive Care During the SARS-CoV-2 Outbreak in Australia.** Jama Netw Open. 2022;5(5):e2211692. doi:10.1001/jamanetworkopen.2022.11692

Doherty Z, Kippen R, Bevan D, Duke GJ, Williams S, Wilson A, Pilcher D. **Long-term outcomes of hospital survivors following an ICU stay: A multi-centre retrospective cohort study.** PLoS One. 2022 Mar 28;17(3):e0266038. doi.org/10.1371/journal.pone.0266038

Duke GJ, Bishara M, Hirth S, Lim LL, Worth LJ. **Performance of hospital administrative data for detection of sepsis in Australia: The sepsis coding and documentation (SECOND) study.** Health Inf Manag J. Published online 2022. doi.org/10.1177/18333583221107713

Duke GJ, Loughnan D, Frietas MD, et al. **Clinical evaluation of the national hospital-acquired complication programme.** Intern Med J. 2022;52(11):1910-1916. doi.org/10.1111/imj.15468

Duke GJ, Moran JL, Bersten AD, et al. **Hospital-acquired complications: the relative importance of hospital- and patient-related factors.** Med J Australia. 2022;216(5):242-247. doi.org/10.5694/mja2.51375

Edwards MJ, Duke GJ, Hakendorf P, Verghese S, Bihari S. **Hospital Acquired Complications in South Australian major public hospitals. Anaesth Intens Care.** Published online 2022. doi.org/10.1177/0310057x221092460

Florescu S, Stanciu D, Zaharia M, et al. **Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.** Jama 16 Dec 2022;329(1). doi.org/10.1001/jama.2022.23257

Nguyen-Duc T, Tay A; Chen D, Nguyen JT, Lyall J, De Frietas M, Chan PY. **Estimation of Clinical Workload and Patient Activity Using Deep Learning and Optical Flow.** IEEE Sensors Letters, vol. 6, no. 7, pp. 1-4, July 2022, Art no. 3501504. doi.org/10.1109/LSSENS.2022.3181600

PLUS Study Investigators and the Australian New Zealand Intensive Care Society Clinical Trials Group. **Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults.** N Engl J Med. 2022 Mar 3;386(9):815-826. PMID: 35041780. doi.org/10.1056/NEJMoa2114464.

Rasiah S, Braude D, Tan AXJ, Fevre PJL, Duke GJ. **Ocular injuries during prone ventilation.** Trends Anaesth Critical Care. Published online 2022. doi.org/10.1016/j.tacc.2022.08.005

REMAP-CAP Investigators. **Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.** JAMA. 2022 Apr 5;327(13):1247-1259. PMID: 35315874; PMCID: PMC8941448. doi.org/10.1001/jama.2022.2910

STARRT-AKI Investigators. **A Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial.** Crit Care. 2022 Aug 25;26(1):255. PMID: 36008827. doi.org/10.1186/s13054-022-04120-y

STARRT-AKI Investigators. **Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial.** Intensive Care Med. 2022 Dec;48(12):1736-1750. doi.org/10.1007/s00134-022-06912-w

STARRT-AKI Investigators. **The Effect of an Accelerated Renal Replacement Therapy Initiation Is Not Modified by Baseline Risk.** Ann Am Thorac Soc. 2022 Sep;19(9):1613-1618. PMID: 35587363. doi.org/10.1513/AnnalsATS.202201-046RL

EMERGENCY MEDICINE

Buntine P, Miller J, Pope A, Guy S, Wong FQA, McDonald H, Ahmed M, Teow KH, Roney M, Mohammadi F, Aldridge E, Hackett L, Jenner S, Davis B. **Negative predictive value of the FebriDx host response point-of-care test in patients presenting to a single Australian emergency department with suspected COVID-19: an observational diagnostic accuracy study.** BMJ Open. 2022 Dec 29;12(12):e065568. doi.org/10.1136/bmjopen-2022-065568

Craige EA, Tagliaferri SD, Ferguson SA, Scott H, Belavy DL, Easton DF, Buntine P, Memon AR, Owen PJ, Vincent GE. **Effects of pharmacotherapy on sleep-related outcomes in adults with chronic low back pain: A systematic review and meta-analysis of randomised controlled trials.** EClinicalMedicine. 2022 Nov 18;55:101749. doi.org/10.1016/j.eclinm.2022.101749

Belavy DL, Tagliaferri SD, Buntine P, Saueressig T, Ehrenbrusthoff K, Chen X, Diwan A, Miller CT, Owen PJ. **Interventions for promoting evidence-based guideline-consistent surgery in low back pain: a systematic review and meta-analysis of randomised controlled trials.** Eur Spine J. 2022 Nov;31(11):2851-2865. doi.org/10.1007/s00586-022-07378-6

Lee C, Beavers J, Pham J, Hackett L, Miller J, Buntine P. **Impact of the Canadian CT head rule supplemented by the original published minimum inclusion criteria to assist emergency department clinicians’ assessment of patients presenting post fall from residential aged care: a retrospective audit.** BMC Geriatr. 2022 Jul 21;22(1):607. doi. org/10.1186/s12877-022-03284-0

Gurazada SG, Gao SC, Burstein F, Buntine P. **Predicting Patient Length of Stay in Australian Emergency Departments Using Data Mining.** Sensors (Basel). 2022 Jun 30;22(13):4968. doi.org/10.3390/s22134968

Nogic J, MacPherson M, Aldridge E, Sajeev JK, Roberts L, Lowman D, Sze S, Kwong A, Buntine P, Teh AW; MAGMAR Investigators. **Magnesium in the Management of Atrial Fibrillation With Rapid Ventricular Response.** JACC Clin Electrophysiol. 2022 Jun;8(6):800-802. doi.org/10.1016/j. jacep.2022.01.017

Stratton H, Buntine P, Ng RBR, Fu JJ, Joshi N, Yip G, Guy S, Chean R, Newnham E, Lau JSY. **Impact of SARS-CoV-2 transmission-based precautions on inpatient management of general medical patients.** Intern Med J. 2022 May;52(5):859-863. doi.org/10.1111/imj.15697

Buntine P, Aldridge ES, Craig S, Crellin D, Stella J, Gill SD, Wright B, Mitchell RD, Arendts G, Rawson H, Rojek AM. **Behavioural drivers influencing emergency department attendance in Victoria during the 2020 COVID-19 pandemic: A mixed methods investigation.** Emerg Med Australas. 2022 Oct;34(5):758-768. doi.org/10.1111/1742-6723.13973

Beavon E, Aldridge E, Grills N, Buntine P. **Working together to strengthen the fence: the interplay between emergency medicine and public health.** Aust N Z J Public Health. 2022 Apr;46(2):109-110. doi.org/10.1111/1753-6405.13220

Belavy DL, Tagliaferri SD, Buntine P, Saueressig T, Samanna C, McGuckian T, Miller CT, Owen PJ. **Reducing Low-Value Imaging for Low Back Pain: Systematic Review With Meta-analysis.** J Orthop Sports Phys Ther. 2022 Apr;52(4):175-191. doi.org/10.2519/jospt.2022.10731

Cody R, Mohsenifard M, Yip G, Aldridge E, Bridge F, Datta M, Guy S, Jordan P, Kyndt C, Newnham E, Ng M, Paul E, Roodenburg O, Senanayake C, Sparham S, Steele M, Dewey H. **Worth the risk? Contemporary indications, yield and complications of lumbar punctures in a metropolitan Australian health service.** Intern Med J. 2022 Mar 30. doi.org/10.1111/imj.15761

Belavy DL, Tagliaferri SD, Buntine P, Saueressig T, Sadler K, Ko C, Miller CT, Owen PJ. **Clinician education unlikely effective for guideline-adherent medication prescription in low back pain: systematic review and meta-analysis of RCTs.** EClinicalMedicine. 2022 Jan 3;43:101193. doi. org/10.1016/j.eclinm.2021.101193

Nguyen AL, Kirkwood B, Hackett L, Buntine P. **Validation of the ECHS non trauma cranial CT rule in Australia: A prospective cohort study.** Am J Emerg Med. 2022 Feb;52:225-231. doi.org/10.1016/j.ajem.2021.12.004

Sedgman R, Aldridge E, Miller J, Fleming D, Buntine P. **Pre-triage wait times for non-ambulance arrivals in the emergency department: A retrospective video audit.** Australas Emerg Care. 2022 Jun;25(2):126-131. doi. org/10.1016/j.auec.2021.11.002

Lines T, Burdick C, Dewez X, Aldridge E, Neal-Williams T, Walker K, Akhlaghi H, Paul B, Taylor DM. **Nature and extent of selection bias resulting from convenience sampling in the emergency department.** Emerg Med J. 2022 Apr;39(4):325-330. doi.org/10.1136/emered-2021-211390

Kwong A, Aldridge ES, Jayawardana R, Brookwick A, Miller J, Buntine PG. **Length of stay outcomes in patients receiving ketamine sedation versus Bier’s block anaesthesia for procedural closed fracture reduction: A retrospective audit of paediatric emergency department patients.** Emerg Med Australas. 2022 Feb;34(1):73-77. doi.org/10.1111/1742-6723.13844

Walker K, Jiarpakdee J, Loupis A, Tantithamthavorn C, Joe K, Ben-Meir M, Akhlaghi H, Hutton J, Wang W, Stephenson M, Blecher G, Paul B, Sweeny A, Turhan B. **Emergency medicine patient wait time multivariable prediction models: a multicentre derivation and validation study.** Australasian College for Emergency Medicine, Clinical Trials Network. Emerg Med J. 2022 May;39(5):386-393. doi. org/10.1136/emered-2020-211000

ENDOCRINOLOGY

Yee, M.L., Gilfillan, C.P. et al. **Evaluation of an alternative skeletal muscle index for skeletal muscle mass assessment in a group of Australian women.** Age Ageing, 2022. 51(2). doi.org/10.1093/ageing/afac002

Potter, E., Gilfillan, C. P. et al. **Physician-Authored Feedback in a Type 2 Diabetes Self-management App: Acceptability Study.** JMIR Form Res, 2022. 6(5): p. e31736. doi. org/10.2196/31736

Peiris, C., Gilfillan, C. P. et al. **Understanding the hidden epidemic of metabolic syndrome in people accessing community rehabilitation: a cross-sectional study of physical activity, dietary intake, and health literacy.** Disabil Rehabil, 2022: p. 1-9. doi.org/10.1080/09638288.2022.2065540

Loganathan, J., Gilfillan, C. P. et al. **A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study).** J Diabetes Complications, 2022. 36(5): p. 108188. doi.org/10.1016/j. jdiacomp.2022.108188

Hamblin PS, Wong R, Ekinci E, et al. **Invited Comment to Letter: Capillary ketone concentrations at the time of colonoscopy: A cross-sectional study with implications for SGLT2 inhibitor-treated type 2 diabetes.** Diabetes Care 2022; 45:e17-e18. doi.org/10.2337/dc21-0256

Wang R, Rajanayagam S, Ngan J, Renouf DA. **Incidence of Post-denosumab Rebound Hypercalcaemia in Bony-Metastatic Breast Cancer.** Calcif Tissue Int. 2022 Oct;111(4):391-395. doi.org/10.1007/s00223-022-01002-x

Wang R, Better N, Sivaratnam D, Westcott J, Forehan S, Christie M, Pattison DA, Fournalanos S. **99m Tc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis : Functional Imaging-Histopathologic Correlation.** Clin Nucl Med. 2022 Sep 1;47(9):e582-e584. doi.org/10.1097/RLU.0000000000004332

Wang R, Renouf DA. **Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.** Osteoporos Int. 2022 Jul;33(7):1625-1629. doi.org/10.1007/s00198-022-06369-z

Wang R, Tan CY. **A rare case of reversible adrenal insufficiency from primary adrenal lymphoma.** Intern Med J. 2022 Apr;52(4):689-690. doi.org/10.1111/imj.15744

Zanker J, ..., Grossmann M et al. **The Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) sarcopenia diagnosis and management task force: Findings from the consumer expert Delphi process.** Australasian Journal on Ageing. (Impact Factor: 1.30). doi. org/10.1111/ajag.13164

Russell N, Hoermann R, Cheung AS, Zajac JD, Grossmann M. **Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial.** European Journal of Endocrinology 2022; 187:617-627. (Impact Factor: 6.66). doi.org/10.1530/EJE-22-0318

Pan B, Ahern NJ, Shakespeare T, Grossmann M, Wong PKK. **Bone health assessment with dual energy X-ray absorptiometry in men with high-risk prostate carcinoma commencing adjuvant androgen deprivation therapy.** Reports of Practical Oncology and Radiotherapy 2022;27(4):677-683. (Impact Factor: 1.31). doi.org/10.5603/RPOR.a2022.0069

Russell N, Ghasem-Zadeh A, Hoermann R, Cheung AS, Zajac JD, Shore-Lorenti C, Ebeling PR, Handelsman DJ, Grossmann M. **Effects of estradiol on bone in men undergoing androgen deprivation therapy: a randomised placebo-controlled trial.** European Journal of Endocrinology 2022; 187:241-256. (Impact Factor: 6.66). doi.org/10.1530/EJE-22-0227

Hudson J, ..., Grossmann M et al. **Adverse cardiovascular events and mortality in men during testosterone treatment: results of individual patient and aggregate data meta-analyses.** Lancet Healthy Longevity 2022; 3:e381-e393. (Impact Factor: not yet reported). doi. org/10.1016/S2666-7568(22)00096-4

Nolan B, Frydman AS, Leemaqz SY, Carroll M, Grossmann M, Zajac JD, Cheung AS. **Effects of micronised progesterone on sleep, psychological distress and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study.** Endocrine Connections 2022; 11:e220170. (Impact Factor: 3.34). doi. org/10.1530/EC-22-0170

Warren AM, Grossmann M, Hoermann R, Zajac JD, Russell N. **Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): Design and implementation of an open-label randomised trial.** Trials 2022; 23:335. (Impact Factor: 2.05). doi.org/10.1186/s13063-022-06237-5

Apostolov R, Gianatti E, Wong D, Kutaiba N, Gow P, Grossmann M, Sinclair M. **Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations.** World Journal of Hepatology 2022; 14:754-765. (Impact Factor: 3.17). doi.org/10.4254/wjh.v14.i4.754

Russell N, Allebone J, Dandash O, Hoermann R, Cheung AS, Zajac JD, Handelsman DJ, Kanaan R, Grossmann M. **Effect of estradiol on cognition in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial.** Clinical Endocrinology (Oxf) 2022; 97:622-633. (Impact Factor: 3.37). doi.org/10.1111/cen.14689

Handelsman DJ, Desai R, Conway AJ, Shankara-Narayana N, Stuckey BGA, Inder W, Grossmann M, Yeap BB, Jesudason D, LY LP, Bracken K, Wittert GA. **Recovery of Male Reproductive Endocrine Function After Ceasing Prolonged Testosterone Undecanoate Injections.** European Journal of Endocrinology 2022; 186:307-318 (Impact Factor: 6.66). doi.org/10.1530/EJE-21-0608

Bretherton I, Ghasem-Zadeh A, Leemaqz SY, Seeman E, Wang X, McFarlane T, Spanos C, Grossmann M, Zajac JD, Cheung AS. **Bone Microarchitecture in Transgender Adults: a Cross Sectional Study.** Journal of Bone and Mineral Research 2022; 37:643-648 (Impact Factor: 5.71). doi.org/10.1002/jbmr.4497

GASTROENTEROLOGY

Nguyen X-v, Zhang J, Chin KL, Bloom SD, Nicoll AJ. **Is Hepatocellular carcinoma in Fatty Liver Different to Non-Fatty Liver?** Nutrients 2022 Sep 19;14(18):3875. PMID: 36145251 PMCID: PMC9504716. doi.org/10.3390/nu14183875

Paul J. Clark, Amanda Nicoll et al. **Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow up.** BMC Gastroenterology (2022) 22:339. doi.org/10.1186/s12876-022-02416-5

Clark, P. J., Nicoll, A. et al. **Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.** Digestive Diseases and Sciences. doi.org/10.1007/s10620-022-07483-y

Patwala K, Nicoll A et al. **Lenvatinib for the treatment of hepatocellular carcinoma-a real-world multicentre Australian cohort study.** Hepatol Int. 2022 Aug 25. PMID: 36006547. doi.org/10.1007/s12072-022-10398-5

Tan N, Nicoll AJ et al. **Epidemiology and Outcomes of Primary Sclerosing Cholangitis: An Australian multicentre retrospective cohort study.** Hepatology International 2022. doi.org/10.1007/s12072-022-10356-1

Hall S, Nicoll AJ et al. **Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.** Aliment Pharmacol Ther.2022;00:1–11. doi.org/10.1111/apt.16968

George E, Reddy A, Nicoll AJ, Ryan M, Itsiopoulos C, Abbott G, Johnson N, Sood S, Roberts SK, Tierney A. **Impact of a Mediterranean Diet on Hepatic and Metabolic outcomes in Non-Alcoholic Fatty Liver Disease: The MEDINA Randomised Controlled Trial.** Liver Int 2022. doi.org/10.1111/liv.15264

Pham AD, Nicoll AJ et al. **Clinical outcomes of patients with two small hepatocellular carcinomas.** World J Hepatol. 2021 Oct 27;13(10):1439-1449.10.4254/wjh.v13.i10.1439. PMID: 34786178. doi.org/10.4254/wjh.v13.i10.1439

George E, Sood S, Kiss N, Daly RM, Nicoll AJ, Roberts SK, Baguley BJ. **The evidence surrounding non-alcoholic fatty liver disease in individuals with cancer: a systematic literature review.** Current Oncology. doi.org/10.3390/curroncol30010005

Con D, Vasudevan A. **Real-World Guidance from Artificial Intelligence? Predicting Outcomes of Inflammatory Bowel Disease Using Machine Learning.** Dig Dis Sci. 2022 May 3. doi.org/10.1007/s10620-022-07511-x

Vasudevan A, van Langenberg DR. **Editorial: delving into the natural history of Crohn’s disease and the impact of medical therapy.** Aliment Pharmacol Ther. 2022 Jan;55(1):108-109. doi.org/10.1111/apt.16640

Bohra A, Vasudevan A, Kutaiba N, Van Langenberg DR. **Challenges and Strategies to Optimising the Quality of Small Bowel Magnetic Resonance Imaging in Crohn’s Disease.** Diagnostics (Basel). 2022 Oct 19;12(10):2533. PMID: 36292222. doi.org/10.3390/diagnostics12102533

Con D, Vasudevan A, van Langenberg DR. **Predictive Scores in Acute Severe Ulcerative Colitis: Which, What, and When are the Decision Points We Should Target?** Clin Gastroenterol Hepatol. 2022 Feb;20(2):e344-e345. PMID: 33905768. doi.org/10.1016/j.cgh.2021.04.035

Con D, Andrew B, Nicolaides S, van Langenberg DR, Vasudevan A. **Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy.** Intest Res. 2022 Jan;20(1):101-113. PMID: 33902267. doi.org/10.5217/ir.2020.00146

Hanrahan TP, Chan R, Tassone D, Ding NS, Basnayake C, Schulberg J, Vasudevan A, Kamm M, De Gregorio M, van Langenberg DR, Niewiadomski O. **Persistence of second and third-line biologics in Inflammatory Bowel Disease: a multi-centre cohort study.** Future Pharmacol. 2022, 2(4), 669-680. doi.org/10.3390/futurepharmacol2040041

Howell J, , , , , , , Sawhney R et al. **Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study.** Clin Liver Dis (Hoboken). 2022 Oct 10;20(4):136-139. PMID: 36245683; PMCID: PMC9549301. doi.org/10.1002/cld.1261

HAEMATOLOGY

Matthew Rees, Ashish Panigrahi, Simon Harrison, Andrew Spencer, Tiffany Kong,Simon Gibbs, Jay Hocking, Andrew Grigg, Daniela Zantomio. **The Impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma.** Bone Marrow Transplant 2022;57(6):1001-1003. doi.org/10.1038/s41409-022-01647-0

Mark S. Taylor, , , , , , , Simon D. J. Gibbs. **Current approaches to the diagnosis and management of amyloidosis.** IMJ. December 2022 Volume52, Issue12. December 2022. Pages 2046-2067. doi.org/10.1111/imj.15974

Dipti Talaulikar, D Joshua, P J Ho, J Gibson, H Quach, S Gibbs, S Ling, C Ward, B Augustson, Judith Trotman, S J Harrison, Constantine S Tam. **Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.** Medical and Scientific Advisory Group, Myeloma Australia. doi.org/10.1111/imj.15980

Sanchorawala V, , , , , , , Gibbs S et al. **Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide and dexamethasone ± daratumumab: Results from the ANDROMEDA study.** Am J Hematol. 2022 Jun 1;97(6):719-730. doi.org/10.1002/ajh.26536

Chen M, Shortt J. **Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP).** Transfus Med Rev 36(4):204–214. doi.org/10.1016/j.tmr.2022.09.001

Wei AH, , , , , , , Ting SB et al. **Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.** Blood. 2022 Dec 22;140(25):2754-2756. doi.org/10.1182/blood.2022016963

Leung HHL, Perdomo J, Ahmadi Z, Zheng SS, Rashid FN, Enjeti A,Ting SB, Chong JJH, Chong BH. **NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia.** Nat Commun. 2022 Sep 5;13(1):5206. doi.org/10.1038/s41467-022-32946-1

Tedjaseputra A, , , , , , , Teh TC et al. **Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic.** Leuk Lymphoma. 2022 Nov;63(11):2731-2734. doi.org/10.1080/10428194.2022.2087065

Nath CE, Grigg A, Rosser SPA, Estell J, Newman E, Tiley C, Ramanathan S, Ho SJ, Larsen S, Gibson J, Presgrave P, Shaw PJ, Trotman J. **Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma.** Eur J Clin Pharmacol. 2022 Dec;78(12):1911-1921. doi.org/10.1007/s00228-022-03396-x

Barr PM, Tedeschi A, Wierda WG, Allan JN, Ghia P, Vallisa D, Jacobs R, O'Brien S, Grigg AP, Walker P, Zhou C, Ninomoto J, Krigsfeld G, Tam CS. **Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.** Clin Cancer Res. 2022 Oct 14;28(20):4385-4391. doi.org/10.1158/1078-0432.CCR-22-0504

Fernandez M, Lokan J, Leung C, Grigg A. **A critical evaluation of the role of iron overload in fatty liver disease.** J Gastroenterol Hepatol. 2022 Oct;37(10):1873-1883. doi.org/10.1111/jgh.15971

Tam CS, ..., Lasica M et al. **Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.** Intern Med J. 2022 Jul;52(7):1286-1287. doi.org/10.1111/imj.15851

Wight J, Ku M, Garwood M, Carradice D, Lasica M, Keamy L, Hawkes EA, Grigg A. **Toxicity associated with high-dose intravenous methotrexate for hematological malignancies. Leuk Lymphoma.** 2022 Oct;63(10):2375-2382. doi.org/10.1080/10428194.2022.2074987

Enjeti AK, Agarwal R, Blombery P, Chee L, Chua CC, Grigg A, Hamad N, Iland H, Lane S, Perkins A, Singhal D, Tate C, Tiong IS, Ross DM. **Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement.** Pathology. 2022 Jun;54(4):389-398. doi.org/10.1016/j.pathol.2022.03.002

Grigg A. **Living Long and Well After an Autograft.** J Clin Oncol. 2022 Jun 20;40(18):1971-1975. doi.org/10.1200/JCO.22.00302

Nguyen PC, Donati V, Vassili C, Grigg AP, Tiong IS. **Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission.** Leuk Res. 2022 May;116:106837. doi.org/10.1016/j.leukres.2022.106837

Cliff ERS, Sasadeusz J, Visvanathan K, Grigg A. **Very late-onset hepatitis B reactivation following chemoimmunotherapy.** Leuk Lymphoma. 2022 Apr;63(4):991-995. doi.org/10.1080/10428194.2021.2010066

Evens AM, Grigg A et al. **Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.** Haematologica. 2022 May 1;107(5):1086-1094. doi.org/10.3324/haematol.2021.278438

Hogg SJ, Motorna O et al. **Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer.** Clin Epigenetics. 2022 Jul 28;14(1):96. doi.org/10.1186/s13148-022-01316-5

Ong J, Brown S, Gilbertson M, Grigoriadis G, Simpson I, Vilcassim S, Low M, Fedele P, Motorna O, Roberts L, Gingold M, Gregory G. **Two cases of refractory IgG4-related disease successfully treated with tocilizumab.** Ann Hematol. 2022 Jul;101(7):1593-1594. doi.org/10.1007/s00277-022-04787-x

Tan M, Zacher N, French R, Borosak M, Lennard S, Le Viellez A, Benson S, Daly J. **Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody).** Intern Med J. 2022 Sep 16. PMID: 36114660. doi.org/10.1111/imj.15934

INFECTIOUS DISEASES

Whyler N, Kong K, Krishnaswamy S, Giles M. **Attitudes toward year-round influenza vaccination in pregnant women.** Aust N Z J Obstet Gynaecol. 2022 Apr;62(2):323-327. doi.org/10.1111/ajog.13485

Tippett E, Hitch D, Irving L, Watters D. **Post-acute COVID-19 condition (PACC): a perspective on collaborative Australian research imperatives and primary health models of care.** Aust J Prim Health. 2022 Dec 12. doi.org/10.1071/PY22009

McQuilten Z, Venkatesh B, Jha V et al. **Anticoagulation Strategies in Non–Critically Ill Patients with Covid-19.** NEJM Evidence. 2022 Dec 10. doi.org/10.1056/EVIDoa2200293

Buntine P, Miller J, Pope A, Guy S, Wong FQA, McDonald H, Ahmed M, Teow KH, Roney M, Mohammadi F, Aldridge E, Hackett L, Jenner S, Davis B. **Negative predictive value of the FebriDx host response point-of-care test in patients presenting to a single Australian emergency department with suspected COVID-19: an observational diagnostic accuracy study.** BMJ Open. 2022 Dec 29;12(12):e065568. doi.org/10.1136/bmjopen-2022-065568

Watt AE, ..., Guy S et al. **State-wide genomic epidemiology investigations of COVID-19 in healthcare workers in 2020 Victoria, Australia: Qualitative thematic analysis to provide insights for future pandemic preparedness.** Lancet Reg Health West Pac. 2022 Jun 3;25:100487. PMID: 35677391. doi.org/10.1016/j.lanwpc.2022.100487

Stratton H, Buntine P, Ng R, Fu J, Joshi N, Yip G, Guy S, Chean R, Newnham E, Lau J. **Impact of SARS-CoV-2 transmission-based precautions on inpatient management of general medical patients.** Int Med J. 2022 Apr 1. doi.org/10.1111/imj.15697

Cody R, Mohsenifard M, Yip G, Aldridge E, Bridge F, Datta M, Guy S, Jordan P, Kyndt C, Newnham E, Ng M, Paul E, Roodenburg O, Senanayake C, Sparham S, Steele M, Dewey H. Worth the risk? **Contemporary indications, yield and complications of lumbar punctures in a metropolitan Australian health service.** Int Med J. 30 March 2022. doi.org/10.1111/imj.15761

MENTAL HEALTH AND WELLBEING PROGRAM (MHPW)

Allchin B, Weimand BM, O'Hanlon B, Goodyear M. **A Sustainability Model for Family-Focused Practice in Adult Mental Health Services.** Front Psychiatry. 2022 Jan 18;12:761889. PMID: 35115958; PMCID: PMC8804966. doi.org/10.3389/fpsy.2021.761889

Allchin B, Solantaus T. **An evidence-based practice developed in-situ: Let's Talk about Children and a consolidation of its evidence base.** Frontiers in Psychiatry. 2022 Jan. doi.org/10.3389/fpsy.2022.824241

tBayer JK, Brown A, Prendergast LA, Bretherton L, Hiscock H, Mihalopoulos C, Nelson-Lowe M, Gilbertson T, Noone K, Bischof N, Beechey C, Muliadi F, Rapee RM. **Follow-up of the Cool Little Kids translational trial into middle childhood.** J Child Psychol Psychiatry. 2022 Jan;63(1):88-98. PMID: 34128236. doi.org/10.1111/jcpp.13464

Bhar, S., Koder, D., Jayaram, H., Davison, T., Knight, B., Laidlaw, K. **Innovative Approaches for Long Term Care.** In: Asmundson, G.J.G. (Ed.), Comprehensive Clinical Psychology, 2nd edition, vol. 7. Elsevier, pp. 311–327. doi.org/10.1016/B978-0-12-818697-8.00107-2

Broadbear JH, Beatson JA, Moss F, Jayaram H, George K, Planinic A, Rodrigo K, Rao S. **Development and Preliminary Evaluation of a Rapid Screening Tool for Detecting Borderline Personality Disorder in People Aged over 60 Years.** Clin Gerontol. 2022 Sep 16:1-11. PMID: 36111819. doi.org/10.1080/07317115.2022.2123727

Chiang YC, Couper J, Chen JW, Lin KJ, Wu HP. **Predictive value of the Distress Thermometer score for risk of suicide in patients with cancer.** Support Care Cancer. 2022 Jun;30(6):5047-5053. PMID: 35201384; PMCID: PMC9046327. doi.org/10.1007/s00520-022-06801-4

Dennett AM, Taylor NF, Williams K, Lewis AK, Brann P, Hope JD, Wilton AM, Harding KE. **Consumer perspectives of telehealth in ambulatory care in an Australian health network. Health Soc Care Community.** 2022 Sep;30(5):1903-1912. PMID: 34558144. doi.org/10.1111/hsc.13569

Foster G, Robertson J, Pallis S, Segal J. **The dual diagnosis clinician shared care model – a clinical mental health dual diagnosis integrated treatment initiative.** Advances in Dual Diagnosis. 2022 15(3), 165-176. doi.org/10.1108/ADD-03-2022-0008

Goodyear MJ, Allchin B, Burn M, et al. **Promoting Self-Determination in Parents With Mental Illness in Adult Mental Health Settings.** Journal of Family Nursing. January 2022. doi.org/10.1177/10748407211067308

Hope J, Keks NA. **Cariprazine: A new partial dopamine agonist with a familiar profile.** Australasian Psychiatry. February 2022. doi.org/10.1177/10398562211064254

Jayaram H. **Innovative Approaches for Long Term Care.** Comprehensive Clinical Psychology, 2nd edition (book chapter). doi.org/10.1016/B978-0-12-818697-8.00107-2

Keks NA, Hope J. **Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?** Australasian Psychiatry. 2022;30(4):530-532. doi.org/10.1177/10398562221092310

Otto J, Makela E, Alam S, Lim H, Maccar R, Hall A, Neef D, Ryan S, Bourke C, Foster G, Vivekananda K. **Co-designing consumer and carer peer support principles to assess quality.** Advances in Mental Health. doi.org/10.1080/18387357.2022.2026235

Perkes IE, Eggleston M, Jacobs B, McEvoy P, Fung D, Robertson PG. **The making of child and adolescent psychiatrists in Australia and New Zealand.** Australian & New Zealand Journal of Psychiatry. 2022;56(8):899-904. doi.org/10.1177/000486742111055654

Sadler P, Gardiner I, Hart S, Aradhye, S, Nolan J. **Age with ACT: a pilot acceptance and commitment therapy groups for older adults receiving a community mental health service.** Psychotherapy and Counselling Journal of Australia 2022. doi: 10.59158/001c.71197. doi.org/10.59158/001c.71197

von Doussa H, Hegarty M, Sanders B, Cuff R, Tivendale K, McLean S, Goodyear M. **Peer support for children of parents with mental illness (COPMI) in Australia: responses from children, parents and facilitators of the CHAMPS peer support program.** Advances in Mental Health. doi.org/10.1080/18387357.2022.2075411

Jo R, Broadbear J, Hope J, Rao S. **Late manifestation of Borderline Personality Disorder: characterisation of an under-recognised phenomenon.** Personality and Mental Health. 2022. doi.org/10.1002/pmh.1571

MONASH ADDICTION RESEARCH CENTRE (MARC)

Cangadis-Douglass, H., Jung, M., Xia, T., Buchbinder, R., Lalic, S., Russell, G., Andrew, N., Pearce, C., Bell, J. S., Ilomäki, J., & Nielsen, S. **Using primary care data to understand opioid prescribing, policy impacts and clinical outcomes: A protocol for the OPPICO study.** Research in Social and Administrative Pharmacy, 18(12), 4129-4137. doi.org/10.1016/j.sapharm.2022.07.041

Curtis, M., Winter, R. J., Dietze, P., Wilkinson, A. L., Cossar, R. D., Stewart, A. C., Agius, P. A., Butler, T., Aitken, C., Kirwan, A., Walker, S., & Stoové, M. **High rates of resumption of injecting drug use following release from prison among men who injected drugs before imprisonment.** Addiction, 117(11), 2887-2898. doi.org/10.1111/add.15971

Dawe, J., ... , Curtis, M. et al. **Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020.** International Journal of Drug Policy, 104, [103696]. doi.org/10.1016/j.drugpo.2022.103696

Dobbin, M., Nielsen, S., & Schumann, J. L. **More pieces of the mosaic describing outcomes of the Australian up-scheduling of over-the-counter codeine to prescription only.** Addiction, 117(3), 687-689. doi.org/10.1111/add.15693

Farrell, M., Nielsen, S. et al. **Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.** International Journal of Drug Policy, 100, [103492]. doi.org/10.1016/j.drugpo.2021.103492

Francia, L., Berg, A., Lam, T., Morgan, K., & Nielsen, S. **“The peer workers, they get it”–how lived experience expertise strengthens therapeutic alliances and alcohol and other drug treatment-seeking in the hospital setting.** Addiction Research and Theory. doi.org/10.1080/16066359.2022.2124245

Gooden, J. R., Cox, C. A., Petersen, V., Curtis, A., Sanfilippo, P. G., Manning, V., Bolt, G. L., & Lubman, D. I. **Predictors of cognitive functioning in presentations to a community-based specialist addiction neuropsychology service.** Brain Impairment. doi.org/10.1017/BrImp.2021.38

Gooden, J. R., Petersen, V., Bolt, G. L., Curtis, A., Manning, V., Cox, C. A., Lubman, D. I., & Arunogiri, S. **Maybe It’s Not the Meth: Considering Biopsychosocial Contributors to Cognitive Impairment in Methamphetamine Polydrug Use.** Frontiers in Psychiatry, 13, [795400]. doi.org/10.3389/fpsy.2022.795400

Haines, S., Savic, M., Nielsen, S., & Carter, A. **Key considerations for the implementation of clinically focused Prescription Drug Monitoring Programs to avoid unintended consequences.** International Journal of Drug Policy, 101, [103549]. doi.org/10.1016/j.drugpo.2021.103549

Haylock, P. A. C., Carter, A., Savic, M., & Lubman, D. I. **Regional and rural clients’ presenting concerns and experiences of care when engaging with an online substance use counseling service.** Addiction Research & Theory. doi.org/10.1080/16066359.2022.2039911

Hopkins, R. E., Campbell, G., Degenhardt, L., Lintzeris, N., Larance, B., Nielsen, S., & Gisev, N. **Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain.** International Journal of Drug Policy, 105, [103708]. doi.org/10.1016/j.drugpo.2022.103708

Hopkins, R. E., Campbell, G., Degenhardt, L., Nielsen, S., Blyth, F. M., Cohen, M. L., & Gisev, N. **Use of pharmacological and nonpharmacological treatments for chronic noncancer pain among people using opioids: a longitudinal cohort study.** Pain, 163(6), 1049-1059. doi.org/10.1097/J.PAIN.0000000000002484

Kleinman, R. A., Nielsen, S., & Weiss, R. D. **Is daily supervised buprenorphine-naloxone dosing necessary?** The BMJ, 378, [e071467]. doi.org/10.1136/bmj-2022-071467

Lam, T., Barratt, M. J., Bartlett, M., Latimer, J., Jauncey, M., Hiley, S., Clark, N., Gerostamoulos, D., Glowacki, L., Roux, C., Morelato, M., & Nielsen, S. **Infrequent detection of unintentional fentanyl use via urinalysis among people who regularly inject opioids in Sydney and Melbourne, Australia.** Addiction. doi.org/10.1111/add.15832

Lam, T., Biggs, N., Xia, T., Evans, J., Stevens, J., da Gama, M., Lubman, D. I., & Nielsen, S. **Comparing opioid types in the persistence of opioid use following surgical admission: a study protocol for a retrospective observational linkage study comparing tapentadol and oxycodone in Australia.** BMJ Open, 12(4), e060151. doi.org/10.1136/bmjopen-2021-060151

Lam, T., Hayman, J., Berecki-Gisolf, J., Sanfilippo, P., Lubman, D. I., & Nielsen, S. **Pharmaceutical opioid poisonings in Victoria, Australia: Rates and characteristics of a decade of emergency department presentations among nine pharmaceutical opioids.** Addiction, 117(3), 623-636. doi.org/10.1111/add.15653

Lam, T., Xia, T., Biggs, N., Treloar, M., Cheng, O., Kabu, K., Stevens, J. A., Evans, J. D., da Gama, M. E., Lubman, D. I., & Nielsen, S. **Effect of discharge opioid on persistent postoperative opioid use: a retrospective cohort study comparing tapentadol with oxycodone.** Anaesthesia. doi.org/10.1111/anae.15933

Lee, P., Xia, T., Zomer, E., van Vreden, C., Pritchard, E., Newnam, S., Collie, A., Iles, R., & Ademi, Z. **Exploring the Health and Economic Burden Among Truck Drivers in Australia: A Health Economic Modelling Study.** Journal of Occupational Rehabilitation. doi.org/10.1007/s10926-022-10081-4

Lubman, D. I., Grigg, J., Reynolds, J., Hall, K., Baker, A. L., Staiger, P. K., Tyler, J., Volpe, I., Stragalinis, P., Harris, A., Best, D., & Manning, V. **Effectiveness of a Stand-alone Telephone-Delivered Intervention for Reducing Problem Alcohol Use: A Randomized Clinical Trial.** JAMA Psychiatry, 79(11), 1055-1064. doi.org/10.1001/jamapsychiatry.2022.2779

Maddern, X. J., Walker, L. C., Campbell, E. J., Arunogiri, S., Haber, P. S., Morley, K., Manning, V., Millan, E. Z., McNally, G. P., Lubman, D. I., & Lawrence, A. J. **Can we enhance the clinical efficacy of cognitive and psychological approaches to treat substance use disorders through understanding their neurobiological mechanisms?** Neuroscience and Biobehavioral Reviews, 142, [104899]. doi.org/10.1016/j.neubiorev.2022.104899

McCoy, J., Nielsen, S., & Bruno, R. **A prospective cohort study evaluating the impact of upscheduling codeine in Australia among frequent users of codeine.** Addiction, 117(3), 677-686. doi.org/10.1111/add.15683

Monds, L. A., Bravo, M., Mills, L., Malcolm, A., Gilliver, R., Wood, W., Harrod, M. E., Read, P., Nielsen, S., Dietze, P. M., Lenton, S., Bleeker, A. M., & Lintzeris, N. **The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions.** Drug and Alcohol Review. doi.org/10.1111/dar.13474

Nielsen, S., & Larney, S. Commentary on Glanz et al. **Longer buprenorphine treatment duration is associated with lower rates of opioid overdose, but can we address barriers to staying in treatment?** Addiction. doi.org/10.1111/add.16032

Nielsen, S., Picco, L. et al. **Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies.** Neuropsychopharmacology. doi.org/10.1038/s41386-022-01322-4

Nielsen, S., Scott, N., Tidhar, T., del Mar Quiroga, M., Lenton, S. R., & Dietze, P. M. **The cost and impact of distributing naloxone to people who are prescribed opioids to prevent opioid-related deaths: findings from a modelling study.** Addiction, 117(4), 1009-1019. doi.org/10.1111/add.15727

Nielsen, S., Tse, W. C., & Larance, B. **Opioid agonist treatment for people who are dependent on pharmaceutical opioids (Review).** Cochrane Database of Systematic Reviews, 2022(9), [CD011117]. doi.org/10.1002/14651858.CD011117.pub3

Picco, L., Lam, T., Xia, T., & Nielsen, S. **Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists.** International Journal of Clinical Pharmacy. doi.org/10.1007/s11096-022-01523-3

Picco, L., Sanfilippo, P., Xia, T., Lam, T., & Nielsen, S. **How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists’ decisions to dispense opioids? A randomised controlled factorial experiment.** International Journal of Drug Policy, 109, [103856]. doi.org/10.1016/j.drugpo.2022.103856

Pritchard, E. K., Kim, H. C., Nguyen, N., van Vreden, C., Xia, T., & Iles, R. **The effect of weight loss interventions in truck drivers: Systematic review.** PLoS ONE, 17(2), [e0262893]. doi.org/10.1371/journal.pone.0262893

Tran, A., Chen, R., Nielsen, S., Zahra, E., Degenhardt, L., Santo, T., Farrell, M. P., & Larance, B. **Economic analysis of out-of-pocket costs among people in opioid agonist treatment: a cross-sectional survey in three Australian jurisdictions.** International Journal of Drug Policy, 9, [103472]. doi.org/10.1016/j.drugpo.2021.103472

Tse, W. C., Scott, N., Dietze, P., & Nielsen, S. **Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths.** Journal of Substance Abuse Treatment, 143, [108871]. doi.org/10.1016/j.jsat.2022.108871

Tse, W., Djordjevic, F., Borja, V. A., Picco, L., Lam, T., Olsen, A., Larney, S., Dietze, P. M., & Nielsen, S. **Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a ‘moral hazard’ associated with naloxone supply.** International Journal of Drug Policy, 100, [103513]. doi.org/10.1016/j.drugpo.2021.103513

Zahra, E., Chen, R., Nielsen, S., Tran, A. D., Santo, T., Degenhardt, L., Farrell, M., Byrne, J., Ali, R., & Larance, B. **Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients.** Drug and Alcohol Review, 41(4), 841-850. doi.org/10.1111/dar.13437

NEPHROLOGY

Wong L, Kent AB, Lee D, Roberts MA, McMahon LP. **Low muscle mass and early hospital readmission post-kidney transplantation.** Int Urol Nephrol. 54(8): 1977-86, 2022. doi.org/10.1007/s11255-021-03085-1

Chua JCM, Mount PF, Lee D. **Lower versus Higher Starting Tacrolimus Dosing in Kidney Transplant Recipients.** Clinical Transplantation 2022 Jun;36(6):e14606. doi.org/10.1111/ctr.14606

Lim WH, Ooi E, Pankaj A, Teixeira-Pinto A, Lin Y, Johnson DW, Hawley CM, Viecei AK, Pilmore H, Roberts MA, Davies CE, Krishnan A, Wong G. **The incidence of cancer recurrence and new cancer following commencement of dialysis in patients with prior cancers.** Clinical Kidney Journal 2022 Jun 2;15(9):1770-1781. doi.org/10.1093/ckj/sfac124

Huang LL, Mah JY, Howard J, Roberts MA, McMahon LP. **Incremental peritoneal dialysis is a safe and feasible prescription in incident patients with preserved residual kidney function.** Nephrology (Carlton). 2022 Jan;27(1):74-81. doi.org/10.1111/nep.13962

Chen JHC, Brown MA, Jose M, Brennan F, Johnson DW, Roberts MA, Wong G, Cheikh Hassan H, Kennard A, Walker R, Davies CE, Boudville N, Borlace M, Hawley C, Lim WH. **Temporal changes and risk factors for death from early withdrawal within 12 months of dialysis initiation-a cohort study.** Nephrol Dial Transplant. 2022 Mar 25;37(4):760-769. doi.org/10.1093/ndt/gfab207

Brumby C, McMahon LP. **Chronic hypertension and pregnancy – emphasising longitudinal care to improve maternal and fetal health.** Medicine Today 2022; 23(6): 26-33

Ethier I, Campbell SB, Cho Y, Hawley CM, Isabel NM, Krishnasamy R, Roberts MA, Semple D, Sypek M, Viecei AK, Johnson DW. **Dialysis modality utilization patterns and mortality in older persons initiating dialysis in Australia and New Zealand.** Nephrology (Carlton) 2022 Aug;27(8):663-672. doi.org/10.1111/nep.14073

Duvuru Geetha, Kathryn Ducharlet et al. **Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions.** Nat Rev Nephrol 2022 Aug 24;1-14. doi.org/10.1038/s41581-022-00618-4

Rabbani N, Adaikalakoteswari A, Larkin JR, Panagiotopoulos S, MacIsaac RJ, Yue DK, Fulcher GR, Roberts MA, Thomas M, Ekinci E, Thornalley PJ. **Analysis of serum advanced glycation endproducts reveals methylglyoxal-derived advanced glycation MG-H1 free adduct is a risk marker in non-diabetic and diabetic chronic kidney disease.** Int J Mol Sci 2022 Dec 21;24(1):152. doi.org/10.3390/ijms24010152

Viecei AK, Roberts M et al. **Study protocol for Vascular Access outcome measure for function: a validation study In hemoDialysis (VALID).** BMC Nephrology 23: 372, 2022 doi.org/10.1186/s12882-022-02987-1

Lisa Paxton, Lawrence McMahon and Limy Wong. **De novo PLA2R positive membranous nephropathy following BNT162b2 mRNA COVID-19 vaccine.** Internal Medicine Journal 2022;52;2191-92. doi.org/10.1111/imj.15915

NEUROSCIENCES

Ross Cody, ... Chris Kyndt et al. **Worth the risk? Contemporary indications, yield and complications of lumbar punctures in a metropolitan Australian health service.** Internal Medicine Journal. doi.org/10.1111/imj.15761

Monique F Kilkenney, ... Helen Dewey et al. **Treatment with Multiple Therapeutic Classes of Medication Is Associated with Survival after Stroke.** Neuroepidemiology 2022; 56(1):66-74. doi.org/10.1159/000520823

Felix C Ng, ... Helen Dewey et al. **Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow).** Neurology 2022 Feb 22;98(8):e790-e801. doi.org/10.1212/WNL.0000000000013210

Vignan Yogendrakumar, ... Helen M. Dewey et al. **Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion.** Neurology March 22, 2022; 98 (12). doi.org/10.1212/WNL.0000000000013302

Felix C. Ng, ... Helen M. Dewey et al. **Microvascular Dysfunction in Blood-Brain Barrier Disruption and Hypoperfusion Within the Infarct Posttreatment Are Associated With Cerebral Edema.** Stroke 2022;53:1597–1605. doi.org/10.1161/STROKEAHA.121.036104

Felix C. Ng, ... Helen M. Dewey et al. **Reduced Severity of Tissue Injury Within the Infarct May Partially Mediate the Benefit of Reperfusion in Ischemic Stroke.** Stroke 2022;53:1915–1923. doi.org/10.1161/STROKEAHA.121.036670

Elise Tan, ... Helen M. Dewey et al. **The economic and health burden of stroke among younger adults in Australia from a societal perspective.** BMC Public Health 22, 218 (2022). doi.org/10.1186/s12889-021-12400-5

Amrou Sarraj, ... Philip Choi et al. **Endovascular Thrombectomy Versus Medical Management in Isolated M2 Occlusions: Pooled Patient-Level Analysis from the EXTEND-IA Trials, INSPIRE, and SELECT Studies.** Annals of Neurology. doi.org/10.1002/ana.26331

Kang H Teow, Peter S Tan, Tanya Frost, Helen M Dewey, Marija Borosak, Philip M C Choi. **Trends in direct oral anticoagulant use in patients presenting with acute stroke.** Internal Medicine Journal 2022 Sep;52(9):1633-1637. doi.org/10.1111/imj.15903

Chris F Bladin et al. **Real-world, feasibility study to investigate the use of a multidisciplinary app (Pulsara) to improve prehospital communication and timelines for acute stroke/STEMI care.** BMJ Open 2022 Jul 18;12(7):e052332. doi.org/10.1136/bmjopen-2021-052332

Mohamed Salah Khlif, ... Amy Brodtmann et al. **Cortical thinning 3 years after ischaemic stroke is associated with cognitive impairment and APOE ε4.** Neuro Image: Clinical 022;36:103200. doi.org/10.1016/j.nicl.2022.103200

Natalia S. Rost, Amy Brodtmann et al. **Post-Stroke Cognitive Impairment and Dementia. Circulation Research 2022;130:1252–1271.** doi.org/10.1161/CIRCRESAHA.122.319951

Taya A. Collyer, ..., Amy Brodtmann et al. **Association of Dual Decline in Cognition and Gait Speed With Risk of Dementia in Older Adults.** JAMA Network Open 2022;5(5):e2214647. doi.org/10.1001/jamanetworkopen.2022.14647

Ning Bu, ..., Amy Brodtmann et al. **Early Brain Volume Changes After Stroke: Subgroup Analysis From the AXIS-2 Trial.** Frontiers in Neurology 2022 Jan 28;12:747343. doi.org/10.3389/fneur.2021.747343

Stanley Hughwa Hung, ..., Amy Brodtmann et al. **Pre-stroke Physical Activity and Cerebral Collateral Circulation in Ischemic Stroke: A Potential Therapeutic Relationship?** Frontiers in Neurology 2022 Feb 15;13:804187. doi.org/10.3389/fneur.2022.804187

Natalia Egorova-Brumley, ..., Amy Brodtmann et al. **Grey and white matter atrophy 1 year after stroke aphasia.** Brain Communications 2022; 4(2): fcac061. doi.org/10.1093/braincomms/fcac061

Warda Syeda, ..., Amy Brodtmann et al. **Long-term structural brain changes in adult rats after mild ischaemic stroke.** Brain Communications Volume 4, Issue 4, 2022, fcac185. doi.org/10.1093/braincomms/fcac185

Sook-Lei Liew, ..., Amy Brodtmann et al. **The ENIGMA Stroke Recovery Working Group: Big data neuroimaging to study brain–behavior relationships after stroke.** Hum Brain Mapp 2022 Jan;43(1):129-148. doi.org/10.1002/hbm.25015

Artemis Zavaliangos-Petropulu, ..., Amy Brodtmann et al. **Chronic Stroke Sensorimotor Impairment Is Related to Smaller Hippocampal Volumes: An ENIGMA Analysis.** Journal of American Heart Association 2022 May 17;11(10):e025109. doi.org/10.1161/JAHA.121.025109

Mohamed Salah Khlif, ..., Amy Brodtmann et al. **Atrophy of Ipsilesional Hippocampal Subfields Vary Over First Year After Ischemic Stroke.** Journal of Magnetic Resonance Imaging. doi.org/10.1002/jmri.28009

Stanley Hughwa Hung, ..., Amy Brodtmann et al. **Poststroke White Matter Hyperintensities and Physical Activity: A CANVAS Study Exploratory Analysis.** Journal of the American College of Sports Medicine 2022 Sep 1;54(9):1401-1409. doi.org/10.1249/MSS.0000000000002946

Sook-Lei Liew, ..., Amy Brodtmann et al. **A large, curated, open-source stroke neuroimaging dataset to improve lesion segmentation algorithms.** Nature – scientific data. doi.org/10.1038/s41597-022-01401-7

Deborah A. Levine, Mellanie V. Springer, Amy Brodtmann **Blood Pressure and Vascular Cognitive Impairment.** Stroke 2022;53:1104–1113. doi.org/10.1161/STROKEAHA.121.036140

Amy Brodtmann, Tobias Loetscher. **What’s Left in Neglect Research?** Neurology 2022 Jan 11;98(2):53-54. doi.org/10.1212/WNL.00000000000013051

Lucy Vivash, ..., Amy Brodtmann et al. **A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia.** Alzheimer’s and Dementia – Translational Research & Clinical Interventions. doi.org/10.1002/trc2.12299

Sifat Sharmin, ..., Olga Skibina et al. **Confirmed disability progression as a marker of permanent disability in multiple sclerosis.** European Journal of Neurology 2022 Aug;29(8):2321-2334. doi.org/10.1111/ene.15406

Vivien Li, ..., Mark Marriott et al. **Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic.** Multiple Sclerosis and Related Disorders. 2022 Jul;63:103913. doi.org/10.1016/j.msard.2022.103913

Pakeeran Siriratnam, Katherine Buzzard, Gary Yip. **Acute haemorrhagic necrotizing encephalopathy in the setting of SARS-CoV-2 vaccination: a case report and literature review.** Acta Neurologica Belgica 123, 303-305 (31 Jan 2022). doi.org/10.1007/s13760-021-01862-4

Charles B Malpas, ..., Katherine Buzzard et al. **Multiple Sclerosis Relapses Following Cessation of Fingolimod.** Clinical Drug Investigation 2022 Apr;42(4):355-364. doi.org/10.1007/s40261-022-01129-7

Marianna Vitkova, ..., Katherine Buzzard et al. **Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis.** Neurology 2022 Jun 14;98(24):e2401-e2412. doi.org/10.1212/WNL.000000000000200545

Allan Bayat, ..., Patrick Carney et al. **PIGN encephalopathy: Characterizing the epileptology.** Epilepsia 2022 Apr;63(4):974-991. doi.org/10.1111/epi.17173

Emma Foster, ..., Patrick W Carney et al. **Prospective multisite cohort study of patient-reported outcomes in adults with new-onset seizures.** Epilepsia Open 2022 Mar;7(1):201-209. doi.org/10.1002/epi4.12571

Pakeeran Siriratnam, ..., Patrick W Carney et al. **The effect of epilepsy surgery on productivity: A systematic review and meta-analysis.** Epilepsia 2022 Apr;63(4):789-811. doi.org/10.1111/epi.17172

Nawaf Yassi, ..., Philip Choi et al. **Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial.** Stroke and Vascular Neurology 2022 Apr;7(2):158-165. doi.org/10.1136/svn-2021-001070

Carlos Garcia-Esperon, ..., Philip M C Choi et al. **Association of Endovascular Thrombectomy With Functional Outcome in Patients With Acute Stroke With a Large Ischemic Core.** Neurology 2022 Sep 27;99(13):e1345-e1355. doi.org/10.1212/WNL.00000000000200908

Andrew Bivard, ..., Philip Choi et al. **Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.** Lancet Neurology 2022 Jun;21(6):520-527. doi.org/10.1016/S1474-4422(22)00171-5

Shuangyue Tan, ..., Philip M C Choi et al. **Practical utility of the ACT-FAST triage algorithm from a primary stroke centre perspective.** BMJ Neurology Open. doi.org/10.1136/bmjno-2022-000325

Darren Shao, Bailey McNamara, Philip M C Choi. **Pseudonormalisation of a subacute infarct following recent intravenous contrast administration.** BMJ Case Reports. doi.org/10.1136/bcr-2022-252379

Sinali O. Seneviratne, Mark Marriott et al. **Failure of alemtuzumab therapy in three patients with MOG antibody associated disease.** BMC Neurology 22, Article number: 84 (2022). doi.org/10.1186/s12883-022-02612-6

Erica Y. Tong, ..., Gary Yip et al. **Partnered pharmacist medication charting (PPMC) in regional and rural general medical patients.** Australian Journal of Rural Health. doi.org/10.1111/ajr.12895

NURSING AND MIDWIFERY

Alexander, L. Rinehart, N. Hay, M. Boyd, L. Foster, K. **Nursing student’s attitudes and experiences with mental illness: A cross sectional study.** Teaching and Learning in Nursing. doi.org/10.1016/j.teln.2022.09.011

McManamny, T. Boyd, L. Sheen, J. Lowthian, J. **The feasibility and acceptability of paramedic-initiated health education for rural-dwelling older people.** Health Education Journal. doi.org/10.1177/00178969221125622

Von Rieben, M. Boyd, L. Sheen, J. **Care in the time of Covid: An Interpretative Phenomenological Analysis of the impact of Covid-19 control measures on post-partum mothers’ experiences of pregnancy, birth and the health system.** Frontiers in Psychology. doi.org/10.3389/fpsyg.2022.986472

Kruger, H. Brusco, N. Taylor, N. Boyd, L. **Nurses sustain manual handling risk assessment behaviours six-months after a training program to move patients safely: a pre-post study.** Disability and Rehabilitation. doi.org/10.1080/09638288.2022.2048908

Ridell, K. Bignell, L. Bourne, D. Boyd, L. Crowe, S. Cucanic, S. Flynn, M. Gillan, K. Heinjus, D. Mathieson, J. Nankervis, K. Reed, F. Townsend, L. Twomey, B. Weir-Phyland, J. Bagot, K. **The context, contribution and consequences of addressing the COVID-19 pandemic: a qualitative exploration of executive nurses’ perspectives.** Journal of Advanced Nursing. doi.org/10.1111/jan.15186

ONCOLOGY

Alice Thomson, Ben Keong, Anthony Longano, Anis Hamid, Shomik Sengupta. **Testicular seminoma metastases presenting as gastrointestinal malignancy: A case report and review of the literature.** ANZ J Surg 2022 Jan;92(1-2):271-273. doi.org/10.1111/ans.17006.

Angelyn Anton et al. **Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.** BJUI compass. 2022 May; 3(3):205-13. doi. org/10.1002/bco2.129

Azad AA, Tran B, Davis ID, Parente P, Evans M, Wong S, Brown S, Evans S, Millar J, Murphy DG, Papa N. **Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.** Internal Medicine Journal. 2022 Aug;52(8):1339-46. doi.org/10.1111/imj.15288

Chong CY, Jalali A, Wong HL, Loft M, Wong R, Lee M, Gately L, Hong W, Shapiro J, Kosmider S, Tie J, Ananda S, Yeung JM, Ma B, Burge M, Jennens R, Tran B, Lee B, Lim L, Dean A, Nott L, Gibbs P. **Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer.** Asia Pac J Clin Oncol. 2022 Oct;18(5):e363-e368. PMID: 35073441. doi.org/10.1111/ajco.13728

Collins, I.M., Blum, R., Segelov, E., Parente, P. and Underhill, C. **Workforce Challenges Across Victorian Medical Oncology Services.** Internal Medical Journal 26 December 2022. doi.org/10.1111/imj.16000

Conduit C, Guo C, Smith AB, Rincones O, Baenziger O, Thomas B, Goad J, Lenaghan D, Lawrentschuk N, Wong LM, Corcoran NM, Ross M, Gibbs P, O’Haire S, Anton A, Liow E, Lewin J, Tran B. **Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study.** JMIR Cancer. 2022 Oct 28;8(4):e39725. PMID: 36306156; PMCID: PMC9652729. doi.org/10.2196/39725

Dennett AM, Harding KE, Peiris CL, Shields N, Barton C, Lynch L, Parente P, Lim D, Taylor NF. **Efficacy of Group Exercise–Based Cancer Rehabilitation Delivered via Telehealth (TeleCaRe): Protocol for a Randomized Controlled Trial.** JMIR Research Protocols. 2022 Jul 18;11(7):e38553. doi.org/10.2196/38553

Elbourne H, Soo WK, O’Reilly V, Moran A, Steer CB. **Exercise as a supportive care strategy in men with prostate cancer receiving androgen deprivation therapy at a regional cancer centre: a survey of patients and clinicians.** Support Care Cancer. 2022 Feb;30(2):1379-1389. doi.org/10.1007/s00520-021-06512-2

Grace Chazan, Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Peter Gibbs, Ben Tran. **Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer (mCRPC): a retrospective multicentre analysis.** Asia-Pacific Journal of Clinical Oncology. 2022 Jan 30. doi.org/10.1111/ajco.13732

Jalali A, Gard G, Banks S, Dunn C, Wong HL, Wong R, Lee M, Gately L, Loft M, Shapiro JD, Kosmider S, Tie J, Ananda S, Yeung JM, Jennens R, Lee B, McKendrick J, Lim L, Khattak A, Gibbs P. **Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.** Curr Probl Cancer. 2022 Apr;46(2):100793. PMID: 34565601. doi.org/10.1016/j.currprobcancer.2021.100793

Kwan EM, Spain L, Anton A, Gan CL, Garrett L, Chang D, Liow E, Bennett C, Zheng T, Yu J, Dai C, Parente P, Azad A. **Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial.** European Urology. 2022 Mar 1;81(3):253-62. doi.org/10.1016/j.eururo.2021.08.011

Lee B, Gately L, Lok SW, Tran B, Lee M, Wong R, Markman B, Dunn K, Wong V, Loft M, Jalili A, Anton A, To R, Andrews M, Gibbs P. **Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities.** Cancers (Basel). 2022 Aug 26;14(17):4131. PMID: 36077668; PMCID: PMC9454529. doi.org/10.3390/cancers14174131

Loft M, Shapiro J, Lee M, Wong R, Tie J, Kosmider S, Wong V, Jalali A, Lee B, Ananda SS, Gibbs P. **Compliance with Therapeutic Goods Association prescribing information: weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer.** Intern Med J. 2022 Jun 6. doi. org/10.1111/imj.15835. PMID: 35668542

Lok SW, de Boer R, Baron-Hay S, Button P, Devitt B, Forster B, Fox P, Harold M, Ketheeswaran S, Kichenadasse G, Kiely B, Marx G, Nott L, Pellegrini L, Tafreshi A, Gibbs P. **Pertuzumab Study in the Neoadjuvant Setting for Her2-Positive Non-Metastatic Breast Cancer in Australia (PeRSIA).** International Journal of Cancer 2022. doi.org/10.1002/ijc.34245

Mendis S, Hong W, Ananda S, Faragher I, Jones I, Croxford M, Steel M, Jalali A, Gard G, To YH, Lee M, Kosmider S, Wong R, Tie J, Gibbs P. **Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer.** JNCI Cancer Spectr. 2022 Jan 5;6(1):pkab100. PMID: 35699496; PMCID: PMC8857921. doi.org/10.1093/jncics/pkab100

James P Buteau, ..., Ian D Davis et al. **PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.** Lancet Oncol 2022 Nov;23(11):1389-1397. doi. org/10.1016/S1470-2045(22)00605-2

Richard Kelly, ..., Phillip Parente et al. **PSMA PET-CT use prior to systemic therapy in metastatic Castrate-Resistant Prostate Cancer (mCRPC).** BJU International. 2022. doi. org/10.1111/bju.15930

Santucci J, Tacey M, Thomson B, Michael M, Wong R, Shapiro J, Jennens R, Clarke K, Pattison S, Burge M, Zielinski R, Nikfarjam M, Ananda S, Lipton L, Gibbs P, Lee B. **Impact of first-line FOLFIRINOX versus Gemcitabine/ Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.** Eur J Cancer. 2022 Oct;174:102-112. PMID: 35988408. doi.org/10.1016/j.ejca.2022.06.042

Tie J, ..., Wong R et al. **Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.** N Engl J Med. 2022 Jun 16;386(24):2261-2272. doi.org/10.1056/NEJMoa2200075

To YH, Shapiro J, Wong R, Thomson B, Nagrial A, Mendis S, Gibbs P, Shapiro J, Lee B. Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitals. Asia Pac J Clin Oncol. 2022 Aug;18(4):448-455. PMID: 34811944. doi.org/10.1111/ajco.13721

Tung I, Moldovan C, Wong V, De Boer R, Yeo B, Malik L, Greenberg S, Anton A, Nott L, Barnett F, Collins IM, Lombard J, Nottage M, Sahu A, Torres J, Gibbs P, Lok SW. **Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study.** Clin Breast Cancer. 2022 Oct;22(7):e764-e772. PMID: 35941066. doi.org/10.1016/j.clbc.2022.07.005

Wee Kheng Soo, Madeleine T King, Alun Pope, Phillip Parente, Pëteris Dărziņš, Ian D Davis. **Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial.** The Lancet Healthy Longevity. 2022 Sep 1;3(9):e617-27. doi.org/10.1016/S2666-7568(22)00169-6

Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, Clarke K, Cuff K, Green M, Lim E, Mok K, Nott L, Nottage M, Tafreshi A, Tsoi D, Uccellini A, Hong W, Gibbs P, Lok SW. **Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.** Clin Breast Cancer. 2022 Dec;22(8):792-800. PMID: 36151018. doi. org/10.1016/j.clbc.2022.08.011

Ashika D. Maharaj, ..., Rachel Wong et al. **The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer.** HPB. doi.org/10.1016/j.hpb.2021.11.005

Shehara Mendis, Margaret Lee et al. **Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer.** JNCI. doi.org/10.1093/jncics/pkab100

Matthew Loft, Jeremy Shapiro, Margaret Lee, Rachel Wong, Jeanne Tie, Suzanne Kosmider, Vanessa Wong, Azim Jalali, Belinda Lee, Sumitra S Ananda, Peter Gibbs. **Compliance with Therapeutic Goods Association prescribing information: weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer.** Internal Medicine Journal. doi.org/10.1111/imj.15835

Zheng, J., Davis, I. D. et al. **Establishing metastatic prostate cancer quality indicators using a modified Delphi approach.** Clinical Genitourinary Cancer, 20(2), E151-E157. doi.org/10.1016/j.clgc.2021.11.018

Mak, B., Lin, H-M., Kwan, E. M., Fettke, H., Tran, B., Davis, I. D., Mahon, K., Stockler, M. R., Briscoe, K., Marx, G., Zhang, A., Crumbaker, M., Tan, W., Huynh, K., Meikle, T. G., Mellett, N. A., Hoy, A. J., Du, P., Yu, J., Horvath, L. G. **Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.** BMC Medicine, 20(1), [112]. doi.org/10.1186/s12916-022-02298-0

Weiner, A. B., Siebert, A. L., Fenton, S. E., Abida, W., Agarwal, N., Davis, I. D., Dorff, T. B., Gleave, M., James, N. D., Poon, D. M. C., Suzuki, H., & Sweeney, C. J. **First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature.** European Urology Oncology, 5(4), 377-387. doi.org/10.1016/j.euo.2022.04.009

Bensley, J. G., Dhillon, H. M., Evans, S. M., Evans, M., Bolton, D., Davis, I. D., Dodds, L., Frydenberg, M., Kearns, P., Lawrentschuk, N., Murphy, D. G., Millar, J. L., & Papa, N. **Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registry.** Psycho-Oncology, 31(3), 496-503. doi.org/10.1002/pon.5833

Turco, F., ..., Davis, I. D. et al. **What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.** European Urology, 82(1), 6-11. doi.org/10.1016/j.eururo.2022.02.010

Stockler, M. R., Martin, A. J., Dhillon, H. M., Davis, I. D., & Sweeney, C. J. **Reply to L. Marandino et al.** Journal of Clinical Oncology. doi.org/10.1200/JCO.22.00497

Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., Caffo, O., Chi, K. N., Clarke, C. S., Clarke, N., Davis, I. D., de Bono, J. S., Duran, I., Eeles, R., Efstathiou, E., ... Omlin, A. **Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.** European Urology, 82(1), 115-141. doi.org/10.1016/j.eururo.2022.04.002

Davis, I. D. **Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?** Therapeutic Advances in Medical Oncology, 14, 1-12. doi.org/10.1177/17588359221086827

Turco, F., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., Caffo, O., Chi, K. N., Clarke, C., Clarke, N., Davis, I. D., de Bono, J., Duran, I., Eeles, R., Efstathiou, E., Omlin, A. **Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021”.** European Urology, 82(1), e18-e19. doi.org/10.1016/j.eururo.2022.04.004

Conduit, C., Mak, B., Qu, W., Lulio, J. D., Burder, R., Bressel, M., Cusick, T., Dhillon, H. M., Lourenço, R. D. A., Underhill, C., Torres, J., Crumbaker, M., Honeyball, F., Linton, A., Allen, R., Davis, I. D., Clark, S. J., Horvath, L. G., & Mahon, K. L. **GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol).** Therapeutic Advances in Medical Oncology, 14, 1-13. doi.org/10.1177/17588359221092486

Viljoen, B., Hofman, M. S., Chambers, S. K., Dunn, J., Dhillon, H. M., Davis, I. D., & Ralph, N. **Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: A nested, qualitative longitudinal study.** PLoS ONE, 17(11), [e0276063]. doi.org/10.1371/journal.pone.0276063

Chiong, E., Murphy, D. G., Buchan, N. C., Chua, M. L. K., Hakim, L., Hamid, A. R., Hong, S. K., Horvath, L. G., Kanesvaran, R., Khochikar, M., Letran, J., Lojanapiwat, B., Malek, R., Ng, A. C. F., Vinh, N. T., Pang, S. T., Poon, D. M. C., Ong, T. A., Saad, M., Davis, I. D. **Managing advanced prostate cancer in the Asia Pacific region: “Real-world” application of Advanced Prostate Cancer Consensus Conference 2019 statements.** Asia-Pacific Journal of Clinical Oncology. doi.org/10.1111/ajco.13722

Oza, B., Eisen, T., Frangou, E., Stewart, G. D., Bex, A., Ritchie, A. W. S., Kaplan, R., Smith, B., Davis, I. D., Stockler, M. R., Albiges, L., Escudier, B., Larkin, J., Joniau, S., Hancock, B., Hermann, G. G., Bellmunt, J., Parmar, M. K. B., Royston, P., & Meade, A. **External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.** Journal of Clinical Oncology, 40(16), 1772-1782. doi.org/10.1200/JCO.21.01090

Min, S. T., Roohullah, A., Tognela, A., Jalali, A., Lee, M., Wong, R., Shapiro, J., Burge, M., Yip, D., Nott, L., Zimet, A., Lee, B., Dean, A., Steel, S., Wong, H. L., Gibbs, P., & Lim, S. H. **S. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population.** Asia-Pacific Journal of Clinical Oncology, 18(2), e56-e63. doi.org/10.1111/ajco.13553

Stockler, M. R., ..., Davis, I. D. et al. **Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.** Journal of Clinical Oncology, 40(8), 837-846. doi.org/10.1200/JCO.21.00941

Davis, I. D. **Triplet therapy for prostate cancer.** The Lancet, 399(10336), 1670-1671. doi.org/10.1016/S0140-6736(22)00427-5

Ussher, J. M., Perz, J., Allison, K., Power, R., Hawkey, A., Dowsett, G. W., Hickey, M., Parton, C., McDonald, F. E. J., Davis, I. D., Quinn, G. P., Boydell, K., Robinson, K. H., Chambers, S., & Anazodo, A. **Attitudes, knowledge and practice behaviours of oncology health care professionals towards lesbian, gay, bisexual, transgender, queer and intersex (LGBTQI) patients and their carers: A mixed-methods study.** Patient Education and Counseling. doi.org/10.1016/j.pec.2021.12.008

Vogl, U. M., Beer, T. M., Davis, I. D., Shore, N. D., Sweeney, C. J., Ost, P., Attard, G., Bossi, A., de Bono, J., Drake, C. G., Efstathiou, E., Fanti, S., Fizazi, K., Halabi, S., James, N., Mottet, N., Padhani, A. R., Roach, M., Rubin, M., ... on behalf of the APCCC 2019 expert panel. **Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.** European Journal of Cancer, 160, 24-60. doi.org/10.1016/j.ejca.2021.09.036

RESPIRATORY AND SLEEP MEDICINE

Huang F, Wang DH, Foo CT, Young AC, Fok JS, Thien F. **The Melbourne epidemic thunderstorm asthma event 2016: a 5-year longitudinal study.** Asia Pac Allergy. 2022 Oct 27;12(4):e38. doi.org/10.5415/apallergy.2022.12.e38

McKenzie CI, Varese N, Aui PM, Reinwald S, Wines BD, Hogarth PM, Thien F, Hew M, Rolland JM, O’Hehir RE, van Zelm MC. **RNA sequencing of single allergen- specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect.** Allergy. 2022 Sep 25. PMID: 36153670. doi.org/10.1111/all.15529

James F, Goh MSY, Mouhtouris E, Vogrin S, Chua KYL, Holmes NE, Awad A, Copaescu AM, De Luca JF, Zubrinich C, Gin D, Cleland H, Douglas A, Kern JS, Katelaris CH, Thien F, Barnes S, Yun J, Tong W, Smith WB, Carr A, Anderson T, Legg A, Bourke J, Mackay LK, Aung AK, Phillips EJ, Trubiano J. **Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR).** BMJ Open. 2022 Aug 17;12(8):e055906. PMID: 35977774; PMCID: PMC9389100. doi.org/10.1136/bmjopen-2021-055906

O’Sullivan CF, Nilsen K, Borg B, Ellis M, Matsas P, Thien F, Douglass JA, Stuart-Andrews C, King GG, Prisk GK, Thompson BR. **Small airways dysfunction is associated with increased exacerbations in patients with asthma.** J Appl Physiol (1985). 2022 Sep 1;133(3):629-636. PMID: 35861519. doi.org/10.1152/japplphysiol.00103.2022

van Nunen SA, Burk MB, Burton PK, Ford G, Harvey RJ, Lozynsky A, Pickford E, Rimmer JS, Smart J, Sutherland MF, Thien F, Weber HC, Zehnwrith H, Newbigin E, Katelaris CH. **5-grass-pollen SLIT effectiveness in seasonal allergic rhinitis: Impact of sensitization to subtropical grass pollen.** World Allergy Organ J. 2022 Feb 23;15(2):100632. PMID: 35280502; PMCID: PMC8873945. doi.org/10.1016/j.waojou.2022.100632

SPECTRUM (STATEWIDE SERVICES FOR PERSONALITY DISORDER, EASTERN HEALTH)

Cheney L, Broadbear JH, Rao S. **Disjunction in the subjective and objective measurement of co-occurring depression in Borderline Personality Disorder – implications for diagnosis.** Australasian Psychiatry, February 2022. doi.org/10.1177/10398562211065296

Merrett Z, Castle DJ, Thomas N, Toh WL, Beatson J, Broadbear J, Rao S, Rossell SL. **Comparison of the phenomenology of hallucination and delusion characteristics in people diagnosed with borderline personality disorder and schizophrenia.** Journal of Personality Disorders, Vol 36, issue 4, 413-430, 2022. doi.org/10.1521/pedi.2022.36.4.413

Brown R, Heidari P, Taylor K, Veltkamp J, Broadbear JH, Rao S. **Assessment of peer-conceptualised, written and led single-session group interventions for carers supporting a person with borderline personality disorder.** Advances in Mental Health, 2022. doi.org/10.1080/18387357.2021.2020139

Broadbear JH, Rotella J-A, Lorenze D, Rao S. **Emergency Department utilisation by patients with a diagnosis of Borderline Personality Disorder – an acute response to a chronic disorder.** Emergency Medicine Australasia 34, 731–737, 2022. doi.org/10.1111/1742-6723.13970

Broadbear JH, Beatson J, Moss F, Jayaram H, George K, Planinic A, Rodrigo K, Rao S. **Preliminary evaluation of a screening tool for detecting Borderline Personality Disorder in people aged over 60.** Clinical Gerontologist (pre-print publication, September 2022). doi.org/10.1080/07317115.2022.2123727

Nolan, J, Mildred H, Broadbear J, Knight T, Rao S. **Are there underlying differences between sexually diverse and non-sexually diverse people diagnosed with Borderline Personality Disorder?** Psychology and Sexuality. doi.org/10.1080/19419899.2022.2137057

Jo R, Broadbear JH, Hope J, Rao S. **Late manifestation of Borderline Personality Disorder – characterisation of an under-recognised phenomenon.** Personality and Mental Health. 2022 Nov 15. doi.org/10.1002/pmh.1571

Cheney, L, Rao S, Beatson J, Choi-Kain L. **Co-Occurring Autism Spectrum and Borderline Personality Disorder: An Emerging Clinical Challenge Seeking Informed Interventions.** Harvard Review of Psychiatry. doi.org/10.1097/HRP.0000000000000361

SUPPORTIVE AND PALLIATIVE CARE SERVICES

Kissane DW, Appleton J, Lennon J, Michael N, Chye R, King T, William L, Poon P, Kanathigoda S, Needham K, Bobevski I. **Psycho-Existential Symptom Assessment Scale (PeSAS) Screening in Palliative Care.** J Pain Symptom Manage. 2022;64: 429–437. doi.org/10.1016/j.jpainsymman.2022.08.002

Russell B, William L, Chapman M. **An ethical framework for visitation of inpatients receiving palliative care in the COVID-19 context.** J Bioeth Inq. 2022. doi.org/10.1007/s11673-022-10173-z

Paynter C, Mathers S, Gregory H, Vogel AP, Cruice M. **The impact of communication on healthcare involvement for people living with motor neurone disease and their carers: A longitudinal qualitative study.** Int J Lang Commun Disord. 2022;57: 1318–1333. doi.org/10.1111/1460-6984.12757

Paynter C, Mather S, Gregory H, Vogel A, Cruice M. **Using the concept of health literacy to understand how people living with MND and carers engage in healthcare: a longitudinal qualitative study.** Healthcare Vol 10. No. 8 MDPI 2022. doi.org/10.3390/healthcare10081371

Paynter C, Mather S, Gregory H, Vogel A, Cruice M. **How people living with Motor Neurone Disease and their carers experience healthcare decision making: A qualitative exploration. Disability and Rehabilitation.** 44.13(2022):3095-3103. doi.org/10.1080/09638288.2020.1855261

Iyer K, Kernick L. **The Impact of ASCITIC Paracentesis on Symptomatic Outcomes in Palliative Patients: 3-Year Experience of a Melbourne Inpatient Palliative Care Unit Using Palliative Care Outcomes Collaboration Assessments.** Gastroenterol Res Pract.; 2022. doi.org/10.1155/2022/7300110

SURGICAL PROGRAM

BREAST AND ENDOCRINE PUBLICATIONS

Hong, A. W. J., James, J., Stoney, D. & Law, M. **‘Breast Cosmesis After Breast-Conserving Therapy’ Who is the Judge, Patient or Surgeon?** World J. Surg. 46, 3051–3061 (2022). doi.org/10.1007/s00268-022-06745-0

COLORECTAL PUBLICATIONS

Steen CJ, Lam D, Chandra R, Chua JYJ, An V, Keck JO. **Pudendal Nerve Block for Post hemorrhoidectomy Pain: A Prospective, Single-Blinded Randomized Control Trial.** Dis Colon Rectum. 2022 Apr 1;65(4):546-551. doi.org/10.1097/DCR.0000000000002293

Wells C, Varghese C, Moss JL, Chandra R et al. The management of peri-operative anaemia in patients undergoing major abdominal surgery in Australia and New Zealand: a prospective cohort study. Medical Journal of Australia. 2022 Oct 217(9). doi.org/10.5694/mja2.51725

Chen MZ, Tay YK, Teoh WM, Kong JC, Carne P, D’Souza B, Chandra R, Bui A. **Melbourne Colorectal Collaboration. Melbourne colorectal collaboration: a multicentre review of the impact of COVID-19 on colorectal cancer in Melbourne, Australia.** ANZ J Surg. 2022 May;92(5):1110-1116. doi.org/10.1111/ans.17603

Hong JT, Kutaiba N, Parameswaran B, James S, Hong A, Ng SC, An V. **Sensitivity of pre-operative imaging and radiologist inter-rater reliability in detecting lesions in Crohn’s disease.** ANZ J Surg. 2022 May;92(5):1085-1090. doi.org/10.1111/ans.17477

Jain A, Lew C, Aksakal G, Hiscock R, Mirbagheri N. **Laser hemorrhoidoplasty in the treatment of symptomatic hemorrhoids: a pilot Australian study.** Ann Coloproctol. 2022 May 19. doi.org/10.3393/ac.2022.00164.0023

Othman B, Chandra R, Nestel D. **Age of the leftie: the lived experience of left-handed surgeons.** ANZ J Surg. 2022 Jun 6. doi.org/10.1111/ans.17837

Othman B, Huang D, Rajkomar A, Pham T, Smart P, Warriar S. **How to do robotic retroperitoneal lymph node dissection in colorectal cancer.** ANZ J Surg. 2022 Jun 28. doi.org/10.1111/ans.17883

Clarke EM, Rahme J, Larach T, Rajkomar A, Jain A, Hiscock R, Warriar S, Smart P. **Robotic versus laparoscopic right hemicolectomy: a retrospective cohort study of the Binational Colorectal Cancer Database.** J Robot Surg. 2022 Aug;16(4):927-933. doi.org/10.1007/s11701-021-01319-z

Hong JT, Jain A, An V, Wong A. **Bottoms up! The clinical consequence of vodka enemas.** ANZ J Surg. 2022 Mar;92(3):561-562. doi.org/10.1111/ans.17075

Othman B, An V. **Umbilical pilonidal sinus: a rare cause of umbilical discharge.** ANZ J Surg. 2022 Apr 6. doi.org/10.1111/ans.17691

Othman B, Tan JYC, Friedman A, Steel M. **Resistive small bowel bleeding secondary to an arteriovenous malformation.** ANZ J Surg. 2022 May 27. doi.org/10.1111/ans.17815

Vadakkenchery Varghese E, Steen C, Juszczuk K, An V. **Splenic flexure intussusception: a rare complication post colonoscopy.** ANZ J Surg. 2022 Jun;92(6):1545-1546. doi.org/10.1111/ans.17325

Deng J, Othman B, Wei M, Wong A. **Colonic lipoma: a rare cause of intussusception and large bowel obstruction.** ANZ J Surg. 2022 Sep 22. doi.org/10.1111/ans.18065

Lew C, Jain A, Chua J, Wong A. **Cryptogenic multifocal ulcerous stenosing enteritis: a difficult diagnosis.** ANZ J Surg. 2022 Sep;92(9):2373-2375. PMID: 35088502; PMCID: PMC9541580. doi.org/10.1111/ans.17489

UPPER GI PUBLICATIONS

Cheung KT, An V, Sorensen JC, Lin OM, Lie E, Mercier LL, Marguccio SA, Gumulia EN, Goonawardena J, Chan LH, Wong E. **Elective Laparoscopic Cholecystectomy as an Entrustable Professional Activity (EPA) for General Surgical Trainees in Australia.** Surg Educ. 2022 May-Jun;79(3):655-660. PMID: 35123911. doi.org/10.1016/j.jsurg.2022.01.008

VERITAS Collaborative. **Chemical thromboprophylaxis before skin closure increases bleeding risk after major ventral hernia repair: A multicenter cohort study.** Surgery. 2022 Jul;172(1):198-204. doi.org/10.1016/j.surg.2022.01.023.

ORTHOPAEDICS PUBLICATIONS

Van Essen J, Stevens J, Dowsey M, Choong PF, Babazadeh S. **Kinematic alignment results in clinically similar outcomes to mechanical alignment: Systematic review and meta-analysis.** Knee. 2022 Nov 17;40:24-41. doi. org/10.1016/j.knee.2022.11.001

Bullen M, Babazadeh S, Van Bavel D, McKenzie D, Dowsey M, Choong PF. **Reduction in offset is associated with worse functional outcomes following total hip arthroplasty.** J Arthroplasty. 2022 Sep 10; S0883-5403(22)00827-0. doi.org/10.1016/j.arth.2022.09.001

Naufal E, Stevens J, Babazadeh S, Choong P, Dowsey M, Wouthuyzen-Bakker M. **Methodological challenges in predicting periprosthetic joint infection treatment outcomes: A narrative review.** Front Rehabil Sci. 2022 Jul 11;3:824281. doi.org/10.3389/fresc.2022.824281

Murphy B, Francis S, Rhee I, Babazadeh S, Stoney J, Stevens J. **Atypical Femur Fractures Associated with Bisphosphonate Therapy: Post-Operative Outcomes.** Eur J Orthop Surg Traumatol. 2022 Jul 29. doi.org/10.3389/fresc.2022.824281

Ng N, Onggo JR, Nambiar MN, Maingard JM, Ng D, Gupta G, Nandurkar D, Babazadeh S, Bedi H. **Which test is the best? An updated literature review of imaging modalities for acute ankle diastasis injuries.** J med Rad Sci, 2022 May 03. doi.org/10.1002/jmrs.589

Naufal ME, Shadbolt MC, Elsiwy Y, Thuraisingam MS, Poy Lorenzo MYS, Darby J, Babazadeh S, Choong PFM, Dowsey MM, Stevens JM. **Patterns And Predictors Of Outpatient Antibiotic Dispensation Following Total Hip And Knee Arthroplasty.** J Arthroplasty 2022 Feb 14. doi.org/10.1016/j.arth.2022.02.024

Onggo JR, Babazadeh S, Pai V. **Smaller gap formation with suture anchor fixation than traditional transpatellar sutures in patella and quadriceps tendon rupture: A systematic review.** Arthroscopy. 2022 Jul;38(7):2321-2330. doi.org/10.1016/j.arthro.2022.01.012

CRISTAL Study Group. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty. The CRISTAL Randomized Trial. JAMA. 2022;328(8):719-727. doi.org/10.1001/jama.2022.13416

Aebischer A, Hau R, de Steiger R, Holder C, Wall C. **Distal Femoral Replacement for Periprosthetic Fractures After TKA: Australian Orthopaedic Association National Joint Replacement Registry Review.** J Arthroplasty. 2022 Jul;37(7):1354-1358. doi.org/10.1016/j.arth.2022.02.115.

Aebischer A, Hau R, de Steiger R, Holder C, Wall C. **Distal femoral arthroplasty for native knee fractures: Results from the Australian Orthopaedic Association National Joint Replacement Registry.** Jt J. 2022; 104-B(7): 894-901. doi.org/10.1302/0301-620X.104B7.BJJ-2021-1136.R3

Zheng Z, Stelmach W, Ma J, Briedis J, Hau R, Tacey M et al. **Health professionals’ attitudes towards acupuncture/acupressure for postoperative nausea and vomiting: a survey and implications for implementation.** Acupunct Med. 2022 May. doi.org/10.1177/09645284221085282

Chua SN, Onggo JR, Nambiar M, Onggo J, Wang KK, Pennington R, Hau R. **Functional outcomes of reverse total shoulder arthroplasty in Boileau Class 1 and Class 2 proximal humeral fracture sequelae: A meta-analysis and systematic review.** Shoulder and Elbow. 2022. doi. org/10.1177/17585732221088496

Kang L, Onggo J, Simpson J, Hau R. **Nature and characteristics of orthopaedic medical emergency team events: A retrospective study 263 MET calls.** Curr Orthop Pract. 2022 Jan. doi.org/10.1097/BCO.0000000000001082

Hookway S, Lambers A, Page R, Bedi H. **The Australian ankle syndesmosis injury survey.** Injury. 2022 Jun; 53(6):2304-2310. Epub 2022 Feb 10. doi.org/10.1016/j.injury.2022.02.024

Ng N, Onggo, J, Nambiar M, Maingard J, Ng D, Gupta G, Nandurkar, D, Babazadeh,Sina, Bedi H. **Which test is the best? An updated literature review of imaging modalities for acute ankle diastasis injuries.** J Med Radiat Sci. 2022 Sep;69(3):382-393. doi.org/10.1002/jmrs.589

Wijetunga CG, Roebert J, Hiscock RJ, Bedi HS, Roshan-Zamir S, Wang O, Fraval A, Tate J, Eden M, Rotstein AH. **Defining Reference Values for the Normal Adult Lisfranc Joint Using Weightbearing Computed Tomography.** J Foot Ankle Surg. 2022 Oct 7:S1067-2516. doi.org/10.1053/j.jfas.2022.09.008

zET Ek, KK Wang, CM Bohan, NJ Goulding, RP Jamieson. **Role of Tranexamic Acid in Arthroscopic Osteocapsular Release of the Elbow for degenerative Arthritis.** Orthopaedic Journal of Sports Medicine 10 (4). doi. org/10.1177/23259671221089608

SE Root, V Sanchez, JA Tracz, DJ Preston, YS Zvi, KK Wang, CJ Walsh. **An Expanding Foam-Fabric Orthopedic Cast.** Advanced Materials Technologies, 2101563, 2022 Mar. doi. org/10.1002/admt.202101563

PLASTICS PUBLICATIONS

Lin F, Goodman GJ, Magnusson MD, Callan P, Roberts S, Hart S, et al. **Movement of the Syringe During Filler Aspiration: An Ultrasound Study.** Aesthet Surg J, 2022 Sep 14;42(10): 1109-1116. doi.org/10.1093/asj/sjac032

Corduff N, Juniarti L, Lim TS, Lin F, et al. **Current Practices in Hyaluronic Acid Dermal Filler Treatment in Asia Pacific and Practical Approaches to Achieving Safe and Natural Looking Results.** Clin Cosmet Investig Dermatol. 2022 Jul 1;15:1213-1223. doi.org/10.2147/CCID.S363583

Cevic J, Hunter-Smith DJ, Rozen WM. **A Novel Optimization Technique Of Computed Tomography Angiographic 3D-Reconstructions For Pre-Operative Planning Of DIEP Flaps.** J Plast Reconstr Aesthet Surg Open. 26 Dec 2022; 35 (1): 38-41. doi.org/10.1016/j.jprra.2022.12.003

Seth I, Bulloch G, Gibson D, Chow O, Seth N, Mann GB, Hunter-Smith DJ, Rozen WM. **Autologous Fat Grafting In Breast Augmentation: A Systematic Review Highlighting The Need For Clinical Caution.** Plast Reconstr Surg. 2022 Oct 24, (Impact Factor 2021/22 = 5.169). doi.org/10.1097/PRS.00000000000010614

Koppa M, House R, Tobin V, Rozen WM, Hunter-Smith DJ, Goldie SJ. **Suture Material Choice Can Increase Risk Of Hypersensitivity In Hand Trauma Patients.** Eur J Plas Surg. 2022 Jul. doi.org/10.1007/s00238-022-01986-7

Rozen WM, Phan R, Ellis L, Seifman MA, Hunter-Smith DJ. **The Innervated Rectus Abdominis Perforator Turndown (RAPT) Flap For Preserving Rectus Continuity: A DIEP Alternative?** Plast Reconstr Surg Glob Open. 2022 Jan; 10 (1): e4037, 1-8. doi.org/10.1097/GOX.0000000000004037

Savage N, Savage S, Doherty Z, Rozen WM, Hunter-Smith DJ, Goldie SJ. **A Systematic Review Of Systematic Review Methodology In Plastic Surgery Journals.** J Plast Reconstr Aesthet Surg. 2022 Sep; 75 (9): 3628-3651. Epub Aug 5 2022. PMID: 35970743. doi.org/10.1016/j.bjps.2022.08.004

Leong J, Hughes K, Fong E, Rozen WM. **The Arterialised Saphenous Venous Flow-Through Flap for Managing the Radial Forearm Free Flap Donor Site.** Microsurgery. 2022 May; 42 (4): 333-340. Epub Mar 10 2022. doi.org/10.1002/micr.30883

Cevik J, Hunter-Smith DJ, Rozen WM. **Infections Following Stingray Attacks: A Case Series and Literature Review of Antimicrobial Resistance and Treatment.** Travel Med Inf Dis. 2022 Mar 7; 47 (May–June) 102312: 1-8. Epub 2022 Mar 15. PMID: 35304330. doi.org/10.1016/j.tmaid.2022.102312

Rozen WM, Cevik J, Hunter-Smith DJ. **Current Advances in Breast Reconstruction.** J Clin Med. 2022 Jun 10; 11 (12): 3328. PMID: 35743399. (Impact Factor 2022 = 4.242). doi. org/10.3390/jcm11123328

Zhu W, Qiu X, Lin N, Fang K, Zhang T, Rozen WM, Huang J (AME Breast Cancer Collaborative Group - sub-group of AME Academic Collaborative Group). **Potential Prognostic Value Of The Lymph Node Ratio And Its Correlation With Circulating Sex Hormone Concentration In Pathological T1/2 Breast Cancer Patients.** Ann Transl Med. 2022 May; 10 (10): 585. PMID: 35722397. doi.org/10.21037/atm-22-2039

Cevik J, Hunter-Smith DJ, Rozen WM. **Anatomical Differences in the Abdominal Wall Between Species with Implications for the Transversus Abdominis Plane Block.** Surg Radiol Anat. 2022 Aug; 44 (8): 1171-1180. PMID: 35864247. doi.org/10.1007/s00276-022-02991-y

UROLOGY PUBLICATIONS

Ong S, Pascoe C, Kelly BD, Ballok Z, Webb D, Bolton D, Murphy D, Sengupta S, Bowden P, Lawrentschuk N. **Distant Nodes Seen on PSMA PET-CT Staging Predicts Post-Treatment Progression in Men with Newly Diagnosed Prostate Cancer-A Prospective Cohort Study.** Cancers (Basel). 2022 Dec 13;14(24):6134. PMID: 36551620; PMCID: PMC9777123. https://www.mdpi.com/2072-6694/14/24/6134

Ngweso S, Nzenza T, McMillan K, Sofield D, Lozinskiy M, Hayne D. **Current trends in penile cancer survivorship amongst remote patients and Aboriginal people in Western Australia.** ANZ J Surg. 8 Dec 2022;93(3):534-540. PMID: 36478516. doi.org/10.1111/ans.18177

Chan CYW, Fernandes RA, Yao HH, O’Connell HE, Tse V, Gani J. **A systematic review of the surgical management of apical pelvic organ prolapse.** Int Urogynecol J. 2022 Dec 3. PMID: 36462058. doi.org/10.1007/s00192-022-05408-x

Viswambaram P, McCombie SP, Hawks C, Wallace DMA, Sengupta S, Hayne D. **Centralization and prospective audit of cystectomy are necessary: a commentary on the case for centralization, supported by a contemporary series utilizing the ANZUP cystectomy database.** Asia Pac J Clin Oncol. 2022 Nov 9. PMID: 36352543. doi.org/10.1111/ajco.13883

Leow JJ, Tan WS, Tan WP, Tan TW, Chan VW, Tikkinen KAO, Kamat A, Sengupta S, Meng MV, Shariat S, Roupret M, Decaestecker K, Vasdev N, Chong YL, Enikeev D, Giannarini G, Ficarra V, Teoh JY; UroSoMe Collaborators. **A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond.** Front Surg. 2022 Oct 4;9:879774. PMID: 36268209; PMCID: PMC9577485. doi.org/10.3389/fsurg.2022.879774

Kanagarajah A, Hogan D, Yao HH, Dundee P, O’Connell HE. **A systematic review on the outcomes of local anaesthetic transperineal prostate biopsy.** BJU Int. 29 Sept 2022;131(4):408-423. PMID: 36177521. doi.org/10.1111/bju.15906

See AW, Bowden P, Wells G, Appu S, Lawrentschuk N, Liodakis P, Pandeli C, Aarons Y, Smyth LML, McKenzie DP. **Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial.** Radiat Oncol. 2022 Jul 25;17(1):131. PMID: 35879722; PMCID: PMC9316359. doi.org/10.1186/s13014-022-02103-5

Chan G, Yanko E, Qu L, Zilberlicht A, Karmakar D, Pirpiris A, Gani J. **Surgical mesh information on YouTube™: Evaluating the usage and reliability of videos for patient education.** Can Urol Assoc J. 2022 Jul;16(7):E399-E402. PMID: 35819915; PMCID: PMC9328856. doi.org/10.5489/cuaj.7706

Ho FCS, He C, Yao HH, O’Connell HE, Gani J. **Response to letter to editor: Efficacy of sacral neuromodulation and percutaneous tibial nerve stimulation in the treatment of chronic nonobstructive urinary retention: A systematic review.** Neurourol Urodyn. 2022 Aug;41(6):1519. PMID: 35708123. doi.org/10.1002/nau.24966

Ong S, Pascoe C, Kelly BD, Ballok Z, Webb D, Bolton D, Murphy D, Sengupta S, Bowden P, Lawrentschuk N. **PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up.** Cancers. (Basel). 2022 May 31;14(11):2717. PMID: 35681697; PMCID: PMC9179348. doi.org/10.3390/cancers14112717

Kwok M, McGeorge S, Mayer-Coverdale J, Graves B, Paterson DL, Harris PNA, Esler R, Dowling C, Britton S, Roberts MJ. **Guideline of guidelines: management of recurrent urinary tract infections in women.** BJU Int. 2022 Nov;130 Suppl 3(Suppl 3):11-22. PMID: 35579121; PMCID: PMC9790742. doi.org/10.1111/bju.15756

Nandurkar R, Sluka P, Warden H, Davis ID, Sengupta S. **Lytic effects of water on cancer cells: Implications for post-operative irrigation.** ANZ J Surg. 2022 Jan;92(1-2):157-161. PMID: 34414644. doi.org/10.1111/ans.17145

Hayne D, Sengupta S et al. **Pain-free TRUS B: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).** BJU Int. 2022 May;129(5):591-600. PMID: 34273231; PMCID: PMC9291594. doi.org/10.1111/bju.15552

Thomson A, Keong B, Longano A, Hamid A, Sengupta S. **Testicular seminoma metastases presenting as gastrointestinal malignancy: A case report and review of the literature.** ANZ J Surg. 2022 Jan;92(1-2):271-273. PMID: 34137494. doi.org/10.1111/ans.17006

TURNING POINT

Bolt, G. L., Piercy, H., Barnett, A., & Manning, V. **‘A circuit breaker’ – Interrupting the alcohol autopilot: A qualitative exploration of participants’ experiences of a personalised mHealth approach bias modification intervention for alcohol use.** Addictive Behaviors Reports, 16, [100471]. doi.org/10.1016/j.abrep.2022.100471

Carter, G., Arunogiri, S. et al. **Diagnostic accuracy for self-reported methamphetamine use versus oral fluid test as the reference standard in a methamphetamine-dependent intervention trial population.** Addiction. doi.org/10.1111/add.16085

Manning, V., Garfield, J. B. B., Reynolds, J., Staiger, P. K., Piercy, H., Bonomo, Y., Lloyd-Jones, M., Jacka, D., Wiers, R. W., Verdejo-Garcia, A., & Lubman, D. I. **Alcohol use in the year following approach bias modification during inpatient withdrawal: secondary outcomes from a double-blind, multi-site randomized controlled trial.** Addiction. doi.org/10.1111/add.15989

Naim-Feil, J., Fitzgerald, P. B., Robinson, M., Lubman, D. I., Sheppard, D. M., Bradshaw, J. L., Levit-Binnun, N., & Moses, E. **Anomalies in global network connectivity associated with early recovery from alcohol dependence: A network transcranial magnetic stimulation and electroencephalography study.** Addiction Biology, 27(2), [e13146]. doi.org/10.1111/adb.13146

Garfield, J. B. B., Piccoli, L. R., Whelan, D., Staiger, P. K., Reynolds, J., Piercy, H., Lubman, D. I., Verdejo-Garcia, A., & Manning, V. **The effect of approach bias modification during alcohol withdrawal treatment on craving, and its relationship to post-treatment alcohol use in a randomised controlled trial.** Drug and Alcohol Dependence, 239, [109621]. doi.org/10.1016/j.drugalcdep.2022.109621

Peart, A., Wells, N., Yu, M-L., & Brown, T. **‘It became quite a complex dynamic’: The experiences of occupational therapy practice educators’ move to digital platforms during the COVID-19 pandemic.** Australian Occupational Therapy Journal, 69(1), 38-49. doi.org/10.1111/1440-1630.12767

Peart, A. **Relationship-centred care and patient navigation.** Health Voices, 2022(30). https://healthvoices.org.au/issues/may-2022/relationship-centred-care-and-patient-navigation/

Kim, J., Phillips, J. G., & Ogeil, R. P. **Nowhere else to go: Help seeking online and maladaptive decisional styles.** Computers in Human Behavior, 128, [107103]. doi.org/10.1016/j.chb.2021.107103

Haines, S., Lam, A., Savic, M., & Carter, A. **Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline.** International Journal of Drug Policy, 109, [103847]. doi.org/10.1016/j.drugpo.2022.103847

Verdejo-Garcia, A., Manning, V. et al. **Cognitive training and remediation interventions for substance use disorders: a Delphi consensus study.** Addiction. doi.org/10.1111/add.16109

Gooden, J. R., Petersen, V., Bolt, G. L., Curtis, A., Manning, V., Cox, C. A., Lubman, D. I., & Arunogiri, S. **Maybe It’s Not the Meth: Considering Biopsychosocial Contributors to Cognitive Impairment in Methamphetamine Polydrug Use.** Frontiers in Psychiatry, 13, [795400]. doi.org/10.3389/fpsyt.2022.795400

Ogeil, R. P., Faulkner, A., Beard, N., Killian, J. J., Arunogiri, S., Phan, V., Wilson, J. C., Smith, K., Lubman, D. I., & Scott, D. A. **Adverse Outcomes of GHB use: Analysis of ambulance attendances in metropolitan and regional Victoria.** International Journal of Drug Policy. https://pubmed.ncbi.nlm.nih.gov/36527909/

Baldwin, R., Miller, P. G., Coomber, K., Patafio, B., & Scott, D. **A systematic narrative review of the effects of alcohol supply reduction policies on children and adolescents.** International Journal of Drug Policy, 101, [103581]. doi.org/10.1016/j.drugpo.2022.103581

Elliott, K., Roberts, S., Ralph, B., Robards, B., & Savic, M. **Understanding autonomy and relationality in men’s lives.** British Journal of Sociology, 73(3), 571-586. doi.org/10.1111/1468-4446.12947

Lubman, D. I., Grigg, J., Reynolds, J., Hall, K., Baker, A. L., Staiger, P. K., Tyler, J., Volpe, I., Stragalinis, P., Harris, A., Best, D., & Manning, V. **Effectiveness of a Stand-alone Telephone-Delivered Intervention for Reducing Problem Alcohol Use: A Randomized Clinical Trial.** JAMA Psychiatry, 79(11), 1055-1064. doi.org/10.1001/jamapsychiatry.2022.2779

Peart, A., Horn, F., Manning, V. C., & Lubman, D. I. **The experiences of affected family members and friends attending BreakThrough: Families Understanding Addiction.** Addiction and the Family International Network Conference 2022. <http://afinetwork.info/afinet-conference/2022-conference-online/2022-conference-videos>

Bernard, C., Grigg, J., Volpe, I., Lubman, D. I. & Manning, V. **Client Experiences of a Telephone-Delivered Intervention for Alcohol Use: a Qualitative Study.** International Journal of Mental Health and Addiction, 20(1), 522-540. doi.org/10.1007/s11469-020-00381-2

Greco, P., Prasanna, A. N., Ackermann, K., Campbell, S., Scott, D. A., Lubman, D. I., & Bergmeir, C. **Probabilistic causal effect estimation with global neural network forecasting models.** IEEE Transactions on Neural Networks and Learning Systems. doi.org/10.1109/TNNLS.2022.3190984

Haines, S., Savic, M., Nielsen, S., & Carter, A. **Key considerations for the implementation of clinically focused Prescription Drug Monitoring Programs to avoid unintended consequences.** International Journal of Drug Policy, 101, [103549]. doi.org/10.1016/j.drugpo.2021.103549

Gooden, J. R., Cox, C. A., Petersen, V., Curtis, A., Sanfilippo, P. G., Manning, V., Bolt, G. L., & Lubman, D. I. **Predictors of cognitive functioning in presentations to a community-based specialist addiction neuropsychology service.** Brain Impairment. doi.org/10.1017/BrImp.2021.38

Caluzzi, G., Livingston, M., Holmes, J., MacLean, S., Lubman, D., Dietze, P., Vashishtha, R., Herring, R., & Pennay, A. **Declining drinking among adolescents: Are we seeing a denormalisation of drinking and a normalisation of non-drinking?** Addiction, 117(5), 1204-1212. doi.org/10.1111/add.15611

Smith, T., Schliephake, K., & Macfarlan, B. **Structural Changes over 3 years: Evolution of 3 models to support learning and teaching in a large research-intensive university.** In O. J. Neisler (Ed.), The Palgrave International Handbook of Academic Professional Development Centers (1st ed.). (Palgrave Studies on Leadership and Learning in Teacher Education). Palgrave Macmillan. doi.org/10.1007/978-3-030-80967-6_10

Dowling, N., Merkouris, S., Lubman, D., Thomas, S., Bowden-Jones, H., & Cowlshaw, S. **Pharmacological interventions for the treatment of disordered and problem gambling (Review).** Cochrane Database of Systematic Reviews, 2022(9), [CD008936]. doi.org/10.1002/14651858.CD008936.pub2

Curtis, L., & Roberts, S. **Exploring alcohol cultures and homosocial relationships in women’s amateur AFL teams.** Journal of Sociology. doi.org/10.1177/14407833221093398

Nielsen, S., & Lubman, D. I. **Time to address addiction treatment inequality in hospital settings.** The Lancet Public Health, 7(1), e6-e7. doi.org/10.1016/S2468-2667(21)00260-7

Roxburgh, A., & Nielsen, S. **Twenty-year trends in pharmaceutical fentanyl and illicit fentanyl deaths, Australia 2001–2021.** International Journal of Drug Policy, 109, [103854]. doi.org/10.1016/j.drugpo.2022.103854

Cook, M., Wilkinson, C., Caluzzi, G., Duncan, T., & Dwyer, R. **Qualitative insights on alcohol and other drug consumption during COVID-19.** Drug and Alcohol Review, 41(6), 1263-1266. doi.org/10.1111/dar.13517

Phillips, J. G., & Ogeil, R. P. **Remote detection of Cannabis-related impairments in performance?** Psychopharmacology. doi.org/10.1007/s00213-022-06145-1

Miller, P., Scott, D. et al. **Learning from alcohol (policy) reforms in the Northern Territory (LEARNT): protocol for a mixed-methods study examining the impacts of the banned drinker register.** BMJ Open, 12(4), [e058614]. doi.org/10.1136/bmjopen-2021-058614

Duncan, T., Roberts, S., Elliott, K., Ralph, B., Savic, M., & Robards, B. **“Looking after yourself is self-respect”: The limits and possibilities of men’s care on a night out.** Contemporary Drug Problems, 49(1), 46-63. doi.org/10.1177/00914509211057294

Zhu, C., Thomas, N., Arunogiri, S., & Gurvich, C. Systematic review and narrative synthesis of cognition in perimenopause: **The role of risk factors and menopausal symptoms.** Maturitas, 164, 76-86. doi.org/10.1016/j.maturitas.2022.06.010

Dowling, N. A., Merkouris, S. S., Youssef, G. J., Lubman, D. I., Bagot, K. L., Hawker, C. O., Portogallo, H. J., Thomas, A. C., & Rodda, S. N. **A Gambling Just-In-Time Adaptive Intervention (GamblingLess: In-The-Moment): Protocol for a Microrandomized Trial.** JMIR Research Protocols, 11(8), [e38958]. doi.org/10.2196/38958

Anderson, A. C., Robinson, A. H., Lubman, D. I., & Verdejo-Garcia, A. **Protocol for a cluster randomised crossover pilot trial of Goal Management Training+ (GMT+) for methamphetamine use disorder.** Contemporary Clinical Trials Communications, 29, [100969]. doi.org/10.1016/j.conctc.2022.100969

Manning, V., Whelan, D., & Piercy, H. **The current evidence for substance use disorder apps.** Current Opinion in Psychiatry, 35(4), 237-245. doi.org/10.1097/YCO.0000000000000800

Lam, T., Laslett, A-M., Fischer, J. A., Salom, C., Ogeil, R. P., Lubman, D. I., Aiken, A., Mattick, R. P., Gilmore, W., & Allsop, S. J. **Disclosures of harming others during their most recent drinking session: Findings from a large national study of heavy-drinking adolescents.** Drug and Alcohol Review, 41(1), 197-207. doi.org/10.1111/dar.13336

Lonne, B., Herronkohl, T. I., Higgins, D. J., & Scott, D. A. **The Implications of Leveraging Administrative Data for Public Health Approaches to Protecting Children: Sleepwalking into Quicksand?** International Journal on Child Maltreatment: Research, Policy and Practice, 5, 501-517. doi.org/10.1007/s42448-022-00126-9

Manning, V. C., & Bolt, G. L. **Cognitive Assessment, Management & Training in Addiction Treatment.** In V. Patel, & V. Preedy (Eds.), Handbook of Substance Misuse and Addictions: From Biology to Public Health (pp. 1-29). Springer Nature. doi.org/10.1007/978-3-030-67928-6_6-1

Perversi, P., Burstein, F., Henderson, Z., Leech, M. T., Schliephake, K., & Kent, F. **How do students enact group reasoning within online interprofessional education?** Journal of Research in Interprofessional Practice and Education, 12(1). doi.org/10.22230/jripe.2022v12n1a339

Sturgiss, E. A., Peart, A., Richard, L., Ball, L., Hunik, L., Chai, T. L., Lau, S., Vadasz, D., Russell, G., & Stewart, M. **Who is at the centre of what? A scoping review of the conceptualisation of ‘centredness’ in healthcare.** BMJ Open, 12(5), [e059400]. doi.org/10.1136/bmjopen-2021-059400

Arunogiri, S., & Loi, S. M. **Diversity and retention in academic psychiatry.** Australian & New Zealand Journal of Psychiatry. doi.org/10.1177/00048674221106679

Grigg, J., Morris, E. E., & Miles, E. **Consumer experiences of long-term oral nicotine replacement therapy and related health information-seeking: A qualitative study.** International Journal of Drug Policy, 110, [103897]. doi.org/10.1016/j.drugpo.2022.103897

Pennay, A., Cook, M., MacLean, S., Lubman, D. I., Dietze, P., Herring, R., Caluzzi, G., Vashishtha, R., & Livingston, M. **Examining trends in the representation of young people and alcohol in Australian newspapers over twenty years (2000-2019).** International Journal of Drug Policy, 99, [103461]. doi.org/10.1016/j.drugpo.2021.103461

van Vreden, C., Xia, T., Collie, A., Pritchard, E., Newnam, S., Lubman, D. I., de Almeida Neto, A., & Iles, R. **The physical and mental health of Australian truck drivers: a national cross-sectional study.** BMC Public Health, 22, [464]. doi.org/10.1186/s12889-022-12850-5

Stam, N. C., Cogger, S., Schumann, J. L., Weeks, A., Roxburgh, A., Dietze, P. M., & Clark, N. **The onset and severity of acute opioid toxicity in heroin overdose cases: a retrospective cohort study at a supervised injecting facility in Melbourne, Australia.** Clinical Toxicology, 60(11), 1227-1234. doi.org/10.1080/15563650.2022.2126371

Anderson, A. C., Robinson, A. H., Potter, E., Kerley, B., Flynn, D., Lubman, D. I., & Verdejo-García, A. **Development of Goal Management Training+ for Methamphetamine Use Disorder Through Collaborative Design.** Frontiers in Psychiatry, 13, [876018]. doi.org/10.3389/fpsy.2022.876018

Rodda, S. N., Bagot, K. L., Merkouris, S. S., Youssef, G., Lubman, D. I., Thomas, A. C., & Dowling, N. A. **Smartphone App Delivery of a Just-In-Time Adaptive Intervention for Adult Gamblers (Gambling Habit Hacker): Protocol for a Microrandomized Trial.** JMIR Research Protocols, 11(7), [e38919]. doi.org/10.2196/38919

Henderson, M., ..., Schliephake, K. et al. **Educational design and productive failure: the need for a culture of creative risk taking.** In R. Sharpe, S. Bennett, & T. Varga-Atkins (Eds.), Handbook of Digital Higher Education (1st ed., pp. 14-25). Edward Elgar Publishing. doi.org/10.4337/9781800888494.00011

Peart, A., Horn, F., & Lubman, D. I. **The experiences of affected family members and friends attending BreakThrough: Families Understanding Addiction.** Drug and Alcohol Review, 41(S1), s108-s109. doi.org/10.1111/dar.13537

Haylock, P. A. C., Carter, A., Savic, M., & Lubman, D. I. **Regional and rural clients' presenting concerns and experiences of care when engaging with an online substance use counseling service.** Addiction Research & Theory. doi.org/10.1080/16066359.2022.2039911



FINANCE

Detailed financial statements are provided for 2022. In brief:

- Revenue: \$25,929,000, an increase of \$1,871,000 over 2021. Research revenue \$13,264,000 (48% favourable to budget despite the COVID19 pandemic).
- Expenditure: \$23,190,000.
- Operating result: \$2,739,000, representing a gross margin of 28.6% and ongoing operating margin of 43.8%.

INCOME STATEMENT 2022

	2021	2022
Ongoing Operating Margin %	54.56%	43.81%
Financial Plan	4,200,881	2,739,457
Operating Revenue	24,058,264	25,929,386
Commonwealth Government Grants DEEWR	6,800,728	6,500,492
Student Fees	2,710,639	3,677,303
Research	11,789,502	13,263,827
Commercial	2,021,330	1,834,506
Other Grants & Donations	85,980	135,464
Other Revenues	-	-
Internal Grants & Support	-	-
Inter Faculty Transfers	-	50,000
Intra Entity Contributions	(814,776)	(844,795)
Intra Entity Allocations	1,464,861	1,312,588
Operating Expenditure	19,857,383	23,189,929
Salary and Related Expenses	11,798,685	13,841,117
Infrastructure related expenses	515,519	383,786
Finance Incentive	-	-
Financial and administration expenses	8,998	38,358
Student scholarships and awards	145,652	199,306
Other Operating Expenses	1,617,034	1,949,324
Depreciation	50,179	58,532
Direct & Central Overhead Charges	4,110,052	4,687,394
Space Charges	25,455	24,023
Other Overhead Costs	1,585,808	2,008,088
Contract Recoveries	-	-
Net Cash Position	18,334,758	21,214,831
Net Cash from Plan	4,251,060	2,797,989
Capital Expenditures	59,975	42,567
Previous Year Funds	14,143,673	18,459,409

